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Elite endurance athletes are strongly suspected to have differing genetic profiles from 
sub-elite endurance athletes and non-athletes. This thesis will contribute to the developing 
knowledge in this area, providing a more detailed analysis of the genetic profile of elite 
endurance athletes in the sport of marathon running. Identifying ‘advantageous’ genetic 
characteristics would be a significant development. The insight provided about the 
underlying physiological mechanisms may have implications for both sport, exercise and 
for the prevention and treatment of disease. 
 
Numerous physiological systems detailing a complex phenotype are required for elite 
endurance performance therefore it is likely that ‘elite status’ is polygenic. Eight 
‘endurance’ alleles have previously demonstrated discrete associations with elite 
endurance athlete status. The human ACE gene contains a restriction fragment length 
polymorphism consisting of the presence (insertion, I) or absence (deletion, D) of a 287 
base pair Alu repeat sequence in Intron 16. The renin-angiotensin aldosterone system 
(RAAS) plays a homeostatic role in the human circulation. Renin catalyses the conversion 
of Angiotensinogen (AGT) to angiotensin I. Angiotensin I-converting enzyme is 
responsible for the breakdown of vasodilator kinins while catalysing the formation of the 
vasoconstrictor angiotensin II. Angiotensin II stimulates adrenal aldosterone release, 
leading to salt and water retention. These two elements maintain blood pressure and 
volume before, during and after a marathon competition and would therefore influence 
aerobic power, V̇O2 kinetics 
 
The alpha actinins cross-link with actin at the z- lines of skeletal muscle and are therefore 
major contributory structural components. ACTN3 is responsible for the stabilisation of the 
contractile apparatus of the sarcomere during exercise. However, knock out mice have 
shown enhanced enzyme expression associated with oxidative capacity and superior 
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endurance running performance and improved recovery time. Extrapolation of this 
information lead to the hypothesis that the ACTN3 XX genotype may confer some 
advantage to endurance athletes based on an enhanced oxidative capacity and 
preferential skeletal muscle fibre type proportion to compete in endurance events such as 
marathon running. 
 
PPARGC1A is thought to indirectly mediate the regulation of several genes encoding key 
enzymes involved in fatty acid oxidation, and mitochondrial biogenesis through its 
interaction with specific transcription factors such as nuclear receptor PPARɣ, nuclear 
respiratory factors 1 and 2 and MEF2, PARAGC1A is thought to influence the fatty acid 
substrate availability during the later stages of a marathon and its conversion to ATP, to 
directly fuel skeletal muscle contraction during a marathon and will therefore influence a 
runners running economy and lactate threshold.  
 
The uncoupling proteins regulate the coupling of oxidative phosphorylation to ATP 
production used in propulsion during a marathon. Their role is not fully understood 
however they have been linked to thermogenesis and the uncoupling of respiration from 
ATP production both important factors in the successful completion of a marathon on race 
day. 
 
Three hundred and ninety-nine Caucasian marathon athletes donated DNA samples for 
analysis. In addition, DNA was collected from 676 non-athlete research participants. Of 
those 1075 samples collected, all 1075 samples were genotyped for actinin, alpha 3 
(gene/ pseudogene) (ACTN3) (399 athletes and 676 non-marathon controls, 932 samples 
(399 athletes and 533 non-marathon controls) were genotyped for Angiotensin I 
Converting Enzyme (ACE), 673 samples (364 athletes) were genotyped for 
angiotensinogen (AGT) and 705 samples (399 athletes) peroxisome proliferator receptor 1 
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alpha (PPARGC1A) as well as uncoupling protein 3 (UCP3). For uncoupling protein 2 
(UCP2) rs660339 702 samples were genotyped (396 athletes). Finally, for UCP r659336, 
578 samples were genotyped (272 athletes). Three hundred and six non-marathon 
controls were genotyped for AGT, PPARGC1A, UCP2 rs659336 and rs660339, and 
UCP3. 
 
In addition, the collected samples contributed to an investigation into whether genetic 
characteristics differ at different levels of ‘eliteness’. We compared the genotype and allele 
frequency distributions in ‘elite’ and ‘sub- elite’ marathon runners with those of a non-
athlete population. Marathon personal best times (PBs) were verified and used to 
determine elite (males <2.5 h; females <3 h) or sub-elite (males 2.5-3 h; females 3-3.5 h) 
status. Chi-squared analysis was used to compare genotype and allele frequency 
distributions between athletes and non-marathon controls, while a genotype-dependent 
difference in marathon PB was investigated using a one-way analysis of variance for both 
males and females. 
 
Analysis of the AGT rs699 polymorphism revealed over-representation of the TT genotype 
and T allele in athletes compared to non-marathon controls. This over-representation of 
the TT genotype and T allele was also noted when sub-elite athletes were compared to 
non-marathon controls. 
 
The PPARGC1A rs8192678 polymorphism analysis showed the A allele tended to be 
more frequent in athletes than non-marathon controls (χ2 = 2.988, p = 0.084). The minor A-
allele was over represented 9.2% in the elite male marathon athletes when compared to 
non-athlete controls (χ2 = 6.871, p = 0.03). An association was also reflected in the male 
elite marathon cohort towards the minor AA genotype (χ2 = 6.890, p = 0.04) when 
compared to non-marathon controls. Further to this, a tendency towards the minor A allele 
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was seen when the male elite marathon group was compared to the male sub-elite 
marathon group (χ2 = 2.986, p = 0.084). In the female cohort, there was a 7.8% higher AA 
genotype frequency in sub-elite marathon athletes when compared to non-marathon 
controls (χ2 = 7.193, p = 0.04) 
 
Tendency for a higher AA frequency in sub-elite vs. elite marathon athletes (χ2 = 5.425, p 
= 0.066). When considering PB, in women the PPARGC1A GG genotypes ran the 
marathon approximately 5 min 38 s faster than other genotypes (p = 0.022), which is 
generally consistent with previous literature. 
 
UCP2 rs660339 analysis revealed A genotype apparent difference was recorded when 
male elite and sub-elite athletes were compared to non-marathon controls independently 
(elite χ2 = 11.173, p = 0.001; sub-elite χ2 = 17.584, p = 0.01) via Pearson’s-Chi squared. In 
the female athletes, a genotype association was observed when compared to non-
marathon controls (genotype χ2=8.376, p = 0.02) 
The female elite athletes also reflected a genotype association when compared to non-
marathon controls (genotype χ2 = 8.942, p = 0.02) 
 
Our findings suggest that the AGT rs699, PPARGCIA and UCP2 rs660339 
polymorphisms are associated independently with marathon performance. In addition, it is 
reported that ACE I/D, ACTN3 R577X, UCP2 rs659366 and UCP3 rs1800849 
polymorphisms are not associated with elite or sub- elite marathon performance when 
either analysed a whole cohort or individually as males and females. TGS analysis 
revealed difference in the combined polygenic profile between athletes and controls (t = 
4.130 p = 0.000041). 
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ACE Angiotensin Converting Enzyme 
ACTN2 α-actinin 2 
ACTN3 α-actinin 3 
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ANGI Angiotensin I 
ANGII Angiotensin II 
ATP Adenosine Triphosphate 
BMI Body Mass Index 
bp Base Pairs 
COOH Carboxylic Acid 
DAG Diacylglycerol 
DNA Deoxyribonucleic Acid 
DZ Dizygotic 
EDTA Ethylenediaminetetraacetic Acid 
GDP Guanosine Diphosphate 
GTP Guanosine Triphosphate 
GWAS Genome Wide Association Study 
HTA Human Tissue Authority 
IAAF International Association of Athletics Federation  
IMP Inosine Monophosphate 
IP3 Inositol trisphosphate 
IPR Institute of Performance Research 
LBM Lean Body Mass 
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LIF Leukaemia Inhibitory Factor 
LV Left Ventricular 




PB Personal Best 
PBS Phosphate Buffered Solution 
PCR Polymerase Chain Reaction 
P Phosphate 
PIP2 Phosphatidylinositol 4,5-Bisphosphate 
PO2 Partial Pressure of Oxygen 
RAAS Renin Angiotensin Aldosterone System 
SNP Single Nucleotide Polymorphism 
TGS Total Genotype Score 
UK United Kingdom 




VIII. GENES OF INTEREST 
GENE NAME ENCODES FOR: 
ACE Angiotensin I converting enzyme 
ACTN3 α-Actinin, alpha 3 (gene/ pseudogene) 
AGT Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
PPARAGC1A Peroxisome proliferator activated receptor gamma, coactivator 1 
alpha 
UCP2 Uncoupling protein 2 (mitochondrial, proton carrier) 
UCP3 Uncoupling protein 3 (mitochondrial, proton carrier) 
* According to convention, in this thesis, gene abbreviations are shown in italics, 
proteins are not italicised. 
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1 INTRODUCTION 
1.1 A BRIEF HISTORY OF MARATHON AND THE MODERN MARATHON OF 26.2 
MILES. 
 
This review will give a brief history of the battle of marathon and recite a selection of the 
modern history of the marathon race focussing on those races that feature in the world 
marathon majors. The world marathon majors, founded in 2006, are series of six races 
(Tokyo, Boston, London, Berlin, Chicago, and New York) (Carter, 2015). The Majors also 
include the World Championships and the Olympics in the appropriate years of 
competition (Boston Athletic Association, 2015c). The world marathon majors offers a $1 
million prize purse split equally between the top male and female marathoners (Carter, 
2015). 
 
The battle of marathon 490BC is a pivotal point in European history and is credited with 
the inception of the marathon race. The legend of the Greek messenger Pheidippides 
running from Marathon to Athens with news of the Greek victory over the Persians 
became the inspiration for this athletic event. Tragically, the legend tells of Pheidippides 
death after the race due to exhaustion (Perros, 2001, Martin and Gynn, 2000). 
 
The marathon race, introduced at the first Modern Olympics in Athens in 1896, was 
originally run between Marathon and Athens on a course of approximately 25miles/ 40km 
in celebration of the ancient glory of Greece (Martin and Gynn, 2000, Perros, 2001, Clark, 
2003, Ostapuk, No Year). The distance was extended to 26 miles 385 yards to cover the 
distance from Windsor Castle to the Olympic Stadium in White City, London, for the 1908 
London Olympics (A&E Television Networks, 2014, Ostapuk, No Year). In Geneva, 1921, 
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the International Association of Athletic Federations (IAAF) standardized the marathon 
distance to 26 mile 385 yards /42.195 km based on the 1908 event held in London (Martin 
and Gynn, 2000) 
 
1.1.1 Boston Marathon 
The Boston marathon is the oldest of the city road races, inspired by the introduction of 
the marathon race at the modern Olympics in 1896. On April 19th 1897, the Boston 
Athletics Association Games concluded its athletic competition with a marathon of 24.5 
miles (39.4 km). The Boston Marathon is run on ‘Patriots Day’ annually (Boston Athletic 
Association, 2015a). The first race in 1897 started with 15 runners, in 2015, 30,333 
runners crossed the starting line (Boston Athletic Association, 2015b, Boston Athletic 
Association, 2015e). In 1924 the race was lengthened to the IAAF standard of 26 miles 
385 yards (Boston Athletic Association, 2015b). Women were not permitted to enter the 
Boston Marathon officially until 1972. Roberta "Bobbi" Gibb was recognized 
retrospectively, by the race organizers, as the first woman to run the entire Boston 
Marathon in 1966 (Boston Athletic Association, 2015b). In 1967, Kathrine Switzer, who 
had registered as "K. V. Switzer", was the first woman to run and finish with a race 
number. She finished despite race official Jock Semple trying to rip off her numbers and 
eject her from the race (Carter, 2015, Boston Athletic Association, 2015b). Because the 
Boston course drops 140 meters/459 feet from the start to the finish, and the start is west 
of the finish, allowing for a tailwind, the Boston Marathon does not satisfy two of the 
criteria necessary for the ratification of world records (IAAF, 2011). This means that the 
2:03:02 course record time by Geoffrey Mutai of Kenya On April 18, 2011 was the fastest 
marathon time ever (Boston Athletic Association, 2015d). However, the IAAF did not 
recognize this impressive time as a world record. Rita Jeptoo of Kenya holds the current 
women’s course record set in 2014 of 2:18:57 (Boston Athletic Association, 2015d). 
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1.1.2 New York Marathon 
The New York Marathon takes place on the first Sunday in November. Fred Lebow 
founded the race in 1970 (New York Road Runners, 2015). The first race consisted of 127 
competitors running four laps around the Park Drive of Central Park. Gary Muhrcke won 
the race in 2:31:38. Only 55 runners crossed the finish line (Fitzgerald and Fraioli, 2014). 
To commemorate the race and intended as a one-time event it was proposed in 1976 that 
the race be run through five boroughs of New York (Staten Island, Brooklyn, Queens, 
Bronx and Manhattan) this has remained the course route since (New York Road 
Runners, 2015). The 2014 New York marathon had grown to a record number of 50869 
starters and 50564 finished the race (Dalek, 2014). Geoffrey Mutai of Kenya, who ran 
2:05:06 in 2011, holds the New York Marathon, men’s course record. In 2003, Margaret 
Okayo set the current women’s course record of 2:22:31(Fitzgerald and Fraioli, 2014, 
Cryer, 2014). 
 
1.1.3 Berlin Marathon 
In 1974, a group of runners from one of Germany’s most prestigious athletics clubs, SC 
Charlottenburg founded the Berlin Marathon. There were 244 finishers of the first race. 
Günter Hallas of West Germany won the men’s race in 2:44:53 (GmbH, 2015a, bytepark 
GmbH, 2015a). In 1981, the race moved to the city centre of West Berlin from the 
Grunewald. Although the Berlin wall collapsed in November 1989 the city was not officially 
reunited. On the 30TH September 1990, three days before the reunification of the city, the 
course of the Berlin Marathon led through Brandenburg Gate and both parts of Berlin 
(GmbH, 2015a, bytepark GmbH, 2015a). The 2014 race saw 28,946 competitors, 
complete the Berlin Marathon. Seven men’s world records have been set at the Berlin 
Marathon(bytepark GmbH, 2015a). Dennis Kimetto of Kenya set the men course record 
and current world record of 2:02:57 in 2014 (GmbH, 2015b). The women’s course record 
is 2:19:12 set by Japans Mizuki Noguchi in 2005 (GmbH, 2015b).  
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1.1.4 Chicago Marathon 
A marathon in Chicago was first run in 1905. Twenty runners registered for the first race, 
15 actually started the race, and seven finished. However, Lee Flaherty founded the first 
‘modern’ Chicago marathon in 1977 with 4,200 starting and 2,128 crossing the finish line. 
Dan Cloeter won the first men’s race and Dorothy Doolittle the women’s in 2:17:52 and 
2:50:47 respectively. In 2014, The Chicago marathon had swelled to 40,801 finishers. The 
current course records are 2:03:45 held by Dennis Kimetto of Kenya set in 2013 and 
2:17:18 set in 2003 by Paula Radcliffe of the UK (Bank of America Corporation, 2015). 
 
1.1.5 London Marathon 
John Didsley and Christopher Brasher founded the London Marathon in 1981 after 
Brasher travelled to New York to compete in the marathon and write about his experience 
(London Marathon Ltd, 2015). The first race had 7055 starters. This grew dramatically in 
the following years and at the 35th annual London marathon in 2015, 37,675 runners 
crossed the finish line (bytepark GmbH, 2015a). Many of the runners were hand in hand 
to commemorate the winners of the first race in 1981, Dick Beardsley from the USA and 
Inge Simonsen of Norway in 2 hours 11minutes 48 seconds. Joyce Smith of the UK was 
the first woman to cross the line in 2 hours 29 minutes 57 seconds (London Marathon Ltd, 
2015). The current course record for the London marathon is held by Wilson Kipsang 
Kiprotich of Kenya who finished in a time of 2:04:29 in 2014. Paula Radcliffe is the 
women’s course record holder. In 2003 Radcliffe completed the London marathon in 
2:15:25 to set a new world record (bytepark GmbH, 2015a). 
 
1.1.6 Tokyo Marathon 
In 2007, Shintaro Ishihara former governor of Tokyo and, Yokei Kono former Japan 
Association of Athletics Federation president established the Tokyo Marathon and the 
Tokyo Marathon Foundation (Tokyo Marathon, 2015, bytepark GmbH, 2015b). The Tokyo 
course became part of the world marathon majors in 2012. At the inaugural race 25,000 
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runners started. In 2015, 35,556 started and 35,310 finished the race (bytepark GmbH, 
2015b). The winner of the first Tokyo marathon Daniel Njenga of Kenya completed the 
race in 2:09:45. The current course record for men and women were both set in 2014. 
Dickson Chumba of Kenya won the race in 2:05:42 and Tirfi Tsegaye of Ethopia finished 
in 2:22:23(bytepark GmbH, 2015b). 
 
The current world records for marathon recognised by the IAAF are 2:02:57, for men’s 
marathon set by Dennis Kimetto of Kenya on September 28, 2014 at the Berlin Marathon 
(IAAF, 2015a). The IAAF recognizes two world records for women both held by Paula 
Radcliffe of the UK. A "Mixed Gender" record of 2:15:25, set on 13th April 2003, at the 
London Marathon, and a "Women Only" record of 2:17:42 on 17th April 2005, also at the 
London Marathon (Baldwin, 2011, September 20, IAAF, 2015b). 
 
The marathon record progression towards a two hour marathon is the result of combined 
technological developments that allow improved training regimens including: nutritional 
strategies, improved footware, and specific year round training facilities such as 
environmental chambers that provide favorable ambient conditions to induce explicit 
training outcomes and, the birth of individuals with favorable genetic architecture 
according to Williams et al., (2011). 
 
1.2 INTER-INDIVIDUAL VARIABILITY IN HUMAN PERFORMANCE 
There is considerable difference in performance phenotypes between elite athletes and 
non-athletes. According to Bouchard et al., (1997), three factors contribute to inter-
individual variability in observed human performance: environmental factors such as diet 
and habitual physical activity levels, genetic variation and experimental error. The 
individual and combinatory contribution of these traits to human physical performance is 
considered complex. Complex traits are phenotypes affected by both multiple genetic and 
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environmental factors. These genetic factors comprise multiple genes and perhaps even 
multiple polymorphisms within those genes contributing in an additive effect to complete a 
polygenic profile (Bouchard et al., 1997, Williams and Folland, 2008, Ahmetov and 
Fedotovskaya, 2012). Gene-gene interactions (the effect of one variant being dependent, 
in part, on the genetic context in a given individual) add further complexity. The 
environmental influences, as well as gene-environment interactions (the effect of one 
variant being dependent, in part, on the environmental exposure an individual 
experiences), provide further factors to be considered (Bouchard et al., 1997). 
Nevertheless, careful selection of important and robust phenotypes and evidence-based 
selection of candidate genes can provide a solid basis on which to base hypothesis-based 
studies of genetics in human performance. 
 
1.3 THE GENETIC CONTRIBUTION TO HUMAN PERFORMANCE 
Detailed, human variation investigations were classically compared using twin pairs. Twin 
pairs usually share very similar or identical environments and thus the environmental 
selection pressures are minimised. Therefore, monozygotic twins (who share an almost 
identical genomic profile) usually show a higher correlation in certain phenotypes than 
dizygotic twin pairs (whose genomic profiles are non-identical), thus demonstrating the 
heritability, or genetic component in determining that trait (Bouchard et al., 1986a, 
Bouchard et al., 1986b, De Moor et al., 2007). Differences record between twin pairs are 
usually attributed to environments, rather than genetics. Though, recent studies have 
shown that many environmentally induced differences are reflected in the epigenome. 
Bouchard et al., (1986a) demonstrated in 106 monozygotic twin pairs, of both sexes, that 
the maximal rate of oxygen uptake (V̇O2 max) showed less variation than V̇O2 max data 
collected in 66 dizygotic twins of both sexes and 42 brothers. The monozygotic twin data 
was used to report the genetic variance effects. V̇O2 max was reported to have a genetic 
inheritance of 40%, indicating a significant genetic component for a key factor of 
endurance performance (Bouchard et al., 1986a). A more recent study that assessed 
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sporting achievement directly in female twins in the UK, demonstrated a clear 
dependence on multiple phenotypes including V̇O2 max, in which the heritability estimate 
was 66% (De Moor et al., 2007). Thus, twin studies have provided the initial evidence for 
a genetic contribution to sporting achievement, exercise capacity and trainability. The 
advent of DNA sequencing subsequently provided a tool to sequence the human genome 
with 99.99% accuracy (Schmutz et al., 2004). This meant that detailed investigation of 
genotype was then possible. The candidate gene approach to genetic association studies 
concentrates on a phenotype of interest and associations between genetic variants within 
genes that are thought to contribute to that phenotype. Suitable candidate genes for 
human performance are selected for investigation based on their already known 
physiological and or functional relevance to the phenotype of interest. This approach is 
limited as it relies on the theoretical or known physiology of the phenotype of interest. The 
rationale to focus on areas specific loci of the genome that are known to be biologically 
relevant to a phenotype is that mutations may directly alter the function of a gene and thus 
be causative in the phenotype of interest. The candidate gene approach to identifying the 
genetic contribution to human performance started with the ACE gene in 1998 
(Montgomery et al). Further advances in sequencing technology and other laboratory tools 
such as gene chips, plus the development of large data sets such as biobanks and the 
HapMap Project (Gibbs et al., 2003, The International HapMap Consortium, 2005, Frazer 
et al., 2007) allowed completion of genetic investigations on a mass scale of several 
hundred polymorphisms at a time, facilitating the investigation by sports scientists into the 
genetic variability in human performance. As such, the field of human performance and 
exercise has moved on from twin studies and now uses a variety of more precise methods 
in molecular biology. Genetic case-control studies that compare athlete populations with 
non-athlete controls and cross-sectional studies completed in non-related individuals 
attempt to associate genotype with phenotype. An example of such a project investigating 
the genetic contribution to physical fitness is the Health, Risk factors, Exercise Training 
and Genetics (HERITAGE) study (Bouchard et al., 1995). In HERITAGE, 700 sedentary 
individuals from almost 200 families participated in a multi-centre collaboration to collect 
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data before and after a period of controlled endurance training. Sedentary behaviour is 
defined as any waking behaviour characterized by an energy expenditure ≤1.5 METs 
while in a sitting, reclining or lying posture (Tremblay et al., 2017). The aim of the 
HERITAGE project was to investigate the role of likely polymorphisms and their genetic 
contribution to the cardiovascular, metabolic and hormonal responses to endurance 
training. These studies range in their genomic depth from single point mutations to full 
genome scans (Bouchard et al., 1998, Bouchard et al., 1999, Bouchard et al., 2000) (not 
equivalent to whole genome sequencing) and provide insight into several candidate genes 
thought to be associated with human performance. 
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1.4 IDENTIFYING CANDIDATE GENES 
The main challenge for genetics researchers in human performance is to determine which 
gene or combination of genes is associated with the variation in the phenotype of interest. 
In essence, the aim is to pinpoint the precise genetic location where allele variation exists 
that influences the nature or extent of expressed protein, and thus phenotype (Bouchard 
et al., 1997, Botstein and Risch, 2003) or to understand the activity and expression of 
protein–coding genes and their modulation by the regulome. There are generally two 
approaches used to identify candidate genes these are outlined in the following sections. 
 
1.4.1 The Candidate Gene Approach 
The initial approach used by sports scientists and geneticists to identify sporting 
genotype-phenotype associations was the ‘candidate gene approach’ (Bouchard et al., 
1997). The candidate gene approach uses well-established physiological theory to identify 
key metabolic or structural proteins that can be used to identify candidate genes. 
Screening of the identified genes encoding these key proteins ascertains common genetic 
sequence variations or polymorphisms that alter translation of the gene and thus protein 
production - the physiological significance of this polymorphism is then investigated 
(Lander and Schork, 1994). An example of this in humans is a rare mutation in the 
myostatin (MSTN) gene. Myostatin is a protein produced by muscle cells that acts to 
inhibit myogenesis and growth, thus inhibition of myostatin leads to muscle hypertrophy 
(Schuelke et al., 2004). The mutation is located at the splice site in the first intron and 
alters splicing that attempts to translate the first 108 bp of the sequence in that intron into 
an amino acid sequence. This completely alters the protein produced, effectively knocking 
out the gene because a premature stop codon in the first intron is read, instead of spliced 
out. In 2004, a 4-year old German boy with greater muscle mass than his peers of similar 
age, and who was considerably stronger than other children his age had the rare mutation 
in both copies of the myostatin gene that caused muscular hypertrophy (Schuelke et al., 
2004). The myostatin mutation was identified in that individual using existing physiological 
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knowledge – i.e. the candidate gene approach. Further genetic variations, relevant to 
human physical performance, that have been identified using the candidate gene 
approach, include the frequently studied ACE and ACTN3 gene polymorphisms. This 
approach to candidate gene selection makes understanding and extrapolating the 
polygenic nature of human physical performance rather difficult as gene polymorphisms 
are often investigated individually rather than in combination. Though, because the 
physiology of the phenotype of interest has often been mapped in advance those proteins 
can be traced back to genes and SNIPs that are likely to have a causative effect. Although 
it should be noted, should a list of identified target genes or SNIPs not include the 
causative variant then this method will fail to detect an association. In an attempt to fully 
characterise the polygenic nature of human performance, increasingly sports scientists 
are favouring another method the Genome Wide Association Study (GWAS). 
 
1.4.2 Genome-wide Association Studies 
The GWAS is a second approach used to identify candidate genes. This method relies on 
a sufficiently large (and thus statistically powered) sample in which to detect an 
association between the genotype and the phenotype of interest. In contrast to the 
candidate gene approach, GWAS do not begin with hypotheses about associations 
between specific genetic variants and relevant phenotypes. Rather, GWAS studies are 
‘hypothesis-free’ and simultaneously consider possible associations between large 
numbers of genetic variations and a given phenotype. Thus, GWAS identifies 
chromosomal regions of interest or loci associated with each other and correlated with the 
phenotype of interest (Visscher et al., 2012). Recently, an international consortium of 
researchers in exercise genomics has been established (Tanaka et al., 2016) which plans 
to, in time, use GWAS and other approaches (e.g. whole genome sequencing) to address 
relevant research questions. However, effective use of the GWAS approach requires 
many thousands of participants to provide the necessary statistical power to identify true 
genotype-phenotype associations from a mass of probable false positive associations – 
the generally accepted level of significance is 5 x 10-8 (www.ebi.ac.uk/gwas/docs/about). 
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Currently, cohorts of hundreds of thousands of research participants (whether elite 
athletes or other individuals with relevant phenotype data) do not exist. Further to this 
funding for this type of research is likely to be of limited availability for sporting purposes 
and most likely to be provided to the medical and health sectors to investigate pathology, 
this means the feasibility of doing such a study may be limited as the causal variants for 
most phenotypes of interest to human sporting performance are unlikely to be available in 
array-based SNIP datasets and will need to be produced at considerable cost. Therefore, 
the candidate gene approach remains a valuable method to investigate genotype-
phenotype associations in exercise science, without the need for extremely large cohorts 
and commensurate levels of funding. 
 
1.5 SELECTING CANDIDATE GENES  
In the candidate gene approach, it is important to have a physiological rationale for the 
proposed association between a candidate gene and the resulting phenotype of interest 
(Bouchard et al., 1997). The method of selection of the phenotype must be consistent 
across the test population and inclusion criteria must be met by all research participants. It 
is important when selecting a test population to ensure factors such as gender, age 
ethnicity and athlete status are taken into consideration should the research sample not 
be homogenous (Ahmetov and Fedotovskaya, 2012). This reduces experimental error and 
the contribution of environmental factors. Usually research participants are screened 




Identifying genetic polymorphisms within individual candidate genes that account directly 
for the phenotype of interest is a challenging process. Sporting performance is a 
combination of several traits, each of which themselves could be considered complex. 
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The extent of the individual SNIP contribution to genetic variation and inter-individual 
variability especially in a complex trait such as human performance continues to be 
debated due to a lack of clarity about the associated physiology of individual 
polymorphisms or groups of polymorphisms of interest and conflicting reported data in 
groups of athletes with limited definition or description. The noted variation may be 
attributed to the likely polygenic nature of an athlete’s genetic profile (Williams and 
Folland, 2008, Ahmetov et al., 2009), though the athletes and phenotypes of interest need 
to be well defined. In addition, it should be noted, because of the complex nature of the 
phenotypes associated with human performance, there is difficulty in quantifying the 
genetic contribution alone. 
 
The work described in this thesis investigates genetic characteristics potentially 
associated with human performance, specifically marathon running. Endurance running 
including marathon running is both a mass-participation sport amongst non-elite athletes 
as well as a highly competitive elite sport on an international scale. Due to the scale of this 
project the candidate gene approach was adopted to investigate selected polymorphisms 
that were chosen based on the existing literature. 
 
In Chapter 2, a review of the literature is presented. It first addresses the physiological 
characteristics of elite marathon runners with specific focus on aerobic power, running 
economy, lactate threshold, V̇O2 kinetics and skeletal muscle fibre proportion. A review of 
the current evidence regarding genetic associations with endurance phenotypes and elite 
endurance athlete status is further presented in Chapter 2, which includes reference to 
marathon performance where appropriate. Lastly, the evidence regarding genetic 
associations with the aforementioned phenotypes in eight selected gene polymorphisms is 
also reviewed. In Chapter 3, some of the core methods that are common to each of the 
following experimental chapters are described. Chapters 4-7 each consist of an 
investigation into the genotype of elite marathon runners and their individual performance 
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capabilities (personal best competitive marathon times). Chapter 4 addresses two genes 
that form part of the renin angiotensin aldosterone system (RAAS), namely ACE and AGT. 
Chapters 5, and 6 address a single gene each (ACTN3, and PPARGC1A, respectively). 
Chapter 7 addresses three polymorphisms in two genes encoding for uncoupling proteins 
(UCP2, UCP3). Chapter 8 incorporates the aforementioned genes into a Total Genotype 
Score analysis. The final chapter (Chapter 9) integrates the findings and conclusions from 
the preceding five chapters and draws conclusions based on the original data contained in 
this thesis. 
 
The aims of this research programme were to (1) compare genetic characteristics of elite 
athletes, sub-elite athletes and non-athletes; (2) compare personal best competitive 
marathon running performances between runners with differing genetic characteristics. 
The objectives were therefore to address aims (1) and (2) for specific variations in the 
genes identified above, namely ACE, AGT, ACTN3, PPARGC1A, UCP2 and UCP3. 
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2 LITERATURE REVIEW 
2.1 THE PHYSIOLOGY OF MARATHON RUNNING 
2.1.1 Introduction 
The important determinants of the elite marathon runner’s endurance performance are 
multifactorial and thus complex. This is evidenced by the large body of knowledge 
published from the 1970’s until the present day. The most common determinants of 
endurance performance were summarised by Bouchard et al. (1997) who suggested that 
each was actually a heading for a larger group of factors, traits and determinants rather 
than a single characteristic. These included, physiological traits, submaximal exercise 
tolerance and efficiency, thermoregulation, nutritional status, biomechanical factors, body 
composition, V̇O2 max, social factors and a group termed ‘others’. In particular, however, 
running the marathon distance of 42.195 km (26 miles 285 yards) on a seriously 
competitive basis undoubtedly requires an extremely high level of aerobic physiological 
function.  Thus, elite athletes provide a unique model in which to base scientific research 
into human physiology at one extreme of the performance-disease continuum. Elite 
marathon runners have typically undergone extensive training to produce large 
physiological adaptations (e.g. in left ventricle size, the oxidative capacity of skeletal 
muscle, etc.) that are probably a result of an interaction between the exercise training 
stimulus and favourable genetic characteristics (Ruiz et al., 2009). World marathon 
records (as at June 2017) are 2 h 2 min 57 s for men and 2 h 15 min 25 s for women 
(http://www.iaaf.org/records/by-category/world-records). The history of the progression of 
marathon records (and other elite performances close to those records) to their current 
levels has been described in detail, with interesting conclusions drawn regarding the 
influence of BMI, geographic ancestry and ambient environmental conditions such as 
temperature and humidity (Marc et al., 2014). Sophisticated mathematical modelling 
predicted further improvements of up to 3% from the 2008 records, with rather larger 
improvements anticipated for men than for women, although the record for men was still 
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expected to remain in excess of 2 h (Denny, 2008).  Indeed, since that paper in 2008, the 
marathon record for men (2 h 3 min 59 s at that time) has been improved on three 
separate occasions to its current level, while the record for women has not changed. It is 
beyond the scope of this piece to extensively review the contribution to marathon running 
of all of its determinants. However, the primary physiological factors will be addressed in 
the following text (see Figure 1). 
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2.1.2 Important Measurable Physiological Parameters 
The performance of an endurance athlete in a sport such as marathon running is 
influenced by a number of well-documented factors. These include physique, 
biomechanical, physiological, behavioural, psychological and social characteristics 
(Bouchard et al., 2008). Classical exercise physiology knowledge, synthesised in several 
respected textbooks (Astrand and Rodahl, 1986, McArdle et al., 2009) from extensive 
original research, confirms that maximal performance during a physical effort in excess of 
2 h that is required to complete a marathon requires high rates of aerobic metabolism to 
be sustained and used efficiently during running. More specifically, high aerobic power 
relative to body mass (maximal rate of oxygen uptake; V̇O2 max), the ability to sustain a 
high percentage of that aerobic power for prolonged periods (strongly related to the 
lactate threshold concept, but also influenced by any sustained rise in oxygen uptake 
beyond that predicted from the relationship between VO2 and exercise intensity at lower 
intensities (V̇O2 kinetics) and an efficient conversion of the energy derived from energy 
substrates for ATP resynthesis and subsequent ATP breakdown into horizontal motion 
during running (running economy) are the key parameters that determine marathon 
running performance (Joyner, 1991, Jones and Carter, 2000). These concepts are 
discussed in more detail in the following sections, in addition to skeletal muscle fibre type 
proportion that has relevance to each of the other concepts discussed. 
 
2.1.2.1 Aerobic power 
Aerobic power, also known as the maximal rate of oxygen uptake or V̇O2 max, is defined as 
the maximal rate at which oxygen can be taken up and utilised by the body during intense 
exercise at normal barometric pressure (Bassett and Howley, 2000). In humans, V̇O2 max is 
usually limited by the ability of the cardiorespiratory system to deliver oxygen to the 
exercising muscles although a high capacity for those activated muscle fibres to 
effectively use the oxygen delivered (thus Type I fibres are more advantageous) is also 
required (Bassett and Howley, 2000, McPhee et al., 2009). V̇O2 max is a clearly definable, 
measurable trait that has high validity and reliability in predicting endurance performance 
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(Bassett and Howley, 2000, Costill, 1970, Costill et al., 1971b, Saltin and Astrand, 1967). 
Traditionally V̇O2 max has been the best laboratory measure for understanding long 
distance competitive running performance (Foster, 1983). Elite runners have exceptionally 
high V̇O2 max usually above 70 ml kg-1 min-1 (Costill, 1970, Costill et al., 1971b, Saltin and 
Astrand, 1967) a much higher level than those reported in untrained individuals and 
thought to be the result of training. Elite marathon runners complete a marathon in just 
over 2 hours and these amazing performances require exercise at a sustained intensity of 
80%-90% of an athlete’s V̇O2 max (González-Alonso, 2007). The repeated correlation 
between fast running performance and high V̇O2 max (Farrell et al., 1979, Hagan et al., 
1981, Foster, 1983, Hagan et al., 1987) supports the theory that a high V̇O2 max is essential 
to compete in marathon at an elite level (Foster, 1983). 
 
2.1.2.2 Economy 
Running economy is considered a good predictor of racing performance. In trained 
runners with similar values of V̇O2 max, running economy correlates more strongly with 
performance than does V̇O2 max itself (Saunders et al., 2004, Conley and Krahenbuhl, 
1980). Running economy is defined as the energy demand for a given velocity of 
submaximal running (Lacour and Bourdin, 2015). Running economy is determined by 
measuring the consumption of oxygen (V̇O2) of an individual at a given (practically 
relevant) running speed (Maud and Foster, 1995). In the marathon, athletes who are able 
to consume less oxygen while running at a given velocity have a better running economy 
than those who require more oxygen at the same velocity. Running economy may 
therefore be influenced by running style learned through training. All else being equal, a 
more economical runner will be able to either run faster than a less economical competitor 
at a given V̇O2, or run at the same velocity as a competitor at a lower V̇O2 and thus a 
lower percentage of V̇O2 max (thus probably reducing heart rate, lactate production and the 
utilisation of carbohydrate as an energy substrate). Accordingly, when compared with 
other marathon runners, one world champion marathon runner demonstrated little aerobic 
power superiority to other elite runners (Costill et al., 1971b). This suggests marathon 
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running success is influenced by running economy and the ability to utilise a large fraction 
of a well-developed V̇O2 max (Costill et al., 1971b). Saunders et al. (2004) reported that, in 
highly trained or elite athletes, running economy was influenced a number of physiological 
and biomechanical factors including increased mitochondrial density and function and the 
activity of various oxidative enzymes. Proliferation of mitochondria and changes in 
mitochondrial enzyme activity have long been known to occur in skeletal muscle in 
response to endurance exercise training (Holloszy, 1967). Bassett and Howley (2000) 
confirmed that endurance training causes an increase in the activity of mitochondrial 
enzymes that, for any given V̇O2, will improve endurance performance by enhancing fat 
oxidation and decreasing lactic acid production. This metabolic adaptation of skeletal 
muscle towards a Type I fibre phenotype is thought to be crucial for improvements in 
economy, efficiency and submaximal endurance performance (Bassett and Howley, 2000, 
Coyle et al., 1992), of which marathon running is an extreme but obviously most pertinent 
example.  Jones and Carter summarise evidence for training-induced improvements in 
running economy (Jones and Carter, 2000). 
 
2.1.2.3 Lactate Threshold 
As explained expertly by Jones and Carter (Jones and Carter, 2000), lactate threshold 
(the exercise intensity corresponding to an increase in the concentration of blood lactate 
above resting levels) is another key, innate and readily-measured parameter related to 
endurance running performance. Exercise above the lactate threshold produces a 
nonlinear increase in metabolic, respiratory and perceptual stress (Katch et al., 1978, 
Simon et al., 1983). Sustained exercise above the lactate threshold is associated with 
metabolic acidosis (accumulation of H+ in muscle tissue and/or blood) which, at the level 
of the skeletal muscle fibre, inhibit phosphofructokinase (the rate limiting enzyme in 
glycolysis) and inhibit the binding of Ca2+ to troponin, thus contributing to local muscular 
fatigue (Sahlin, 1992). On the other hand, the accumulation of H+ is indicative of increased 
muscle glycogen utilisation at the expense of deriving energy for ATP resynthesis from the 
breakdown of fatty acids (Boyd et al., 1974), and higher rates of glycogen utilisation during 
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a marathon are strongly related to premature fatigue (Burke, 2007, Costill et al., 1971a, 
Costill et al., 1971b). It is important to note, however, that an exercise intensity 
corresponding to lactate threshold (as defined at the beginning of this paragraph) is 
actually exceeded by many competitive athletes during competition and some training 
sessions (Jones and Carter, 2000). The concept of the maximal lactate steady state 
(MLSS) is therefore probably more practically relevant than lactate threshold per se to 
competitive athletes. MLSS may be defined as the highest exercise intensity that can be 
maintained with a stable or only a small increase (< 1 mmol L-1) in blood lactate 
concentration during the period 10-30 min after the onset of constant intensity exercise 
(Jones and Doust, 1998). Thus, an increase of blood lactate concentration above resting 
levels (lactate threshold) is not as accurate an indicator of fatigue related to acidosis as 
MLSS. Nevertheless, the lactate threshold and MLSS are very closely related in 
conceptual and physiological terms, and lactate threshold is much more easily measured 
in a single, short laboratory test. Elite endurance athletes typically have lactate threshold 
values approaching ~80% of V̇O2 max (and MLSS a little higher), which is considerably 
higher than other athletes and non-athletes (Jones and Carter, 2000). Elite marathon 
runners typically have V̇O2 max values ranging from ∼70 to ∼85 ml·kg−1·min−1 . 
 
2.1.2.4 VO2 Kinetics 
At constant exercise intensities below the lactate threshold, ventilatory and pulmonary gas 
exchange responses respond quite rapidly to the onset of exercise to attain a new steady 
state within 2-3 min (Whipp and Wasserman, 1972). However, at exercise intensities 
above MLSS there is an additional, relatively slow increase in ventilation rate and V̇O2 and 
that probably reflects the innate recruitment of an increasing recruitment of faster, larger, 
less efficient motor units as fatigue develops within muscle fibres of the motor units 
recruited nearer the initial onset of exercise (Barstow et al., 1996). That secondary 
increase in V̇O2 during constant load exercise above MLSS has become known as the 
V̇O2 slow component (Jones and Carter, 2000). All else being equal, a smaller V̇O2 slow 
component will allow a marathon runner to complete a marathon more quickly than a 
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competitor even if V̇O2 max and running economy at intensities below MLSS are 
comparable between the two runners. Therefore, V̇O2 kinetics, although related to V̇O2 max, 
lactate threshold (or MLSS) and running economy at certain intensities, has relatively 
recently been added to those other three concepts as an important parameter that (with 
appropriate real-time measurement of pulmonary gas exchange) is now widely considered 
one of the four main measurable components of running performance during laboratory 
assessment of endurance runners. 
 
2.1.2.5 Skeletal Muscle Fibre Type 
Skeletal muscle fibres are divided into two sub groups based on specialized contractile 
and metabolic properties and on distinctive patterns of muscle gene expression (Naya et 
al., 2000). Type I fibres are smaller in diameter and produce force as a relatively slow 
‘twitch’ in response to brief electrical stimulation, but have high levels of mitochondria and 
capillarity to support oxidative metabolism, are more efficient, and are therefore rightly 
considered fatigue-resistant fibres. Type II fibres can be denoted IIa or IIx in humans while 
IIb (faster contractile properties) also exists in rodents. Type II fibres produce a relatively 
large and fast ‘twitch’ response to electrical stimulation, have a larger diameter for 
increased contraction strength and are generally found in larger motor units (Folland and 
Williams, 2007). Type II fibres rapidly release calcium from an extensive sarcoplasmic 
reticulum, rely on their large glycolytic enzyme capacity for rapid release of energy from 
glycogen and thus have lower levels of mitochondria and oxidative enzymes than Type I 
fibres and are less mechanically efficient (Boron and Boulpaep, 2012). 
It is well-established that skeletal muscle fibre composition differs between elite athletes in 
different sports (Ahmetov et al., 2011). Endurance training like that completed by 
marathon runners causes various innate changes to the activated skeletal muscle as a 
result of the high frequency, low force output, activity (Brooke et al., 2005). This leads to 
increased endurance capacity and fatigue resistance primarily via an increase in the 
expression of genes that are components of mitochondrial proteins and oxidative 
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enzymes and resultant increases in fatty acid oxidative capacity (Brooke et al., 2005). It is 
thought that these changes in gene expression, in response to prolonged endurance 
training and repeated stimuli for activation of some genes and suppression of others, 
slowly induce the myoplasticity of Type 2 fast twitch glycolytic fibres towards Type 1 slow 
twitch, high-oxidative fibres (Malisoux et al., 2007, Pette and Staron, 1997). Accordingly, 
high proportions of Type I muscle fibres are observed in the trained muscle of endurance 
athletes (Gollnick et al., 1972, Gollnick et al., 1973, Ahmetov et al., 2011) such as 
marathon runners. It is thought that in both rodent and human skeletal muscle, fibre type 
characteristics are controlled by calcium-dependent signalling via the calcium, calmodulin-
dependent protein phosphatase, calcineurin (Naya et al., 2000, Seto et al., 2013). 
Calcineurin has been shown to stimulate slow fibre specific gene promotors in in vitro 
cultured rodent skeletal muscle cells (Naya et al., 2000). Calcineurin, once activated, can 
(via a promoter) upregulate slow twitch Type I fibre gene expression effectively 
reprogramming skeletal muscle fibres from the fast twitch Type II phenotype to the slow 
twitch Type I phenotype, thus increasing the proportion of Type I fibres in the muscle. This 
may positively affect skeletal muscle mitochondrial function and consequently marathon 
performance, via influences on the parameters more amenable to measurement than 
muscle fibre type composition itself, namely aerobic power, economy, lactate threshold 
and V̇O2 kinetics, as described in the preceding sections. 
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Figure 1 Important measurable parameters of marathon performance 
 
2.1.3 Conclusion 
To briefly conclude this section on the physiology of marathon running and bring the focus 
back to real-world competitive performances once again, the effort from athletes, coaches 
and scientists to develop a male athlete sufficiently to complete the marathon in under 2 h 
receives much attention (www.sub2hrs.com). For example, a special issue in the Journal 
of Applied Physiology (Joyner et al., 2011) with contributions from many authors in many 
separate opinion pieces provides several novel views and perspectives on this fascinating 
topic. It is illuminating to read the views of some eminent scientists about the future of 
sport performance in this historic event, especially when they do not appear to agree. Of 
particular interest in the context of the present thesis is the article in that special issue by 
Williams regarding the importance of genetics in the potential progression of the male 
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marathon record towards or even below the 2 h ‘barrier’ (Williams, 2011). In this article 
Williams commented on the prominence of the genetic contribution to marathon 
performance and proposed a TGS approach to describing the combined genetic 




2.2 GENETIC ASSOCIATIONS WITH ENDURANCE PERFORMANCE AND ELITE 
ATHLETE STATUS 
2.2.1 Introduction 
As outlined in the previous sections the primary determinants of endurance performance 
in elite marathon running are multifactorial, polygenic in nature and thus complex. 
Although complex in nature, scientists have attempted to elucidate the genetic 
contribution to endurance performance and elite athlete status for decades. This 
originated in 1974, with an association study between athlete participation in the 1968 
Mexico City Olympic Games and allelic variation in red blood cell antigens or enzymes, 
although no association was reported (De Garay et al., 1974). A further study was 
completed during the 1976 Montreal Olympic Games to search for markers of aerobic 
performance in a group of Caucasian endurance athletes and controls. Red blood cell 
antigens and four erythrocyte enzymes were compared between athletes and controls, 
although again there were no reported differences between the groups (Chagnon et al., 
1984, Couture et al., 1986) the lack of association may have resulted in a lack of 
sensitivity of the methods used at the time. Between the first publication of a genetic 
association study in an athlete population and the present day there has been an 
explosion of interest in the genetic contribution to human performance and elite athlete 
status. The increasing number of publications in the field year on year reflect this. 
 
Between 2000 and 2007, common genetic variants associated with at least one 
performance phenotype were reported in a human gene map for performance and health-
related fitness phenotypes (Rankinen et al., 2001, Rankinen et al., 2002, Pérusse et al., 
2003, Rankinen et al., 2004, Wolfarth et al., 2005, Rankinen et al., 2006, Bray et al., 
2009). A more recent literature review by Ahmetov and Fedotovskaya (2012) identified 79 
gene polymorphisms associated with elite athlete status. Of these, 59 were associated 
with endurance performance. In the section that follows, the evidence for selected nuclear 
51 
and mitochondrial candidate genes will be reviewed for their individual contribution to 
endurance performance with a focus on elite endurance athlete status and marathon. 
 
2.2.2 Renin Angiotensin Aldosterone System (RAAS) 
ACE was the first gene to be considered a human physical performance gene 
(Montgomery et al., 1998, Puthucheary et al., 2011, Gayagay et al., 1998). The encoded 
protein is a key element in the Renin Angiotensin Aldosterone System (RAAS). RAAS is 
predominantly characterised as an endocrine system although paracrine, autocrine and 
intracrine elements of RAAS influence tissues locally and at a cellular level (Dzau, 1988, 
Dzau, 1989, Paul et al., 2006). As an endocrine system RAAS is a key regulator of blood 
pressure homeostasis (Bae et al., 2007) amongst other physiological processes that may 
influence endurance performance through V̇O2 max, V̇O2 kinetics, Running economy and 
lactate threshold. The RAAS is a complex molecular pathway initiated by the detection of 
low blood pressure (hypotension) by the juxtaglomerular cells baroreceptors in the 
afferent arteriole of the nephron causing the release of the aspartyl protease renin.  
52 
 
Figure 2: A simplified schematic of the RAAS pathway to indicate the roles 
of AGT and ACE 
 
Angiotensinogen (AGT) synthesized in the liver (see Figure 2), in response to 
hypovolemia and thus blood pressure or a decrease in sodium concentrations, cause the 
renin dependent catalyses of the α-2 globulin AGT to the inactive decapeptide angiotensin 
I (ANGI). ANGI is transported in the blood to the pulmonary circulation where the 
dipeptidyl carboxypeptidase angiotensin I converting enzyme (ACE) cleaves the 
dipeptides from the C-terminal His-Leu dipeptide to give the vasoactive peptide 
angiotensin II (ANGII) (Woods et al., 2000). ANGII causes hypertension via the AT-1 
receptor in three ways. Firstly, ANGII directly stimulates the AT-1 receptor in vascular 
smooth muscle cells which causes vasoconstriction of the efferent arterioles. This causes 
a reduction in blood flow and an increase in hydrostatic pressure increasing the total 
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peripheral resistance of the vasculature and thus the mean arterial pressure. In the kidney 
the increase in hydrostatic pressure favours filtration in an attempt to regulate the blood 
pressure. Secondly, ANGII binds to expressed membrane bound AT-1 receptors of 
vascular endothelium causing a hypertensive response via a direct reduction in the 
synthesis of the vasodilator nitric oxide. ACE further catalyses the inactivation of 
bradykinin (Erdös and Skidgel, 1987, Woods et al., 2000) required for the synthesis of 
nitric oxide causing a further reduction in its availability. The reduced availability of nitric 
oxide and the AT-1 receptor activation by ANGII stimulates the release of aldosterone 
from the zona glomerulosa of the adrenal gland initiating the third cause of hypertension. 
Aldosterone affects the sodium potassium ATPase pump on principal cells influencing the 
reabsorption of both sodium and water (Myerson et al., 1999). This increased plasma 
volume can cause hypervolaemia and lead to hypokalaemia and hypertension if not 
regulated (Boron and Boulpaep, 2012). Further to this aldosterone effects the ATP pump 
of alpha intracalated cells in the cortical collecting tubule, causing the increased excretion 
of hydrogen ions (that acidify the urine) and the reabsorption of water. These two 
pathways result in hypervolaemia and hypertension. Negative feedback resulting from the 
hypertension is detected by the juxtaglomerular baroreceptors and causes the kidney to 
reduce the production of renin regulating blood pressure. 
 
As a paracrine system the RAAS mediated release of ANGII causes cardiac myocyte 
hypertrophy by increasing DNA synthesis, protein synthesis and cell number via the 
membrane expressed AT-1 receptor, (Sadoshima and Izumo, 1993). ANGII initiates a gq-
protein coupled cascade causing the activation of phospholipase C. Phospholipase C 
hydrolyses phosphatidylinositol 4,5,-bisphosphate (PIP2) to produce diacylglycerol (DAG) 
and inositol 1,4,5, triphosphate (IP3). IP3 acts on the sarcoplasmic reticulum to release 
intracellular calcium stores that increases cardiac inotropy and stoke volume (Levick, 
2013, Boron and Boulpaep, 2012) to meet the oxygen demand of the respiring skeletal 
muscle. This can result in a normal remodelling of the cardiac muscle to the increased 
physiological demand for oxygen by the skeletal muscle as a result of the large volumes 
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aerobic cardiovascular exercise commonly completed by endurance athletes as part of 
their training and competition program (Levick, 2013). This adaptation is commonly known 
as Athletic Heart Syndrome. Athletic heart syndrome causes the heart ventricles to 
enlarge as a result of eccentric and concentric hypertrophy of the muscle wall (Levick, 
2013). During eccentric hypertrophy new sarcomeres are added in series to those already 
constructing the cardiac wall causing the wall to extend further (Levick, 2013). Concentric 
hypertrophy causes sarcomeres to be added in parallel to those already in the wall 
causing the wall to thicken further increasing cardiac inotropy, stroke volume and thus 
cardiac output and blood pressure (Levick, 2013). The physiological mechanisms outlined 
make the key RAAS components ACE and AGT attractive as candidate genes for blood 
pressure homeostasis, oxygen delivery to respiring skeletal muscle during endurance 
exercise and thus endurance performance in competition. 
 
2.2.2.1 Angiotensin I Converting Enzyme - ACE 
The structural organisation of ACE gene was determined in 1991 (Hubert et al., 1991). 
The ACE gene is located on chromosome 17q23 and consists of 26 exons. The insertion 
deletion (I/D) polymorphism in this gene refers to an Alu repetitive sequence 287 base 
pairs (bp) long, in intron 16, resulting in three genotypes, DD and II homozygotes and ID 
heterozygotes (Rigat et al., 1992). The insertion I allele has been reported to cause lower 
ACE activity in serum and cardiac tissue (Rigat et al., 1990, Danser et al., 1995). 
 
The ACE I and D alleles are both favourably associated with human performance in elite 
athlete populations. ACE I allele associations with endurance performance are reported in 
elite endurance runners (Myerson et al., 1999, Alvarez et al., 2000, Scanavini et al., 2002, 
Hruskovicova et al., 2006), Ironman triathletes (Collins et al., 2004), elite rowers (Gayagay 
et al., 1998, Jelaković et al., 2000, Ciȩszczyk et al., 2009), elite cyclists (Alvarez et al., 
2000, Scanavini et al., 2002), elite swimmers (Tsianos et al., 2004) and elite mountaineers 
(Montgomery et al., 1998).  
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Myerson et al. (1999) reported an I allele association with competitive running distance in 
British Olympians. Athletes running longer distances had higher I allele frequencies than 
those running shorter distances, healthy control participants and athletes in 19 other 
sporting disciplines where endurance performance was not a primary determinant of 
success. Alvarez et al. (2000) genotyped 60 elite Spanish athletes including 20 long 
distance runners (marathon and cross-country), and similarly to Myerson et al. (1999) 
reported an increased frequency of the I allele in the elite athlete population compared to 
400 controls. Scanavini et al. (2002) selected an elite group of 52 athletes from their initial 
athlete cohort. Olympic Games participation and V̇O2 max values of 65-80 ml / kg / min -1 for 
aerobic athletes determined elite athlete status, while elite anaerobic athletes had V̇O2 max 
values of 40-55 ml / kg / min -1. Again, the authors reported a higher frequency of the II 
genotype in the 33 Olympic aerobic athletes than in the 19 Olympic anaerobic athletes or 
controls, with the most marked difference between track and field runners and controls. 
Increased ACE I/I genotype frequency was determined amongst marathon runners placed 
1st to 150th (classified by performance based on marathon competition results) (p = <0.01) 
of the 215 elite marathon runners participating in the study suggesting an association 
between the ACE I/D polymorphism and elite marathon performance (Hruskovicova et al., 
2006). 
 
Hagberg et al. (2001) reported that the increased frequency of the ACE I allele or the II 
genotype in endurance based athletes may be partially explained by an association of the 
ACE II genotype with higher V̇O2 max (Hagberg et al., 1998, Hagberg et al., 2001) . 
Furthermore, Hagberg et al. (2002) reported elite female runners with the ACE II genotype 
had a 25% greater cardiac output than ACE DD genotype women runners, with 
corresponding genotype-dependent differences in stroke volume observed in both 
physically active and athletic women. Hagberg et al. (2001) further hypothesised based on 
the work of Montgomery et al. (1997) that ACE II genotype carriers (due to less LV 
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hypertrophy) were superior at matching cardiac afterload to cardiac output and thus more 
efficient at modulating cardiovascular function during physical exertion. Gayagay et al. 
(1998) went on to hypothesize that the ACE I allele and II genotype may result in reduced 
cardiac afterload and thus enhanced ventriculo-vascular coupling efficiency during 
exercise. Hagberg et al. (2002) reported after measuring cardiovascular haemodynamics 
during maximal exercise that ACE genotype had not influenced stroke volume or heart 
rate and thus cardiac output but that female runners with the II genotype had considerably 
higher maximal arteriovenous O2 difference than those with the ID and DD genotypes. 
The authors concluded that peripheral vascular mechanisms that determine V̇O2 max and 
thus endurance performance may be influenced by ACE genotype. These peripheral 
vascular mechanisms may in part be related to a higher proportion of slow-twitch type 1 
fibres in human skeletal muscle with the ACE I allele (Zhang et al., 2003, Ahmetov and 
Rogozkin, 2009). The II genotype is also related to a genotype-dependent improvement in 
skeletal muscle mechanical efficiency of ~9% with aerobic training (Williams et al., 2000). 
 
In contrast, there are investigations that have found no significant association between the 
ACE I allele and endurance performance and related phenotypes (Rankinen et al., 2000c, 
Scott et al., 2005, Oh, 2007, Papadimitriou et al., 2009, Ash et al., 2011). For example, 
the HERITAGE study found no association between baseline V̇O2 max and ACE genotype 
(Rankinen et al., 2000b), while in one subgroup training-induced changes in V̇O2 max were 
associated with the ACE DD genotype. Similarly, Day et al. (2007), having found that the 
ACE genotype was strongly associated with circulating ACE activity, found no association 
to support a role for systemic ACE activity or ACE genotype in the regulation of endurance 
performance in females with low physical activity. 
 
In those studies that included athlete populations, elite participants were included. 
However, they varied in endurance sporting discipline. As endurance sports are so 
diverse (varying in duration, skill and physical demand) different athletic characteristics 
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are required to succeed (Nazarov et al., 2001). In addition, in some studies the ethnic 
ancestry of the participants was mixed. It should be noted that allele frequencies and 
genotype distributions for this gene vary across different populations (Eleni et al., 2008). 
For example, the genotype distribution in European Caucasian adults is approximately DD 
25% ID 50% II 25% (Myerson et al., 1999) and in Jamaicans with recent west-African 
ancestry DD 36% ID 47% II 17% (Scott et al., 2010). 
 
In contrast, there are investigations that have found significant association between the 
ACE D allele and endurance performance. A study of 121 elite Israeli marathon runners 
demonstrated a higher frequency of the ACE D allele and ACE DD genotype than in 
sprinters (Amir et al., 2007). Muniesa et al. (2010) concurred with the results of Amir et al. 
(2007) and found that elite endurance runners had a significantly higher proportion of DD 
genotype. This may suggest a positive association between the D allele and elite 
endurance athletic performance in some ethnic groups (Amir et al., 2007). Indeed 
Puthucheary et al. (2011) suggest that this atypical association may be explained by the 
heterogeneity of the Israeli Caucasian Jewish population. However, those results could 
also be artefacts of the small population sizes in those studies. 
 
In summary, despite some contradictory evidence, the ACE genotype-dependent 
associations with elite endurance running performance cited in the preceding text imply 
that the I allele may enhance the favourable adaptations to endurance training and thus 
competitive performance. That conclusion is supported by a thorough meta-analysis that 
reported an odds ratio of 1.35 for association between ACE II genotype and endurance 
athlete status (Ma et al., 2013). 
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Some research groups have suggested that other genes encoding key RAAS elements 
may further our understanding of the influences of the RAAS pathways on elite endurance 
performance. One of these RAAS components of interest is Angiotensinogen. 
 
2.2.2.2 Angiotensinogen (serpin peptidase inhibitor, clade A, member 8)- AGT 
The AGT gene is located on chromosome 1q42.2 and consists of 5 exons (Gaillard et al., 
1989). The AGT Met235Thr polymorphism refers to a C to T nucleotide substitution at 
(rs699) position 4072, in exon 2 culminating in the conversion of Methionine to Threonine 
in the angiotensinogen protein. This gives three genotypes, CC and TT homozygotes and 
CT heterozygotes. The threonine variant is encoded by the C allele and has been 
associated with 10–30% higher plasma angiotensin concentration in men and women 
(Jeunemaitre et al., 1992). 
 
The AGT rs699 polymorphism has been associated with the response to endurance 
training, cardio-respiratory endurance and blood pressure (Rankinen et al., 2000a). Males 
carrying the TT and CT genotypes have greater reductions in diastolic blood pressure at 
50 W in response to 20 weeks of endurance training (Rankinen et al., 2000a). However, 
TT genotype males also carrying the D allele of the ACE gene showed no response to 
training. Females showed no genotype-dependent differences in either systolic or diastolic 
blood pressure or training response. This lack of genotype-dependent training response 
was further suggested by Bae et al. (2007) who found no association of the AGT rs699 
polymorphism with the response to endurance training. In that study, 17 Korean women 
completed endurance training for 12 weeks, then tested for ventilatory response, glucose, 
body composition, total cholesterol, triglyceride concentrations, blood pressure, V̇O2 max 
and BMI. No AGT rs699 genotype or allele associations were reported though the findings 
of this study should be regarded with caution as the study was underpowered. 
It has also been suggested that AGT rs699 polymorphism influences the variability in left 
ventricular hypertrophy as a result of endurance training in elite endurance athletes 
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(Karjalainen et al., 1999). Eighty endurance athletes (long distance runners, orienteers, 
cross country skiers and triathlon competitors) from the Finnish national teams were 
genotyped and completed echocardiography. The CC homozygotes had greater left 
ventricular mass than TT homozygotes in both males and females (Karjalainen et al., 
1999). It was also noted that there was a sex-dependent association between heart mass 
and AGT genotype. In males, those with the TC genotype were similar to the homozygous 
CC genotype and the reverse was observed in females (Karjalainen et al., 1999). In 
contrast, a study of 83 Caucasian, male international and national endurance athletes 
showed no association of left ventricular mass with the AGT rs699 polymorphism (Diet et 
al., 2001). However, an increase in left ventricular mass was recorded in individuals 
carrying both the ACE DD and AGT TT genotypes (Diet et al., 2001). 
 
Although some studies mentioned in the preceding paragraphs genotyped AGT rs699 
polymorphism in elite athlete cohorts, they did not directly assess genotype distributions in 
relation to elite athlete status. Those studies that have assessed associations of AGT 
rs699 polymorphism with elite athlete status give mixed results. The AGT rs699 
polymorphism genotype distributions of 63 power athletes, 100 endurance athletes and 
119 Caucasian male controls revealed a higher CC genotype in the power group when 
compared to the endurance and control groups. No difference in genotype frequency was 
noted between the endurance and control groups (Gomez-Gallego et al., 2009). Similarly, 
Zarebska et al. (2013) reported no association with elite endurance athlete status. It 
should also be noted that among both the power athlete genotype distributions of the 
Spanish and Polish studies there was a lack of Hardy-Weinberg equilibrium. Hardy-
Weinberg equilibrium is a law which states that allele and genotype frequencies will 
remain constant from generation to generation. This requires the maintenance of the 
following 6 parameters: 
A large breeding population 
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A large breeding population size helps to ensure that the genetic equilibrium is not 
disrupted by chance alone. A sharp reduction in population is called a population 
bottleneck and can lead to inbreeding due to lack of sexual selection or the founder effect. 
For example, in a small population, it may be that only a few copies of an allele exist. If by 
chance the organisms with that allele do not reproduce successfully, the allelic frequency 
will change. This random, nonselective change is what happens with genetic drift. In 
contrast, it may be that alleles are equally represented in the parent population but that 
identical individual’s mate through lack of population numbers and new populations 
lacking genetic variety are established. As a result of the loss of genetic variation, the new 
population may be distinctively different, both in genotype and phenotype, from the 
derived parent population. The population sample of this study has not been restricted or 
isolated from the general population in anyway before during or after inclusion in this 




In a population that conforms to Hardy Weinberg equilibrium, mating between individuals 
must be random to ensure no departure in the allelic frequency from the equilibrium. In 
assortative mating were individuals select partners that are similar to themselves fewer 
heterozygotes are observed though this does not alter the allelic frequencies observed 
when compared to a population where mating is random. It is assumed mating between 
individuals is random for those offspring included in this study. 
 
No change in allelic frequency due to mutation 
For a population to maintain the law of Hardy-Weinberg equilibrium there can be no 
alteration in allelic frequency due to mutation. Gene mutation would alter the allelic 
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balance introducing new alleles into the gene pool and altering the composition of the 
gene pool from generation to generation.  
 
No immigration or emigration 
For a population to exhibit equilibrium the allelic frequency must remain constant. 
Therefore, no new alleles can be introduced to the population and no alleles may be lost. 
Both immigration and emigration may alter the allelic frequency by introducing or 
removing alleles to and from a population. All athletes included in this study were from the 
continent of Europe, none were known to have emigrated or immigrated to Europe. 
 
No natural selection  
In a population at equilibrium no alleles exhibit preferential selection over any other alleles 
present. Should a selection pressure be introduced, those alleles that are preferentially 
selected will become more common. For example in the case of bacteria if resistance to 
particular antibiotic allows bacteria to thrive when an individual is treated with that 
particular antibiotic, the allele for resistance may become more prevalent in the population 
of bacteria. No known selection pressures were influencing the alleles chosen. 
 
Lab error 
Genotype frequencies should comply with HWE proportions. Deviation from these 
proportions can be caused by many factors, one of which is genotyping error. Genotype 
mistakes can lead to increased random error and bias in gene-phenotype associations. All 
samples were genotyped in duplicate to confirm the genotype group status of each 




Genotyping frequencies may in some cases deviate from the HWE proportions just 
through chance. 
 
If anyone of these assumptions is not met than the population of interest will not be in 
Hardy-Weinberg Equilibrium. Deviation from Hardy-Weinberg equilibrium may indicate a 
selection pressure or evolution of the allele frequencies from one generation to the next. 
This maybe the result of mutation, non-random mating, gene flow, genetic drift and natural 
selection. 
 
Based on the contribution of ACE and AGT to cardio-respiratory endurance, blood 
pressure regulation and left ventricular hypertrophy, it is hypothesised that the ACE I/D 




2.2.3 Actinin Alpha 3 - ACTN3 
Skeletal muscle fibre type plays and important role in elite marathon performance. 
Skeletal muscle fibre type has been shown to alter in rodent and human populations 
(detailed below) as a result of ACTN3.  
The α-actinins are major structural components of the Z line in skeletal muscle where they 
crosslink the actin thin filaments to the Z-line maintaining sarcomeric integrity (Blanchard 
et al., 1989, Mills et al., 2001, Yang et al., 2003) as shown in Figure 3. 
 
Figure 3 Localisation and domain structure of the sarcomeric α-actinins. 
The sarcomeric α-actinins anchor thin filaments to the Z-line. Figure 
adapted from (MacArthur and North, 2004). 
 
Two genes encode the skeletal muscle α-actinins: actinin alpha 2 (ACTN2) and ACTN3. 
ACTN2 expression is ubiquitous to skeletal muscle fibres whereas ACTN3 has restricted 
expression to Type II fibres. ACTN3 is located on chromosome 11q13.1. A common 
nonsense polymorphism (rs1815739) in exon 16, codon 577, results in the conversion of 
arginine (CGA; R allele) to a stop codon (TGA; X allele) (North et al., 1999). The X allele 
homozygote is completely prevented from producing functional ACTN3 protein. Both 
alleles are common within the general population with 18% of European population and 
around 1 billion world-wide presenting as X allele homozygotes (Yang et al., 2003). The 
absence of ACTN3 protein (XX genotype) has no known pathological consequence in 
I band 
myosin 
A band Z line M line 
actin α-actinin 
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humans. The lack of pathology in X allele homozygotes may be explained by the 
conserved nature of the α-actinins. The ACTN2 protein is 80% identical to ACTN3 with a 
further 10% that is very similar (Beggs et al. 1992). The ACTN3 protein is comprised of 
three domains these are termed the NH3 terminal actin binding domain, a 4x repeat of 122 
amino acid motifs, that share homology with spectrin, known as the central rod domain 
and a COOH terminal domain (Berman and North, 2010). 
 
The SNP transition from C>T at position 1747 (codon 577) in the ACTN3 coding sequence 
results in three genotypes - homozygous RR and XX and the heterozygous RX (North et 
al., 1999). The 577R allele has been associated with strength in both rodent and human 
populations (MacArthur et al., 2008, Clarkson et al., 2005, MacArthur and North, 2007). 
 
Multiple case controlled studies have reported that the RR genotype is represented more 
frequently than that of the XX genotype in strength athletes and sprinters when compared 
to a control population (Niemi and Majamaa, 2005, Roth et al., 2007, Druzhevskaya et al., 
2008). An Australian study reported the XX genotype was significantly reduced in elite 
Australian power athletes and completely absent from the Australian Olympic female 
power athletes (Yang et al., 2003). 
 
These findings have been replicated in several independent case controlled studies 
including elite Finnish sprint athletes (Niemi and Majamaa, 2005), elite Greek track and 
field athletes,(Papadimitriou et al., 2008) elite strength athletes from the United States of 
America (USA) (Roth et al., 2007) and Russian power athletes (Ahmetov and Rogozkin, 
2009). The R allele conferring some athletic advantage in strength based sport was 
further evidenced by a study that reported the percentage surface area and number of 
type IIx (fast twitch glycolytic) fibres was greater in the RR than the XX genotype group of 
young healthy men (Vincent et al., 2007, Ahmetov and Rogozkin, 2009). 
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In addition, ACTN3 knockout mice had smaller muscle fibre cross sectional area, lower in 
vivo strength and lower in vitro force generating capacity, and longer twitch half relaxation 
times when compared to wild type mice (MacArthur et al., 2008). The ACTN3 knockout 
mice showed enhanced endurance running performance and better recovery from 
fatiguing muscle contractions compared to the wild type mice (MacArthur et al., 2007, 
MacArthur et al., 2008). Lastly the ACTN3 knockout mice showed higher expression of 
enzymes associated with oxidative capacity (MacArthur et al., 2008). It is not thought that 
ACTN3 protein infers any extra protection from contraction induced muscle damage or Z 
line damage as similar levels of muscle damage were observed in single muscle fibres 
following eccentric contractions from ACTN3 knockout mice (MacArthur et al 2007; Chan 
et al 2008; MacArthur et al 2008).This evidence would suggest that ACTN3 577R may 
confer some advantage in strength-based events but this has not been examined in a 
British population. 
 
Yang et al. (2003) hypothesized a competitive ACTN3 577X advantage in athletes 
competing in endurance based events. They studied 194 elite Australian endurance 
athletes 18 of whom had competed at Olympic level. The endurance group included long-
distance cyclists, rowers, swimmers with a competition distance ≥400 m, cross country 
skiers and 15 track athletes who ran distances ≥5000 m. Yang et al. (2003) found a 
tendency for a higher XX genotype frequency in female athletes though this was not noted 
in male athletes. A large European study was conducted later, comprising 633 Caucasian, 
Polish, Russian and Spanish mixed sporting discipline athletes (278 elite endurance 
athletes) and 808 non-athletic controls (Eynon et al., 2012). Athletes were considered elite 
if they had competed at a national or international level. The authors found that the XX 
genotype was over-represented in the endurance athlete population when compared to 
the power athletes (OR 1.88) and those athletes of elite endurance athletic status were 
66 
~3.7 times more likely to have the XX genotype compared with the RX and RR genotypes 
when compared to the national-level athletes (Eynon et al., 2012). 
 
Triathlon is an endurance sport requiring good ability in prolonged swimming, cycling and 
running. Two studies have investigated whether the ACTN3 R577X polymorphism was 
associated with triathlon performance or triathlon athlete status. In a cohort of 196 elite 
endurance athletes racing in the 2008 Kona Ironman championship triathlon, the 577X 
allele was not associated with performance time (Grealy et al., 2012). Similarly, in a large 
study of Caucasian male triathletes the ACTN3 R577X polymorphism was not associated 
with performance time, nor was there and difference in genotype frequency between 
athletes and non-athlete controls (Saunders et al., 2007). It is unknown whether a study of 
athletes who excel in one of the triathlon disciplines alone (e.g. prolonged endurance 
running) would give similar or differing results. 
 
Other studies have also noted no ACTN3 XX genotype or X allele associations in their 
endurance athlete populations when compared to controls. In a small Finnish population 
of 52 athletes including 20 endurance track athletes who ran distances between 800 m 
and Marathon or race walkers, there were no differences in the ACTN3 577X genotype or 
allele frequency between athletes and controls this may be explained by the variation in 
competitive distances completed by the athletes.  In another small study involving Spanish 
Olympic level runners (52), professional cyclists (50) and 123 male controls with low 
physical activity (Lucia et al., 2006), ACTN3 genotype conferred no advantage for elite 
endurance performance (Lucia et al., 2006). This finding was similar to that reported in a 
larger study of 316 male endurance athletes from six different sports comprising the 
Genathlete cohort, where there was no difference in the frequency of the XX genotype 
between athletes and controls (Döring et al., 2010). Finally, a meta- analysis reviewing the 
association of human sporting performance with the ACTN3 R577X polymorphism found 
no association of the 577X allele or genotype with endurance performance (OR, 1.03; 
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95% CI, 0.92–1.15) (Ma et al., 2013). However, the authors concluded that the varieties of 
sex, ethnicity, and sporting discipline in the studies may explain the lack of an observed 
association. 
 
The association of the ACTN3 577X allele and XX genotype with elite endurance 
performance in the literature is therefore contentious. The clearly expressed endurance 
phenotype in the mouse and associated plausible biological pathways do suggest strong 
biological rationale for an association between the ACTN3 577X allele and human 
endurance performance. The studies in humans to date, however, are limited by relatively 
small sample sizes and/or a lack of clearly defined endurance athlete status and discipline 
athlete phenotypes. Therefore, there remains sufficient prior evidence to hypothesise that 
the ACTN3 R577X polymorphism may contribute to marathon runner elite performance. 
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2.2.4 Peroxisome proliferator activated receptor gamma, coactivator 1 alpha - 
PPARGC1A 
Mitochondrial oxidative phosphorylation provides the vitally important ATP, required for 
skeletal muscle propulsion during marathon running. PARAGC1A is thought to influence the 
fatty acid substrate availability during the later stages of a marathon and its conversion to 
ATP, to directly fuel skeletal muscle contraction during a marathon and will therefore influence 
a runners running economy and lactate threshold. 
 
PPARγ coactivator 1α (PGC1α) is a nuclear protein that regulates gene expression by 
enhancing transcriptional factor activation (Puigserver et al., 1998, Esterbauer et al., 
1999), coordinating gene expression in signalling pathways responsible for improved 
mitochondrial oxidative phosphorylation (OXPHOS), especially in brown fat and skeletal 
muscle (Arany et al., 2005). Total mitochondrial volume and density, influenced by 
mitochondrial biogenesis, in turn regulates OXPHOS (Puigserver et al., 1998, Wu et al., 
1999), transport and oxidation of glucose and lipid (Tunstall et al., 2002) and skeletal 
muscle fibre type (Lin et al., 2005, Lin et al., 2002).  
 
Coordination of mitochondrial and nuclear genomes regulates mitochondrial biogenesis 
(Baar, 2004). The mitochondrial genome encodes 13 proteins associated with the electron 
transport chain (approximately 10% of the genes required for mitochondrial biogenesis) 
(Baar, 2004). The nuclear genome encodes proteins required for the replication and 
expression of mitochondrial DNA (mtDNA), the remaining electron transport proteins and 
those associated with OXPHOS of fatty acids, ketones and pyruvate (totalling 
approximately 90% of the genes required for mitochondrial biogenesis). PGC1α regulates 
OXPHOS gene expression via interaction with specific transcription factors, such as 
nuclear receptor PPARγ, nuclear respiratory factor 1 (NRF1) and muscle specific 
transcription factors such as MEF2 (Lin et al., 2002), Interaction of PGC1α with 
transcription factor targets is linked to specific tissues as shown in Figure 4. 
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PGC1α knock out (KO) murine skeletal muscle cells show lower expression of genes 
influencing mitochondrial function and reduced expression by 30-50% of the genes 
implicated in OXPHOS, fatty acid oxidation and ATP resynthesis in murine cardiac muscle 
(Arany et al., 2005). PGC1α reportedly doubles MtDNA content, leading to a 57% 
increase in mitochondrial number in murine skeletal myoblasts expressing PPARGC1A 
(Wu et al., 1999, Puigserver et al., 1998). Transgenic mice, over-expressing PGC1α in 
cardiac and skeletal muscle cells, demonstrated mitochondrial proliferation and OXPHOS 
gene expression (Lehman et al., 2000, St-Pierre et al., 2003). KO mouse Type 1 skeletal 
muscle fibres showed decreased mitochondrial numbers and respiratory capacity, while 
KO Type II fibres showed normal mitochondrial density and function (Leone et al., 2005), 
suggesting PGC1α mediated activation of mitochondrial biogenesis and OXPHOS in slow 
skeletal and cardiac muscle. These data demonstrate that PGC1α is a requirement for 




Figure 4 The PGC-1 gene regulatory cascade (Finck and Kelly, 2006). 
Illustrates upstream signalling events and downstream gene regulatory actions of the inducible PGC-1 coactivators. Interaction of PGC-1α 
with transcription factor targets is linked to specific tissues. For example, PGC-1α coactivates PPAR nuclear receptor transcription factors to 
express genes involved in mitochondrial fatty acid oxidation. LXR, liver X receptor; TAG, triacylglycerol; RXR, retinoid X receptor; mtDNA, 
mitochondrial DNA; OXPHOS, oxidative phosphorylation. (Finck and Kelly, 2006). 
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Wu et al. (1999) reported that PGC1α translocates to the mtDNA D-loop to interact with 
NRF1 on the mitochondria transcription factor A (Tfam) promotor. Upregulation in Tfam 
expression further implicates PGC1α in the biogenesis of mitochondria (Shadel and 
Clayton, 1993, Baar, 2004). In addition, PGC1 α coactivates PPARα, shown to control 
transcriptional activity of mitochondrial enzymes involved in the β-oxidation of fatty acids 
(Gulick et al., 1994, Baar et al., 2002). Increases in mitochondrial proteins and glycolytic 
enzymes increasing fatty acid oxidative capacity of skeletal muscle may induce Type II 
fast glycolytic fibre conversion to Type I slow, high-oxidative fibres, with Type 1 fibres 
showing increased expression of PGC1α (Brooke et al., 2005). Lin et al. (2002) 
demonstrated in transgenic mice that forced expression of PGC1α at physiological levels 
caused an approximate 10% fibre type conversion in muscles normally rich in Type II 
fibres. Those muscles were observed to be redder, they showed increased expression of 
contractile proteins characteristic of Type I fibres, genes of mitochondrial oxidative 
metabolism were activated and there was increased resistance to electrically stimulated 
fatigue (Lin et al., 2002). Using a PGC1α knockout mouse model, Arany et al. (2005) 
found that PGC1α was not required for mitochondrial biogenesis, or for the differentiation 
of skeletal muscle fibres. However, the absence of PGC1α reduced mitochondrial function 
and decreased levels of ATP (Arany et al., 2005). These combined data indicate that 
PGC1α is likely a key regulatory factor for the determination of muscle fibre type (Lin et 
al., 2002) in rodents and humans (Finck and Kelly, 2006). 
 
Due to the complex interactions of PGC1α, the exercise-induced expression pathways of 
PGC1α are unclear (Finck and Kelly, 2006). PGC1α is thought to interact with myocyte 
enhancer factor 2 through the calcineurin A and CaMK pathway (Lin et al., 2002). More 
recently, after endurance exercise, expression of PGC1α has been postulated to occur 
through the p38 MAPK and AMPK pathways (Akimoto et al., 2005) detailed in Figure 5. 
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Figure 5 Regulation of PGC1α gene expression (Kang and Li Ji, 2012). 
PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; Tfam, mitochondria transcription factor A; MAPK, mitogen-
activated protein kinase; MKK6, MAP kinase kinase: CaMK, Ca2+/calmodulin-dependent protein kinase, CREB, cyclic AMP response 
element binding protein; MEF, myocyte enhancer factor; ATF, activating transcription factor; NRF, nuclear respiratory factor; ERR, 
oestrogen-related receptor; XO, xanthine oxidase; PKC, protein kinase C. 
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In rats (Baar et al., 2002, Goto et al., 2000, Terada et al., 2002) and humans (Russell et 
al., 2003, Pilegaard et al., 2003), acute endurance exercise and chronic endurance 
training increases PGC1α expression primarily in Type IIa fibres (Russell et al., 2003, 
Finck and Kelly, 2006). In response to endurance exercise and expression of PGC1α, 
there is increasing mitochondrial content, the presence of more oxidative fibres and 
resistance to fatigue (Wu et al., 1999, Baar et al., 2002, Terada et al., 2002, Lin et al., 
2002, Russell et al., 2003). In humans, endurance training significantly increases 
PPARGC1A mRNA levels between 2-fold and 10-fold (Tunstall et al., 2002, Pilegaard et 
al., 2003, Norrbom et al., 2004) and thus may enhance translation and modulation of the 
PGC1α protein.  
 
The PPPARGC1A gene of 13 exons is located on chromosome 4p15.1. The gene 
produces a protein with a calculated molecular mass of 91kDa (Esterbauer et al., 1999). A 
functional SNP (rs8192678) causes a transition substitution of the ancestral glycine (G 
allele) to serine (A allele) at amino acid position 482. The minor A allele is associated with 
reduced PPARGC1A expression (Ling et al., 2004, Ahmetov and Rogozkin, 2009).  
 
PPARGC1A has been shown to influence V̇O2 max in both rodent (Baar et al., 2002, Lin et 
al., 2002, Terada et al., 2002) and human populations (Lucia et al., 2005, Norrbom et al., 
2004, Russell et al., 2003). Indeed, oxygen consumption doubled in murine myotubes 
expressing PGC1α, treated with FCCP (a chemical uncoupler that completely uncouples 
mitochondria and maximizes their respiratory capacity) indicating that these cells have a 
higher content and/or electron transport activity of mitochondria (Wu et al., 1999). 
Therefore, it could be postulated those individuals carrying the PPARGC1A G allele may 
have an increased mitochondrial content in their muscle fibres and therefore an increased 
ATP production capacity via the electron transport chain when compared to A allele 
carriers. This would be a clear advantage for an individual competing in endurance sport 
such as marathon where OXPHOS is the primary mechanism of energy generation for 
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muscle contraction. However, there was no association between V̇O2 max and the 
PPARGC1A rs8192678 polymorphism in German, Dutch or Japanese populations 
(Stumvoll et al., 2004, He et al., 2008, Nishida et al., 2015). Nishida et al. (2015) observed 
in 112 Japanese middle-aged men that A allele carriers had a higher lactate threshold 
than G allele carriers. This suggests that the PPARGC1A A allele may be associated with 
a higher aerobic capacity in Japanese middle-aged men, although no association with 
V̇O2 max was observed according to an indirect estimation (using age-predicted maximum 
heart rate) known to have rather poor validity. Although lactate threshold is a good 
measure of aerobic function, it is not synonymous with V̇O2 max (Nishida et al., 2015). 
Furthermore, V̇O2 max is usually limited by the oxygen delivery capacity, not the ability of 
mitochondria to utilise oxygen in the skeletal muscle. Marathon runners are also reliant on 
the oxygen delivery capacity of the cardio respiratory system during a race, and therefore, 
both V̇O2 max and lactate threshold are considered important parameters of aerobic 
function in endurance runners (Foster, 1983). 
 
In elite Spanish athletes, Lucia et al. (2005) suggested that PPARGC1A rs8192678 may 
be one of a collection of genetic factors to affect athletic aerobic capacity after reporting 
an under-representation of the A allele in their elite male endurance athletes. The A allele 
was further associated with lower aerobic capacity in Russian rowers (Ahmetov et al., 
2007). Tural et al. (2014) reported that the A allele was associated with higher aerobic 
capacity in Turkish elite endurance athletes in combination with the PPARA G allele. A 
lower frequency of the A allele of PPARGC1A rs8192678 has been associated with elite 
endurance athlete status in several cohorts of athletes of mixed sporting discipline 
(Maciejewska et al., 2011, Lucia et al., 2005, Eynon et al., 2009c). In contrast, no 
association of the PPARGCIA rs8192678 with elite athlete status was observed in elite 
Polish athletes of mixed discipline (Maruszak et al., 2014). No difference in PPARGC1A 
rs8192678 genotype frequency distributions between Ironman triathletes and controls 
were noted by Grealy et al. (2015), nor was there any association with performance time. 
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In 60 elite Turkish endurance athletes, the A allele was associated with endurance athletic 
performance. 
 
Although the athletes in all of these studies were reported to be at an elite level, the 
criteria used to define elite athlete status was variable across studies. In addition, in some 
of the studies, the endurance athlete groups were of a mixed sporting discipline (Tural et 
al., 2014). Where sporting disciplines were defined, the association of PPARGC1A 
rs8192678 with athletes/performance from the individual sports were not statistically 
significant, potentially due to insufficient statistical power. This makes it difficult to 
determine if the PPARGC1A rs8192678 polymorphism does indeed have an influence on 
performance in a single endurance discipline such as the marathon. 
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2.2.5 Uncoupling protein (mitochondrial, proton carrier) – UCP 
The ability to perform at an elite level in endurance events such as marathon running 
requires training of the skeletal muscle to ensure the tight coupling and efficiency of 
oxidative phosphorylation of carbohydrate at the start of the race and fatty acids as the 
race progresses, to provide the energy required for skeletal muscle contraction used in 
propulsion during running (Jiang et al., 2009, Bruton, 2002, Coyle, 2007). In contrast, the 
generation of superoxide and free radical species through large oxygen flux through the 
electron transport chain would inhibit skeletal muscle contraction efficiency and in high 
concentrations may inhibit the functionality of the skeletal muscle cells (Jiang et al., 2009). 
The regulation of oxidative phosphorylation coupling to ATP production is thought to be 
the role of the uncoupling proteins. UCP function in skeletal muscle is not fully understood 
though they have been implicated in uncoupling respiration from ATP production and thus 
in the control of energy expenditure (Boss et al., 1997) and thermogenesis incredibly 
important factors in a prolonged endurance event such as marathon. 
 
The UCPs are a family of intramembranous mitochondrial proteins that are responsible for 
the facilitation of anion transfer from the inner to the outer member of the mitochondria 
(Boss et al., 1997). The UCPs also transfer protons from the outer mitochondrial 
membrane to the inner mitochondrial membrane causing a reduction in the membrane 
electrical potential. Several publications have suggested further roles for UCP3 and these 
are addressed in Muzzin et al. (1999) and Brand and Esteves (2005). Muzzin et al (1999) 
propose that due to its homologous nature with UCP1, UCP3 may have a role in 
thermogenesis and the metabolic adaption of the mitochondria towards inproved 
degradation of fatty acids. Brand and Esteves (2005) report that UCPs do not mediate 
adaptive thermogenesis and that fatty acid transportation although reported in the 
literature has limited evidence, but that under specific pharmacological conditions they 
may have specific thermogenic properties. The uncoupling that they regulate significantly 
attenuates ROS production and protects against cellular damage likely to be of 
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importance during marathon performance due to the increased acid production and 
inflammation caused by prolonged exercise bouts. 
 
The UCPs are expressed in multiple selective tissues. UCP3 is preferentially expressed in 
brown fat (Boss et al., 1997, Vidal-Puig et al., 1997) while UCP2 is found in most tissues 
(Gimeno et al., 1997, Fleury et al., 1997). Mitochondrial uncoupling proteins 2 and 3 are 
both expressed in skeletal muscle (Boss et al., 1997, Fleury et al., 1997, Gimeno et al., 
1997) and exercise is a known stimulus for UCP2 and UCP3 mRNA expression. Acute 
exercise in vivo rapidly increases UCP3 mRNA expression (Jiang et al., 2009, Cortright et 
al., 1999, Zhou et al., 2000, Tonkonogi et al., 2000) and UCP2 expression is up regulated 
by exercise in rodent models (Cortright et al., 1999, Pedersen et al., 2001) and in humans 
(Tonkonogi et al., 2000). Increases in UCP3 mRNA expression have been shown to 
accompany GLUT-4 overexpression in mice (Pedersen et al., 2001, Tsuboyama-Kasaoka 
et al., 1998). In addition, UCP2 and UCP3 mRNA expression in rat muscle shows a dose-
dependent increase with insulin and muscle contraction in vitro (Pedersen et al., 2001). 
These studies suggest that changes in glucose concentration and/or fatty acid metabolism 
may regulate skeletal muscle UCP mRNA expression. Because elite marathon runners 
usually consume a high carbohydrate diet and consume carbohydrate during competition 
races insulin will be present (Burke, 2007). In addition, the repeated contraction during 
marathon training and competitive performance may give rise to upregulation of UCP2 
and UCP3 mRNA expression in the skeletal muscle of marathon runners and thus 
increased efficiency in the coupling of respiration and ATP production (Zhou et al., 2000, 
Tsuboyama-Kasaoka et al., 1998, Jiang et al., 2009).  
 
Uncoupling proteins have also been implicated in the regulation of free radicals and 
reactive oxygen species (ROS) by mitochondria (Brand et al., 2002) and super-oxides 
(Echtay et al., 2002). It is generally though that UCP2 and UCP3 require an activator to 
transport hydrogen ions across the mitochondrial membrane, this is evidenced by the lack 
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of change in the basal mitochondrial hydrogen ion conductance in isolated mitochondria of 
the UCP2 or UCP3 knock out mouse (Brand and Esteves, 2005, Krauss et al., 2003, 
Cadenas et al., 2002, Couplan et al., 2002). One suggested activator is fatty acids (Echtay 
et al., 2002, Brand and Esteves, 2005). Fatty acids play an important role in heavily 
respiring skeletal muscle in the latter stages of a marathon, therefore based on the theory 
put forward by Brand and Esteves (2005) that UCPs 2 and 3 attenuate the production of 
free radicals by mitochondria and therefore protect against ROS related oxidative damage 
in muscle cells (Jiang et al., 2009) this may give a competitive advantage under racing 
conditions when elite runners often push themselves to the limits of their skeletal muscle 
capabilities (Joyner, 1991, Joyner and Coyle, 2008, Joyner et al., 2011). 
 
Several gene polymorphisms in the genes of UCP2 and UCP3 have been identified as 
markers of aerobic capacity in 1423 Russian athletes when compared to 1132 controls 
(Ahmetov et al., 2009, Ahmetov et al., 2008)and oxidative phosphorylation (Astrup et al., 
1999, Buemann et al., 2001) which make them attractive candidate genes for elite 
endurance athlete status (Buemann et al., 2001). The common polymorphism rs660339 in 
the UCP2 gene results in a C/T substitution and subsequent Ala55Val amino acid change. 
The T allele has been associated with increased metabolic efficiency in muscles 
(Buemann et al., 2001, Astrup et al., 1999). The UCP2 rs659366 gene polymorphism has 
been associated with training related enhancement in delta efficiency in, a marker of 
skeletal muscle performance in 58 participants (Dhamrait et al., 2012). Carriers of the T 
allele had higher training induce gains in delta efficiency, and it was reported in carriers of 
the T allele 8.4% of the interindividuality in delta efficiency associated with endurance 
training was the result of UCP2 rs659366 polymorphism (Dhamrait et al., 2012). 
 
Relatively few studies have been conducted assessing the association of the UCP 
polymorphisms and athlete status. Those that have been completed tend to assess UCP2 
rs660339 and UCP3 rs1800849. In fact, there were no records in the literature of prior 
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studies assessing UCP2 rs659366 and elite athlete status in endurance athlete 
populations. UCP2 rs659366 is thought to be in linkage disequilibrium with UCP2 
rs660339 The genotype and allele frequency distributions of the UCP2 rs660339 
polymorphism were investigated in 230 Russian rowers and a control group of 855 
Russian college and high school students. The frequency of the UCP2 rs660339 T allele, 
thought to be associated with endurance performance, increased in correlation with the 
sporting eliteness of the rowers (Ahmetov et al., 2008) furthermore, the UCP2 rs660339 T 
allele was associated with higher V̇O2 max in male Russian rowers (Ahmetov et al., 2008) 
suggesting the T allele may be favourable for competitive success in endurance sports. 
Further evidence to support this hypothesis found the UCP2 rs660339 T allele was 
recorded at a higher frequency in an elite Russian mixed sporting discipline endurance 
cohort of 684 participants that included 134 runners, when compared to 1132 controls 
(Ahmetov et al., 2009). These studies also investigated another uncoupling protein 
polymorphism in UCP3.  
 
The UCP3 -55C/T polymorphism at rs1800849, results in a C/T substitution 55 
nucleotides before the start codon in a functional promoter region. The T allele is 
associated with higher protein expression (Schrauwen et al., 1999) higher aerobic 
potential, increased basal energy expenditure thought to be due to the increased gene 
expression, therefore a decreased risk of obesity (Liu et al., 2005, Schrauwen et al., 
1999). Ahmetov et al. (2008) investigated the UCP3 rs1800849 genotype and allele 
frequencies in a large cohort of Russian rowers and controls (outlined above) they found 
the UCP3 T allele increased in frequency in association with elite athlete status. The T 
allele was further associated with high aerobic performance and was therefore regarded 
as a genetic marker of endurance performance (Ahmetov et al., 2009). This research 
group completed further analysis in 287 long endurance (a race duration of 5-30 min) and 
middle endurance (race duration of 45 s to 5 min) groups of Russian national competitive 
standard and controls. They found the UCP3 rs1800849 T allele carrier were more 
frequent in the athletes when compared to 1132 controls. Interestingly no association was 
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reported in the very long endurance group (a race duration of >30 min). Hudson et al. 
(2004) compared 89 fastest Caucasian male ultra-endurance Ironman triathletes and of 
the 89 slowest to determine whether the UCP3 gene was associated with the performance 
in either the 2000 and 2001 South African Ironman Triathlon. There were no differences 
between the groups in either UCP3 rs1800849 C/T genotype or allele frequency. These 
two athlete groups were further compared to 92 Caucasian male controls who had not 
trained for or participated in an ultra-endurance athletic event. No difference in either 
genotype frequency or allele frequency of the UCP3 -55C/T polymorphism was noted 
between the groups analysed (Hudson et al., 2004). The athletes were grouped together 
and a genotype association with race completion time was conducted, this included 
further analysis of the completion times of the swim, cycle and run stages independently. 
No genotype association was found in any of the individual sporting stages (swim, cycle or 
run) or when the entire race event time was analysed (Hudson et al., 2004). Therefore it 
was concluded that the UCP3 -55C/T polymorphism was not associated with endurance 
performance in tri-triathletes. Of note and a possible explanation for the lack of 
association in the triathlete population is the varying sporting elements that make up a 
triathlon and the phenotypes of the athletes that traditionally perform well in these 
individually sporting elements. Elite swimmers invariably have larger volumes of fat-free 
mass in their upper bodies whereas elite cyclists have over developed skeletal muscle in 
the thigh and lower legs, neither of these attributes are favourable to be successful in 
endurance running where the excess weight of increased fat-free mass Is hypothesised to 
be hindrance to running economy. Therefore the lack of association reported in these 
studies must be viewed with caution. The purpose of this study therefore was to assess 
an association of marathon sporting performance with the UCP2 rs659366, UCP2 




The experimental method outlined in this section was applied to all samples. Gene 
specific methods will be further outlined in the relative chapters. 
3.1 ETHICS AND GOVERNANCE 
The study was approved by the ethics committee of the Department of Exercise and 
Sports Science, Manchester Metropolitan University, in accordance with the Declaration of 
Helsinki for human research of 1974 (last modified in 2000). Sample collection, storage 
and disposal were within the framework of the Human Tissue Authority (HTA). All 
research participants gave their written informed consent after an explanation of the 
procedure and the purpose of this study. Participants had gap period of between 10 
minutes and several days depending on location of data collection. Those with the 
smallest gap period were collected at the London Marathon Expo. Participants 
approached at the London Marathon Expo were fully informed of the project to elicit 
interest on the expo floor and then relocated to a quiet consultation space and fully 
informed once in the consultation space. Participants were then given 10 minutes to 
discuss with peers, coaches and management staff before being asked for consent to 
participate. Participants were informed they could withdraw from the study at any point 
even if consent had previously been granted. 
 
3.2 ATHLETE SELECTION CRITERIA  
The McCain Power of 10 website (www.thepowerof10.info/) records athlete particulars 
and sporting achievements on an annual basis. Published data records for athlete 
rankings date back to 2006. To determine the elite selection criteria these records were 
accessed, to assess the recorded times of the top 100 UK male and female marathon 
athletes (on 31ST December 2012). The data were averaged and the resulting mean time 
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was rounded to the nearest 10 mins. Table 4 shows the male and female annual recorded 
times used to set the data collection boundaries for the elite and sub-elite groups. 
Table 1 Annual recorded times for UK male and female marathon runners  
 
Male top 100 Female top 100 
2012 02:33:06 03:00:20 
2011 02:33:59 03:01:27 
2010 02:33:36 03:01:22 
2009 02:33:42 03:03:20 
2008 02:34:18 03:02:36 
2007 02:37:14 03:04:28 
2006 02:34:53 03:01:32 
Mean 02:34:24 03:02:09 
Threshold times for marathon 
runner classification 







The athletes meeting the selection criteria were invited to take part in the project via their 
primary athletics club affiliation. The author also attended national competitions such as 
the National Cross Country Championships (2013) and the London Marathon Expo (2013-
2015) to collect samples and data from athletes meeting the selection criteria. 
 
83 
3.3 NON-ATHLETE CONTROL SAMPLE SELECTION 
Caucasian individuals who had never competed in high level sport (i.e. at an international, 
national or regional competition) were recruited to participate in the project as non- athlete 
control participants. 
 
3.4 DATA COLLECTION 
All research participants completed a questionnaire detailing their ethnicity, height, body 
mass and age (see Appendix 1 for details). Athletes had their personal bests and highest 
placed sporting achievements recorded. The control group recorded details of their 
personal health to confirm the lack of pathology and that participants were apparently 
‘healthy’. 
 
3.5 DNA COLLECTION 
All research participants gave a sample of DNA via one of the following methods 
depending on their preferences for an invasive / non - invasive method of collection. 
Because of the nature of the collections, primarily in the 4 days in the run up to the 
London marathon athletes were given the choice as to the method of DNA collection. It is 
acknowledged that the venepuncture site does take a few days to heal completely and 
this may cause irritation during an extended race like marathon and may affect race day 
performance. Therefore, DNA was collected in accordance with the method of choice of 
the athlete. 
 
3.5.1 Whole Blood 
A phlebotomist (the author and those marked in bold listed in table 4) collected a 5 mL 
venous blood sample from a superficial forearm vein. The phlebotomist transferred the 
sample into Ethylenediaminetetraacetic acid (EDTA) treated collection tubes and stored 
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on ice for transportation to the laboratory. The samples were frozen at -20°C until DNA 
extraction was completed. To date 679 samples have been collected via this method (452 
non-marathon controls and 227 marathon athletes). The author collected 20 non-
marathon controls and 227 marathon athletes. 
 
3.5.2 Buccal Swab 
Research participants were asked not to eat, drink, smoke or chew gum for 30 min prior to 
sample collection. Participants were asked to collect a buccal DNA sample from either 
side of the mouth using two OmniSwabs (Whatman, Sanford) as shown in Figure 6. One 
swab was agitated on the inside of the right cheek to slough off loose cheek cells onto the 
swab. Swabs with collected cells were ejected from the ‘handle’ into 2 mL snap cap tubes 
and placed on ice for transportation. The process was repeated with the second swab on 
the left inside cheek. Samples were stored at -20°C until DNA extraction was completed. 
236 samples have been collected via this method (10 marathon athletes and 225 non-




Figure 6 Buccal swab cell collection using OmniSwabs. Adapted from 
https://www.fishersci.com/shop/products/whatman-omniswab-
sterileomniswab-100-pk/09923376 accessed 24/09/15 
 
3.5.3 Saliva Tube 
Research participants were asked not to eat, drink, smoke or chew gum for 30 min prior to 
sample collection. Each participant expelled 2 mL of saliva into the Oragene® DNA OG-
500 (DNA Genotek Inc. Ottawa, ON, Canada) collection tube until the saliva fluid without 
bubbles reached the fill line as shown in Figure 7. The top was snapped closed to release 
the ‘stabilisation’ fluid stored in the cap into the sample. The funnel was removed, and the 
tube sealed with the smaller screw top plastic lid (provided). Samples were inverted 10 
times to ensure even distribution of the ‘stabilisation’ fluid throughout the saliva sample. 
Samples were transported at room temperature. Samples were heat treated in an 
incubator for 1 hour at 56°C to complete cell lysis. Heat-treated samples were stored at 
room temperature until DNA extraction was completed. The author collected 112 athlete 
samples using this method. 
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Figure 7 Saliva sample collection using Oragene® DNA OG-500. Adapted 
from http://www.macleans.ca/society/health/the-end-of-blood-samples/ 
accessed 24/09/15 original photo by Andrew Tolson. 
 
Data collection of the non- athlete control cohort for this thesis was a collaborative effort 
with data included from several previous studies. These included data are attributed to 
their associated researchers and details of their contributions are presented in Table 5. 
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USED IN THIS 
PROJECT 
GENES ANALYSED DURING THIS PROJECT 
ROBERT 
ERSKINE 
PhD 60 All Blood ACE I/D and 
ACTN3 rs1815739 
AGT rs699, PPARGC1A rs8192678, UCP2 
rs659336, UCP2 rs660339, and UCP3 rs1800349 
BRANDON 
FOSTER 
PhD 160 All Buccal 
swab 





BSc 62 All Blood ACTN3 rs1815739 None 
JAMIE 
GUNEY 
MSc 17 11 buccal  
6 blood 
ACE I/D and 
ACTN3 rs1815739 
AGT rs699, PPARGC1A rs8192678, UCP2 





40 All Buccal 
swab 
None ACE I/D, ACTN3 rs1815739, AGT rs699, 
PPARGC1A rs8192678, UCP2 rs659336, UCP2 
rs660339, and UCP3 rs1800349 
JAMIE 
MCPHEE 
PhD 61 All Blood ACE I/D, ACTN3 
rs1815739 
AGT rs699, PPARGC1A rs8192678, UCP2 
rs659336, UCP2 rs660339, and UCP3 rs1800349 
GEORGINA 
STEBBINGS 
PhD 120 22 Buccal  
98 Blood 
ACE I/D and 
ACTN3 rs1815739 
ACTN3 rs1815739, AGT rs699, PPARGC1A 




GENESIS 67 All Blood ACTN3 rs1815739 None 
Those marked in bold are trained phlebotomists that took blood samples for this project
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3.6 DNA EXTRACTION METHOD 
3.6.1 Whole Blood And Heat Treated Saliva 
DNA was extracted from a 200 μL sample of either peripheral, EDTA treated, anti-
coagulated whole blood or heat-treated saliva using the automated QIAGEN® QIAcube 
spin column technique according to the manufacturer’s instructions (QIAGEN, Crawley, 
West Sussex, UK). All buffers for DNA extraction were supplied in the QIAGEN® DNA 
Blood Mini kit (QIAGEN). The procedure is detailed in Figure 8. 
 
Briefly, the 200 μL sample was heated to 56°C for 10 min and lysed using QIAGEN 
Protease Enzyme. To the samples, 200 μL of 96% ethanol was added. The samples were 
agitated vigorously to mix. The mixture was transferred to a QIAamp mini spin column 
tube containing a DNA collection filter and was centrifuged at 6,000 g for 1 min. Three 
further wash buffer centrifugation cycles followed to wash out any remaining protein and 
impurities. During these wash cycles genomic DNA remains bound to the silica gel DNA 
filter membrane in the spin column. After each wash the filtrate was discarded. In the final 
buffer centrifugation, the sample genomic DNA was eluted into 100 μL of low salt buffer to 
provide purified genomic DNA. The purified genomic DNA was stored at 4°C until the 




Figure 8 The QIAGEN® DNA Blood Mini procedure performed by the 




3.6.2 Buccal Swab 
DNA was extracted from the buccal swab using the automated QIAGEN® QIAcube spin 
column technique according to the manufacturer’s instructions (QIAGEN). All buffers for 
DNA extraction were supplied in the QIAGEN® DNA Blood Mini kit (QIAGEN). 
 
Briefly, buccal swabs were immersed in 600 μL of phosphate buffered solution (PBS). 
Samples were lysed using 20 μL of QIAGEN Protease Enzyme and 600 μL of buffer AL 
was added. The sample was briefly agitated to mix and incubated at 56°C for 10 mins. To 
the samples 600 μL of 96% ethanol was added and again the samples were agitated 
vigorously on the mixer. Then 700 μL of the mixture was transferred to a QIAamp mini 
spin column tube containing a DNA collection filter and was centrifuged at 6,000 g for 1 
min. Three further wash buffer centrifugation cycles followed to wash out any remaining 
protein and impurities. Samples were centrifuged at 20,000 g for 3 min. During these 
wash cycles genomic DNA remains bound to the DNA filter membrane in the spin column. 
After each wash cycle the filtrate was discarded. In the final buffer centrifugation at 6,000 
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g for 1 min, the sample genomic DNA was eluted into 100 μL of low salt buffer to provide 
purified genomic DNA. The purified genomic DNA was stored at 4°C until the process of 
genotyping was performed. The author extracted 6 samples using this method. 
 
3.7 DETERMINATION OF DNA PURITY AND YIELD 
A Biophotometer Plus (Eppendorf UK Limited, Stevenage, UK) was used to assess the 
purity (whether the protein had been removed) of the extracted genomic DNA samples. 
Approximately 10 μL of extracted genomic DNA sample was placed into a cuvette and 
exposed to 260 nm of ultra violet light (optimal wavelength absorption of DNA), and then 
exposed to 280 nm of ultra violet light (optimal wavelength absorption of protein). The 
ratio of absorbance at 260 nm:280 nm was calculated and ratios within the range 1.7-2.1 
were acceptable to use as PCR template (Ehli et al., 2008). Any samples that failed to 
achieve this level of purity were re-run through the DNA extraction process using a new 
QIAamp spin column. After purification and purity testing the remainder of genomic DNA 
sample was stored at 4°C until genotyping analysis was completed. A total of four samples 
were re-run all were initially collected using the buccal swab method. It may be inferred 
that the dna yield was less from the buccal samples for these for samples. However, on re 




Genotyping was determined using real time polymerase chain reaction (rtPCR). 
Genotyping assay mixes including pre-designed primers and probes and Taqman® 
Genotyping Master Mix (Life Technologies, Carlsbad, California, USA). Genotyping was 
completed on the Chromo4 (BioRad Laboratories Ltd, Hertfordshire, UK), Lightcycler 
(Roche, West Sussex, UK) and StepOne Plus (Life Technologies, Carlsbad, California, 
USA) thermocycling and detection platforms. rtPCR is an in vitro method of producing 
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large amounts of specific DNA fragments from small amounts of DNA template. During a 
single cycle of rtPCR oligonucleotide primers hybridise with the nucleotide sequences on 
the complementary template strands at each end of the DNA fragment to be amplified 
(Figure9). A single stranded oligo probe synthesised to hybridise to the DNA sequence 
between the two primers binds to the template strand (Figure 11). The probe has a 
fluorescent tag conjugated to a terminal nucleotide. At the opposite end of the probe 
sequence, a quencher is tagged to the terminal nucleotide. In close proximity, the 
quencher rapidly absorbs any fluorescence emitted by the fluorescent tag (Figure 10). The 
polymerase enzyme that secures individual nucleotides to the complementary template 
strand also has a secondary function as an exonuclease. This means that when the 
enzyme encounters the double stranded DNA of the bound probe in its synthesis path, it 
will disassemble the strand in its way and replace all of the nucleotides in effect destroying 
the anchoring mechanism of the reporter and quencher tags (Figure 12). This means they 
are no longer bound in close proximity. In the absence of a nearby quencher, the 
fluorescent tag is free to emit detectable light (Figure 13). Each time another amplicon is 
produced another fluorescent marker is released from its neighbouring quencher. 
Therefore, as the number of PCR amplicons doubles during each PCR cycle so does the 
amount of emitted fluorescence. Cyclical polymerisation by thermostable DNA polymerase 
produces millions of identical copies of the DNA fragment of interest thus allowing 
detection of the emitted fluorescence by the fluorimeter. 
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Figure 9 Oligonucleotide primers hybridise with the nucleotide sequences 
on the complementary template strands 
 
 




Figure 11 In close proximity, the quencher rapidly absorbs any fluorescence 
emitted by the fluorescent tag 
 
 
Figure 12 When the exonuclease encounters the double stranded DNA of the 




Figure 13 The fluorescent tag is free to emit detectable light. Figures 9-13 are 
adapted from the animation video at 
https://www.youtube.com/watch?v=kvQWKcMdyS4 developed by Yaw Adu-
Sarkodie of Kwame Nkrumah University of Science and Technology and 
Cary Engleberg of University of Michigan. Copyright 2009-2010, Kwame 
Nkrumah University of Science and Technology and Cary Engleberg. 
 
Reactions were all 10 µL volume. Thermocycling conditions were 95°C for an initial 10 
min, then 40 cycles of 15 s at 95°C and 60 s at 60°C (annealing and extension). 
Genotypes were determined using Opticon Monitor 3.1 software (BioRad Laboratories 
Ltd, Hertfordshire, UK), Lightcycler 96 sw1.1 software (Roche, West Sussex, UK) or 
StepOnePlus software version 2.3 (Life Technologies, Carlsbad, California, USA). All 
genotyping was completed in duplicate and there was 100% agreement between 
duplicates. 
 
Within a single gene polymorphism, where the athlete cohort was analysed across 
multiple thermocycling and detection platforms, a selection of control samples 
representing the three genotype groups were also genotyped across those same 
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platforms, in duplicate to ensure continuity of the results. There was 100% agreement 
across the genotyping platforms. 
 
3.8.1 ACE I/D Polymorphism Genotyping Using The Method Outlined By Koch et al. 
(2005) 
Three hundred and thirteen control samples were genotyped for the ACE I/D 
polymorphism using the method detailed by Koch et al. (2005). Reactions were all 10 µL 
volume and contained the elements shown in Table 6. Thermocycling conditions were 
95°C for an initial 10 min, then 50 cycles of 15 s at 92°C (denaturation) and 60 s at 57°C 
(annealing and extension). All reactions were completed in duplicate. There was 100% 
agreement between duplicate samples. Figure 14 shows a schematic of the Koch et al. 
(2005) primer and probe locations. To confirm identical genotyping results between the 
Koch et al. (2005) and the tagSNP rs4341 method a small number of samples, including 
those of II, ID and DD genotype, were assayed using both methods giving identical 
genotype results in all cases.  
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Table 3 rtPCR reaction materials for the Koch et al. (2005) method 
PCR Material [concentration] Amount required for 
DNA derived from 
whole blood and saliva 
(µL) 
Amount required for DNA 
derived from buccal lysate 
(µL) 
Genotyping Master Mix 5 5 
Nuclease free H2O 1.55 0.05 
I allele specific probe [150 nm] 0.9 0.9 
D allele specific probe [75 nm] 0.9 0.9 
ACE primer 111 [150 nm] 0.38 0.38 
ACE primer 112 [150 nm] 0.38 0.38 
ACE primer 113 [150 nm] 0.38 0.38 
DNA solution 0.5 2 
All DNA used as template was analysed for purity and yield and fell within the range of 
1.7-2.1 µg/ ml 
 
Figure 14 Schematic of the binding sites of primers ACE111, ACE112, and 
ACE113 and probes VIC-AC100 (VIC) and FAM AC100 (FAM) adapted from 
Koch et al. (2005). 
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3.9 STATISTICS 
This section will give an overview of the tests used to analyse the data presented in each 
chapter of this thesis. All descriptive statistics were determined in SPSS version 21 (IBM 
corporation, Florida, USA). To determine differences in height and body mass distributions 
amongst athletes and controls independent t-tests were completed in SPSS version 21 
(IBM corporation). Hardy-Weinberg Equilibrium assessment was completed using Excel 
(Microsoft). Calculation and comparison of genotype and allele frequencies was 
performed in SPSS version 21 (IBM corporation) using a Pearson’s chi-squared test 
where Hardy-Weinberg Equilibrium was apparent. In the few instances where there was a 
departure from hardy Weinberg-Equilibrium a Cochran-Armitage trend test was used to 
assess genotype and allele comparisons. This method was chosen as it modifies the 
Pearson Chi squared test to incorporate a suspected ordering to the effects of the 
categories. This test is often used a genotype based test for case controlled genetic 
association studies. Benjamini Hochberg corrections for multiple testing were applied 
where appropriate using Excel (Microsoft). In this method of correction the p-values are 
ordered in descending order therefore the most likely hypothesis, those supported most 
strongly by the evidence are assessed first. This method of correction gives a more 
stringent alpha value from 0.05 by dividing the rank ordered p-values by the total number 
of hypothesis being tested. In this analysis each gene polymorphism with be treated a 
separate category. 
 
To determine any association of genotype with personal best one way ANOVA were 
completed in SPSS. Positive associations were corrected using the Brown-Forsythe 
method in SPSS. This is because when a 1 way ANOVA is performed the distributions are 
assumed to have equal variance if this assumption is not valid as in the F test is invalid 
and thus it is necessary to use the Brown-Forsythe correction to adjust the F statistic to 
.the absolute deviations from the median.  
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4 GENES ASSOCIATED WITH BLOOD PRESSURE 
REGULATION DURING A MARATHON – ACE AND AGT 
4.1  INTRODUCTION 
Athlete fuel and oxygen delivery through adequate respiratory and haemodynamic 
perfusion relies on cardiac output and adequate blood pressure regulation (Boron and 
Boulpaep, 2012). Theoretically during a race V̇O2 max could be limited by the cardiac 
output, the respiratory systems ability to deliver oxygen to the blood or the exercising 
muscles ability to use oxygen. In untrained individuals it is usually cardiac output that 
determines V̇O2 max. Cardiac output is directly linked to blood pressure through the 
following equation 
 
Blood pressure = cardiac output x Total Peripheral Resistance 
 
With increasing workload one determinant of cardiac output (heart rate) increases 
progressively until it reaches a maximum. With training stroke volume also increases 
though to a lesser degree. As both these elements contribute to cardiac output and thus 
dynamic blood pressure, blood pressure can therefore be viewed as an essential element 
to endurance performance at an elite level in events such as marathon. The RAAS 
controls the haemodynamic status of blood pressure through endocrine mediated 
pathways that include the two key elements AGT and ACE (Boron and Boulpaep, 2012).  
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Figure 15 Adapted from Figure 25.18 The Sympatho-adrenal response to shock. Page 1151 chapter 25 Kumar and Clark. The effect of 
increased catecholamines is shown on the left of the diagram, and the release of angiotensin and aldosterone on the right. Both 









AGT is released by the liver in response to hypovolaemia prolonged hypotension and 
reduced blood sodium concentrations, it is cleaved by renin to form ANGI. ANGI is further 
cleaved by ACE to the potent vasoconstrictive peptide ANGII (see Figure 15). ANGII 
mediates actions via the AT-1 receptor cause vasoconstriction via the following three 
mechanisms. Initially ANGII causes efferent arteriole smooth muscle constriction directly 
via the AT-1 receptor. Resulting in increased total peripheral resistance and hydrostatic 
pressure and reduced blood flow through the kidney increasing the glomerular filtration 
rate in an attempt to regulate blood volume (Boron and Boulpaep, 2012). Binding of ANGII 
to the AT-1 receptor induces the hypertensive response of a reduction in the synthesis of 
nitric oxide. Reduction in nitric oxide synthesis and ANGII mediated AT1-receptor 
activation induces aldosterone release and an increase in the reabsorption of sodium and 
water from the nephron lumen increasing the blood volume and thus hydrostatic pressure 
(Boron and Boulpaep, 2012). ANGII further mediates increases in blood pressure through 
the AT1-receptor in cardiac cells, causing myocyte hypertrophy and increases in cell 
number. The increased muscle mass increases cardiac inotropy, stroke volume, cardiac 
output and thus blood pressure and may be beneficial to meet the increased oxygen 
demand in heavily respiring skeletal muscle during training and competition in endurance 
events such as marathon.  
 
The association of the ACE I/D polymorphism with human performance according to the 
literature appears unclear. The literature suggests that larger cardiac muscle mass is 
associated with the ACE D allele and AGT C allele, and both of these alleles have been 
associated with sporting performance in power based events suggesting some 
commonality between cardiac and skeletal muscle in mechanisms of hypertrophy 
(Gomez-Gallego et al., 2009, Ruiz et al., 2010, Ben-Zaken et al., 2013, Zarebska et al., 
2013). An established clear link between the ACE I allele or ACE II genotype and 
endurance performance remains to be elucidated. Though several studies in British 
(Myerson et al., 1999), Italian (Scanavini et al., 2002) and Spanish (Alvarez et al., 2000) 
athletes have established a link there are numerous studies that have found no 
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association in elite endurance sporting populations (Scott et al., 2005, Oh, 2007, 
Papadimitriou et al., 2009, Ash et al., 2011). Puthucheary et al. (2011) were the first to 
review the published literature on the ACE I/D polymorphism (1998-2010) with 
associations in sporting performance. They suggested a tendency for carriers of the ACE I 
allele to have superior endurance sporting performance. In an attempt to provide a more 
solid evidence base for an association between the ACE II genotype and endurance 
based events a meta-analysis was recently competed. The study by Ma et al. (2013) 
systematically reviewed 25 journal articles addressing the association of the ACE I/D 
polymorphism and sporting performance. Subsequent sporting sub group analysis of 
endurance (17 studies) and power groups (13 studies) was completed. The main finding 
of the meta analysis was an association of the ACE II genotype with physical performance 
when compared to ACE D allele carriers (OR,1.23; CI, 1.05-1.45). Further to this, the ACE 
II genotype was positively associated with performance in endurance athletes (OR,1.35; 
CI, 1.17-1.55). 
 
A lack of clear association with elite athlete status is further reflected in the published AGT 
rs699 studies. Several studies have reported an association of the AGT CC genotype with 
increased left ventricular mass in endurance athletes either when analysed alone 
(Karjalainen et al., 1999) or in combination with the ACE DD genotype (Diet et al., 2001). 
Other have reported no association in 75 elite endurance cyclists and 70 elite distance 
runners (Alvarez et al., 2000, Gomez-Gallego et al., 2009) and in 123 elite and sub-elite 
endurance athletes of mixed discipline including marathon runners (n=12), triathletes 
(n=4) and road cyclists (n=14) (Zarebska et al., 2013). 
 
The results reported thus far in the literature are inconsistent and are difficult to interpret, 
with changing nomenclature in the reporting of results, particularly in the AGT rs699 
polymorphism literature. Therefore, this study aimed to assess the difference in ACE I/D 
and AGT rs699 genotype and allele frequency between athletes and non-athletes. It was 
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hypothesised based on the literature that the ACE II genotype and the AGT rs699 CC 
genotype would be overrepresented in the athletes when compared to non-athletes. In 
addition, comparisons of both genotype and allele frequency and elite athletes status were 
completed. The hypothesis stated the ACE I allele and the AGT C allele would be more 
frequently observed in elite athletes when compared to sub-elite athletes and non-
athletes. Further to this, an investigation of whether genotype was associated with 
personal best time was completed in male and female marathon runners. 
 
4.2 METHOD 
4.2.1 Research Participant Characteristics 
Nine hundred and thirty two Caucasian adults provided written informed consent to take 
part in the ACE I/D analysis. This total cohort comprised 399 marathon runners (male, n = 
243; female, n = 156) and a non-athlete (non-marathon running) cohort, comprising 337 
men and 196 women (Table 7). Six hundred and seventy Caucasian adults provided 
written informed consent to take part in the AGT rs699 analysis. This total cohort 
comprised 364 marathon runners (male, n = 216; female, n = 148) and a non-athlete (non-
marathon running) cohort, comprising 224 men and 82 women (Table 8). The marathon 
runners were stratified into elite and sub-elite subgroups according to their official 
marathon personal best performance time (http://www.powerof10.co.uk). ACE I/D 
research participant age, height and body mass are shown in Table 9. AGT rs699 
research participant age, height and body mass are shown in Table 10 
  
103 
Table 4 Numbers of research participants in the ACE I/D analyses 
  Male Female  Total 
Marathon Athletes 243 156 399 
Elite Marathon Athletes 86 87 173 
Sub-Elite Marathon Athletes 157 69 226 
Non-Athletes 337 196 533 
 
Table 5 Numbers of research participants in the AGT rs699 analyses 
  Male Female  Total 
Marathon Athletes 216 148 364 
Elite Marathon Athletes 75 82 157 
Sub-Elite Marathon Athletes 141 66 207 
Non-Athletes 224 82 306 
 
Table 6 ACE I/D participant characteristics (mean (standard deviation)) 
 Athletes Elite Sub-Elite Non-Athletes 
Height (m) Male 1.78 (0.06) 1.79 (0.06) 1.78 (0.06) 1.79 (0.07) 
Female 1.65 (0.07) 1.65 (0.07) 1.66 (0.08) 1.65 (0.07) 
Mass (kg) Male 67.0 (6.5) 67.1 (7.5) 67.0 (5.9) 77.7 (11.2) 
Female 53.6 (5.3) 52.7 (5.4) 54.8 (5.0) 66.7 (12.7) 
Age (years) Male 36 (8) 37 (10) 35 (6) 24 (9) 
 Female 37 (7) 37 (8) 37 (7) 29 (15) 
 
Table 7 AGT rs699 participant characteristics (mean (standard deviation)) 
 Athletes Elite Sub-Elite Non-Athletes 
Height (m) Male 1.79 (0.06) 1.79 (0.06) 1.78 (0.07) 1.79 (0.06) 
Female 1.65 (0.07) 1.65 (0.07) 1.66 (0.08) 1.65 (0.07) 
Mass (kg) Male 67.0 (6.4) 66.6 (6.8) 67.2 (6.1) 77.0 (11.3) 
Female 53.8 (5.2) 53.0 (5.2) 54.7 (5.1) 66.3 (11.0) 
Age (years) Male 36 (8) 37 (10) 35 (7) 23 (7) 
 Female 37 (7) 37 (8) 37 (7) 25 (10) 
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4.2.2 DNA Collection  
Participant DNA collection is outlined in section 3.5 of the methods. In brief, 588 blood 
samples, 231 buccal samples and 113 saliva samples were collected from participants for 
the ACE I/D analysis. Participant DNA collection from 507 blood samples, 68 buccal 
samples and 95 saliva samples was completed for AGT rs699 analysis. 
 
4.2.3 DNA Isolation  
Automated DNA extraction was performed using a QIAcube (Qiagen, Crawley, UK), 
following the QIAamp blood mini protocol as detailed in the methods section. Concisely, 
200 μL of blood or saliva was lysed with QIAGEN Protease Enzyme. To each lysed 
sample, 200 μL of 96% ethanol was added. Samples were agitated vigorously to mix. The 
sample mixture was transferred to a QIAamp mini spin column tube containing a DNA 
collection filter and bound by centrifugation at 6000 g for 1 min. Remaining protein and 
impurities were removed by three further wash buffer centrifugation cycles. Genomic DNA 
remained bound to the silica gel DNA filter membrane in the spin column during these 
wash cycles. After each wash the filtrate was discarded. In the final buffer centrifugation, 
the participant genomic DNA was eluted into 100 μL of molecular grade H2O to provide 




ACE I/D genotyping of each participant was completed by real-time polymerase chain 
reaction (rtPCR). Three hundred and thirteen non-athletes were genotyped for the ACE 
I/D polymorphism using the method outlined by Koch et al. (2005). In brief, each 10 mL 
reaction contained: 5 mL Genotyping Master Mix (Applied Biosystems, Foster City, 
California, USA), 1.55 μL nuclease-free H2O (Qiagen), 0.9 μL of I and D allele-specific 
probes and 0.38 μL of ACE primer 111, 112, 113 (sequences below) were combined with 
0.5 μL DNA solution per well for blood and saliva. For DNA derived from buccal cells, 
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identical primer and probe volumes were used but 0.05 μL H2O and 2 μL DNA solution 
were used. 
 
Primers and probes produced by applied biosystems (Outlined in Figure 14) 
For the direct ACE I/D assay (Koch et al., 2005), three primers (150 nM each) and probes 
VIC (150 nM) and FAM (75 nM) were used; 
Primer ACE111: 5ˈ-CCCATCCTTTCTCCCATTTCTC-3ˈ 
Primer ACE112: 5ˈ-AGCTGGAATAAAATTGGCGAAAC-3ˈ 
Primer ACE113: 5ˈ-CCTCCCAAAGTGCTGGGATTA-3ˈ 
I Allele specific probe (VIC-ACE100): VIC-5ˈAGGCGTGATACAGTCA-3ˈ-MGB 
D Allele specific probe (FAM-ACE100): FAM-5ˈTGCTGCCTATACAGTCA-3ˈ-MGB 
 
ACE I/D genotype was established for all participants by rtPCR using either a Chromo4 or 
StepOnePlus real-time PCR system. Briefly, there were 50 cycles of denaturation at 92°C 
for 15 s then annealing and extension at 57°C for 1 min. Initial analysis was performed 
using Opticon Monitor 3.1 software for the Chromo4 or StepOnePlus software version 2.3. 
There was 100% agreement within duplicates of all samples. 
Five hundred and fifty nine athletes and non-athletes were ACE I/D genotyped using the 
TaqMan assay for rs4341 that contained the appropriate TaqMan primers and probes 
(Applied Biosystems). Each 10 μL rtPCR experiment contained 5 μL Genotyping Master 
Mix (Applied Biosystems), 4.3 μL nuclease-free H2O (Qiagen), 0.5 μL ACE rs4341 
TaqMan genotyping assay mix (Applied Biosystems), and 0.2 μL of participant DNA. For 
control wells, 0.2 μL nuclease-free H2O replaced the DNA template. ACE rs4341 TaqMan 
genotyping was completed on the StepOnePlus real-time PCR system. There were 40 
cycles of denaturation at 95°C for 15 s then annealing and extension at 60°C for 1 min 
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according to the manufacturer’s instructions. StepOnePlus software version 2.3 was used 
for analysis. There was 100% agreement within duplicates of all samples. 
 
AGT rs699 genotype was also established for all participants by rtPCR. The genotyping 
protocol was identical to that described in the preceding paragraph, except the AGT rs699 
TaqMan assay that included the appropriate TaqMan primers and probes was used 
(Applied Biosystems). 
 
4.2.5 Data Analysis and Statistics 
SPSS was used to perform independent T-tests to compare height and body mass 
between athletes and non-athletes. Genotype and allele frequencies in all groups were 
calculated and compared using chi-square analyses in SPSS (version 21, SPSS Inc). 
Excel (Microsoft, 2013) was used to assess Hardy-Weinberg equilibrium. Genotype 
associations with personal best were assessed in SPSS by one way ANOVA.  
 
4.3 ACE I/D RESULTS 
4.3.1 Height and Body Mass 
Self-reported participant height and body mass are shown in Table 9. Male non-athletes 
were 10.7 kg heavier than male marathon athletes (p = 1.0 x10-13) and female non-
athletes were 13.1 kg heavier than female marathon athletes (p = 1.0 x10-13). There was 
no difference in height between marathon athletes and non-athletes for either males (p = 
0.229) or females (p = 0.507). 
 
4.3.2 ACE I/D Hardy-Weinberg Equilibrium 
The ACE I/D genotype distributions amongst research participants were in Hardy-
Weinberg equilibrium (Marathon athlete χ2 = 0.011, Elite marathon athletes χ2 = 0.212, 
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Sub-Elite marathon athletes χ2 = 0.299, and Non-Athlete χ2 = 1.488, p > 0.05 for all 
groups). When stratified by sex, there was also no deviation from Hardy-Weinberg 
equilibrium (Males: Marathon athlete χ2 = 0.053, Elite marathon athletes χ2 = 0.731, Sub-
Elite marathon athletes χ2 = 0.127, and Non-Athlete χ2 = 1.124, p > 0.05 for all groups), 
(Females: Marathon athlete χ2 = 0.208, Elite marathon athletes χ2 = 0.044, Sub-Elite 
marathon athletes χ2 = 0.204, and Non-Athlete χ2 = 0.392, p > 0.05 for all groups). 
 
4.3.3 ACE I/D Genotype and Allele Frequencies 
Table 11 details the ACE I/D genotype and allele frequency distributions in the marathon 
athlete and non-athlete cohorts. The primary analysis between the entire marathon athlete 
cohort and the non-athletes showed no genotype or allele association of the ACE I/D 
polymorphism and endurance marathon running (genotype χ2 = 2.145, p = 0.342; allele χ2 
= 1.143, p = 0.285). Further analysis considering genotype and allele frequencies in elite 
marathon and sub-elite marathon athlete cohorts compared independently to non-athletes 
revealed no ACE I/D polymorphism associations (elite marathon athletes vs non-athletes 
genotype χ2 = 2.632, p = 0.268; allele χ2 = 1.167, p = 0.280). For completeness, the elite 
marathon athlete cohort was compared to the sub-elite marathon athlete cohort and again 
no differences were observed (genotype χ2 = 0.752, p = 0.687; allele χ2 = 0.252 p = 
0.616). In essence, neither genotype nor allele associations were observed when males 
and females were combined in any group comparison (marathon athletes, elite marathon 
athletes, sub-elite marathon athletes, non-athletes).
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Table 8: ACE I/D genotype and allele frequencies in marathon athletes and non-athletes. 
  ACE Genotype ACE Allele 
Total Cohort DD ID II D I 
Marathon athletes 123 (30.8%) 198 (49.6%) 78 (19.5%) 444 (55.6%) 354 (44.4%) 
Elite Marathon 
athletes 
57 (32.9%) 82 (47.4%) 34 (19.7%) 196 (56.6%) 150 (43.4%) 
Sub-Elite Marathon 
athletes 
66 (29.2%) 116 (51.3%) 44 (19.5%) 248 (54.9%) 204 (45.1%) 
Non-Athletes 147 (27.6%) 279 (52.3%) 107 (20.1%) 573 (53.8%) 493 (46.2%) 
Males  
Marathon athletes 77 (31.7%) 118 (48.6%) 48 (19.8%) 272 (56.0%) 214 (44.0%) 
Elite Marathon 
athletes 
31 (36.0%) 38 (44.2%) 17 (19.8%) 100 (58.1%) 72 (41.9%) 
Sub-Elite Marathon 
athletes 
46 (29.3%) 80 (51.0%) 31 (19.7%) 172 (54.8%) 142 (45.2%) 
Non-Athletes 94 (27.9%) 177 (52.5%) 66 (19.6%) 365 (54.2%) 309 (45.8%) 
Females  
Marathon athletes 46 (29.5%) 80 (51.3%) 30 (19.2%) 172 (55.1%) 140 (44.9%) 
Elite Marathon 
athletes 
26 (29.9%) 44 (50.6%) 17 (19.5%) 96 (55.2%) 78 (44.8%) 
Sub-Elite Marathon 
athletes 
20 (29.0%) 36 (52.2%) 13 (18.8%) 76 (55.1%) 62 (44.9%) 
Non-Athletes 53 (27.0%) 102 (52.0%) 41 (20.9%) 208 (53.1%) 184 (46.9%) 
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Independent analysis of the male marathon athlete cohort detailed in Table 11 
demonstrated no difference in genotype or allele frequencies when compared to non-
athletes (genotype χ2 = 2.164, p = 0.339; allele χ2 = 0.959, p = 0.327). Nor were any 
differences observed when comparing the elite marathon athletes and non-athlete 
(genotype χ2 = 3.333 p = 0.189; allele χ2 = 1.332, p = 0.248), sub-elite marathon athletes 
and non-athlete (genotype χ2 = 0.235, p = 0.889; allele χ2 = 0.133, p = 0.716) or elite 
marathon athlete and sub-elite marathon athlete groups (genotype χ2 = 1.323, p = 0.516; 
allele χ2 = 0.541, p = 0.462). 
 
Also shown in Table 11 are the genotype and allele frequencies of the female participants.  
Similarly to the men, there was no difference in genotype or allele distribution frequency 
between female marathon athletes and non-athletes (genotype χ2 = 0.295, p = 0.863; 
allele χ2 = 0.238, p = 0.626), nor between the elite marathon athletes and non-athlete 
(genotype χ2 = 0.232 p = 0.890; allele χ2 = 0.141, p = 0.707), sub-elite marathon athletes 
and non-athlete (genotype χ2 = 0.102, p = 0.950; allele χ2 = 0.097, p = 0.756) or elite 
marathon and sub-elite marathon athlete groups (genotype χ2 = 0.040, p = 0.980; allele χ2 
= 0.005 p = 0.945). 
 
4.4 AGT RS699 RESULTS 
4.4.1 Height and Body Mass 
No difference in height was observed between marathon athletes and non-athletes in 
either the male (p = 0.599) or the female (p = 0.747) cohorts. However, non-athletes 
males were 10 kg heavier than male marathon athletes (p = 1.0 x10-13), while female non-
athletes were 12.5 kg heavier than female marathon athletes (p = 1.003 x10-10), as shown 
in Table 10 all data are self-reported by participants. 
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4.4.2 AGT rs699 Hardy-Weinberg Equilibrium 
There was no deviation from Hardy-Weinberg equilibrium in AGT rs699 genotype 
distributions amongst research participants and non-athletes (Marathon athlete χ2 = 0.009, 
Elite marathon athletes χ2 = 0.011, Sub-Elite marathon athletes χ2 = 0.041, and Non-
Athletes χ2 = 0.042, p > 0.05 for all groups). When stratified by sex, Hardy-Weinberg 
equilibrium also existed in all groups (Males: Marathon athlete χ2 = 2.307, Elite marathon 
athletes χ2 = 3.193, Sub-Elite marathon athletes χ2 = 0.300, and Non-Athletes χ2 = 0.059, 
p > 0.05 for all groups), (Females: Marathon athlete χ2 = 2.831, Elite marathon athletes χ2 
= 3.476, Sub-Elite marathon athletes χ2 = 0.196, and Non-Athletes χ2 = 0.002, p > 0.05 for 
all groups). 
 
4.4.3 AGT rs699 Genotype and Allele Frequencies 
The genotype frequency distributions of the AGT rs699 polymorphism differed between 
marathon athletes and non-athletes, with a 5.6% higher TT genotype frequency in the 
marathon athletes (χ2 = 6.248, p = 0.044; Table 12, OR = 0.777, 95% CI 0.562 – 1.074. p 
= 0.126). Similarly, the T allele was 4.5% more frequent in marathon athletes compared 
with non-athletes (χ2 = 5.961, p = 0.015; Figure 16, OR = 0.832, 95% CI 0.669 – 1.034 p = 
0.097). There was no difference in either genotype (χ2 = 1.079, p = 0.583) or allele (χ2 = 
1.060, p = 0.303) frequencies between elite marathon athletes and non-athletes, although 
the sub-elite marathon cohort tended to contain more TT genotypes (χ2 = 5.844, p = 
0.054) and 5.7% more T alleles (χ2 = 5.480, p = 0.019 allele: OR = 0.790, 95% CI 0.613 – 
1.019. p = 0.069) when compared to non-athletes (shown in Figure 16). No further 
differences were observed when the male and female data were combined. 
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Table 9 AGT rs699 genotype and allele frequencies in marathon athletes and non-athletes 
  AGT Genotype AGT Allele 
Total Cohort TT TC CC T C 
Marathon Athletes 131 (36.0%) 174 (47.8%) 59 (16.2%) 436 (59.9%) 292 (40.1%) 
Elite Marathon 
Athletes 
53 (33.8%) 77 (49.0%) 27 (17.2%) 183 (58.3%) 131 (41.7%) 
Sub-Elite Marathon 
Athletes 
78 (37.7%) 97 (46.9%) 32 (15.5%) 253 (61.1%) 161 (38.9%) 
Non Athletes 93 (30.4%) 153 (50.0%) 60 (19.6%) 339 (55.4%) 273 (44.6%) 
Males  
Marathon Athletes 83 (38.4%) 93 (43.1%) 40 (18.5%) 259 (60.0%) 173 (40.0%) 
Elite Marathon 
Athletes 
29 (38.7%) 29 (38.7%) 17 (22.7%) 87 (58.0%) 63 (42.0%) 
Sub-Elite Marathon 
Athletes 
54 (38.3%) 64 (45.4%) 23 (16.3%) 172 (61.0%) 110 (39.0%) 
Non Athletes 65 (29.0%) 113 (50.4%) 46 (20.5%) 243 (54.2%) 205 (45.8%) 
Females  
Marathon Athletes 48 (32.4%) 81 (54.7%) 19 (12.8%) 177 (59.8%) 119 (40.2%) 
Elite Marathon 
Athletes 
24 (29.3%) 48 (58.5%) 10 (12.2%) 96 (58.5%) 68 (41.5%) 
Sub-Elite Marathon 
Athletes 
24 (36.4%) 33 (50.0%) 9 (13.6%) 81 (61.4%) 51 (38.6%) 




Figure 16 AGT rs699 allele frequencies in marathon athletes and non-
athletes. The T allele is more frequent in marathon athletes (* p = 0.015) and 
sub-elite marathon athletes († p = 0.019) compared to non-athletes. 
 
In men, marathon athletes showed a 9.7% higher TT genotype frequency than non-
athletes (χ2 = 6.801, p = 0.033; Table 12, OR = 0.655, 95% CI 0.440 - 0.975, p = 0.037). 
In agreement, there was a tendency for the T allele to be more frequent in marathon 
athletes than non-athletes (χ2 = 3.638, p = 0.056). No differences in genotype or allele 
frequencies were observed between elite marathon athletes and non-athletes (genotype 
χ2 = 3.974, p = 0.137; allele χ2 = 0.413, p = 0.521). Neither were genotype frequencies 
different between sub-elite marathon athletes and non-athletes (χ2 = 4.280, p = 0.118; 
Table 12), although there was a tendency for the T allele to be more frequent in the sub-
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genotype (χ2 = 1.583, p = 0.453) or allele frequency distributions (χ2 = 0.445, p = 0.505) 
between elite and sub-elite marathon athletes.  
 
Figure 17 AGT rs699 allele frequencies in male marathon athletes and non-
athletes. The T allele tended to be more common in marathon athletes (* p = 
0.056) and sub-elite marathon athletes († p = 0.058) than non-athletes. 
 
Female marathon athletes showed no difference in genotype or allele frequency 
distributions when compared to non-athletes (genotype χ2 = 4.324, p = 0.115; allele χ2 = 
2.325, p = 0.127). Neither were any differences observed when comparing elite marathon 
athletes and non-athlete (genotype χ2 = 3.527, p = 0.171; allele χ2 = 0.656, p = 0.418), 























































1.905, p = 0.168) or elite and sub-elite marathon athlete groups (genotype χ2 = 1.114, p = 
0.573; allele χ2 = 0.325, p = 0.568). 
 
4.4.4 Comparison of Marathon PB and Genotype 
Performance times were not significantly different between ACE I/D genotype groups 
(males F = 0.939, p = 0.393; females F = 0.010, p = 0.990; Figure 18 and 19). Neither 
were performance times different between the AGT rs699 genotype groups (males F = 
0.142 p = 0.868; females F = 0.315, p = 0.730; Figure 20 and 21). 
 
Figure 18 Marathon personal best times for males grouped by ACE I/D 




Figure 19 Marathon personal best times for females grouped by ACE I/D 




Figure 20 Marathon personal best times for males grouped by AGT rs699 
genotype. Data are medians and minimum and maximum. 
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Figure 21 Marathon personal best times for females grouped by AGT rs699 
genotype. Data are medians and minimum and maximum. 
 
4.5 DISCUSSION 
This study assessed the association of marathon sporting performance with the ACE I/D 
and AGT rs699 polymorphisms via a candidate gene approach. The main finding of this 
study was that the AGT rs699 TT genotype and T allele were associated with marathon 
athlete status compared to non-athletes. When males and females were combined, the 
sub-elite marathon athletes showed an AGT rs699 polymorphism TT genotype tendency 
(p = 0.054) and T allele association with marathon performance rather than the elite 
marathon athletes. A T allele tendency was also recorded in the whole male marathon 
athlete cohort when compared to non-athletes. The sub-elite male marathon athletes 
(those who complete a marathon in times between 2 hours 30 min and 2 hours 45 min) 
also showed a T allele tendency. There were no other AGT rs699 genotype or allele 
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associations with marathon performance. This result may be explained by adaptedness in 
the context of population genetics. It may be that the physiological phenotype fits the sub-
elite marathon athletes to a greater extent than the elite athlete and the relative fitness is 
higher in the sub-elite marathon population than the elite marathon population. It may also 
be that gene flow has influenced this sample though as the laws of Hardy-Weinberg were 
met this is unlikely.  
 
Elite endurance athlete status was not associated with either genotype or allele frequency 
distribution of the ACE I/D polymorphism when analysed by the same methods. There 
was no association between personal best marathon time in males or females marathon 
runners and either the ACE I/D polymorphism or the AGT rs699 polymorphism. 
 
These results support the notion that AGT rs699 may signify a RAAS-dependent 
association with endurance performance in marathon running (Karjalainen et al., 1999, 
Diet et al., 2001). The AGT rs699 polymorphism has been reported to influence cardio-
respiratory endurance, left ventricular hypertrophy and circulating ANGII levels in several 
cohorts (Diet et al., 2001, Karjalainen et al., 1999, Gomez-Gallego et al., 2009). The 
results of this study contrast those of Karjalainen et al. (1999) and Diet et al. (2001) who 
found CC genotype associations with increased left ventricular mass in endurance 
athletes and extrapolated that the CC genotype may be influential in elite endurance 
sporting performance due to increased oxygen delivery. However, the current study of 364 
Caucasian elite and sub-elite marathon athletes suggested association with the TT 
genotype and T allele when compared to non-athletes. Although an increased left 
ventricular mass may be postulated to improve oxygen delivery to the skeletal muscle 
during endurance exercise it will undoubtedly also increase the oxygen demand of the 
cardiac muscle to execute the same workload. An increased cross-sectional area of 
cardiac muscle tissue may also negatively influence the volume of the left ventricular 
chamber, reducing end-diastolic volume and thus stroke volume. This increased cardiac 
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workload and possible reduction in stroke volume, in addition to an increased metabolic 
demand by a higher cardiac tissue mass facing an already high metabolic demand by 
skeletal muscle, would have a detrimental effect on an endurance athlete. Carriers of the 
AGT rs699 CC genotype exhibit higher diastolic blood pressure (Rankinen et al., 2000a) 
and then T allele carriers (TT and TC genotypes) after 20 weeks of endurance training 
(Rankinen et al., 2000a). TT and TC genotype carriers also showed a greater decrease in 
diastolic pressure when compared to CC homozygotes (Rankinen et al., 2000a) and this 
may indicate that the pressor response induced via AGT and the AT1-R is detrimental to 
endurance performance in marathon running - thus TT genotype and T allele carriers may 
be preferential for endurance competition at an elite level. 
 
In addition, the RAAS-mediated association with endurance performance may be 
explained by preferential degradation of the vasodilator bradykinin by ACE over the 
formation of the vasoconstrictor ANGII. Higher kinin activity has been associated with the 
ACE I allele (Murphey et al., 2000). It could therefore be postulated that the reduced 
levels of AGT, a precursor substrate in the RAAS for ANGII, exhibited by the T allele 
carriers could cause a pathway flux towards bradykinin production. Bradykinin (a 
vasodilator) increases skeletal muscle perfusion and glucose uptake (Wicklmayr et al., 
1983). Greater skeletal muscle substrate availability for respiration is likely to mediate 
positive alterations in metabolic activity and increased efficiency of oxygen utilisation 
during the exertion of a prolonged endurance event like a marathon. 
 
4.6 CONCLUSION 
Although this study found there was no direct ACE I/D polymorphism association with 
endurance performance, it may be that through the mechanisms outlined above RAAS 
mediates enhancements in marathon performance. Previous studies that reported an 
association between ACE activity and endurance performance in humans have typically 
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used cohorts containing relatively small numbers and mixed athlete groups that often lack 
a clearly defined performance phenotype. Often, cohort data appear to have been reused 
in subsequent studies and therefore there are might be some bias in the published 
research. While the Puthucheary et al. (2011) review and Ma et al. (2013) meta-analysis 
attempted to address these limitations, the current study is the first to do so with a 
relatively large and homogenous group of marathon athletes. 
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5 MUSCLE STRUCTURAL GENE - Α-ACTININ 3 
5.1 INTRODUCTION 
The α-actinin 3 (ACTN3) gene has previously been associated with rodent and human 
physical performance and elite athlete status in both endurance (Ahmetov et al., 2010, 
Niemi and Majamaa, 2005, Grealy et al., 2012) and sprinting events (Yang et al., 2003, 
Niemi and Majamaa, 2005). The human sarcomeric α-actinins are a family of actin-binding 
proteins related to dystrophin. They are major structural components of the Z line in 
skeletal muscle. The α-actinins crosslink the actin thin filaments to the Z-line and therefore 
play a static role in the structural organisation of the sarcomeric myofibrils (see Figure 3). 
In addition, it is thought the α-actinins ensure sarcomeric integrity during rapid myofibre 
contraction (Yang et al., 2003, Blanchard et al., 1989, Mills et al., 2001). 
 
In humans, two genes encode the skeletal muscle: α-actinin 2 (ACTN2) and ACTN3. α 
actinin-2 is expressed in all skeletal muscle fibres whereas α actinin-3 has restricted 
expression to fast twitch (type II) fibres (Yang et al., 2003). A common nonsense 
polymorphism (rs1815739) results in a transition from C>T at position 1747 in the ACTN3 
coding sequence causing a premature stop codon (TGA; X allele) at position 577 (Mills et 
al., 2001) leading to a non-functioning protein. Both the R (coding for a functioning 
protein) and X alleles are common within the general population although 18% of the 
European population and around 1 billion world-wide are XX homozygous and thus 
deficient of any functioning α-actinin-3 protein (Yang et al., 2003).  
 
Yang et al. (2003) were the first to hypothesize that a deficiency in α-actinin-3 protein may 
elicit an advantage to athletes competing in endurance-based events such as the 
marathon, based on a study of a cohort of Australian endurance athletes. Further studies 
detailing α actinin-3 expression in a knockout mouse model demonstrated a decrease in 
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muscle fibre cross sectional area as a result of an increase in the type 1 fibre type and 
also increased oxidative enzyme expression in the muscle associated with oxidative 
capacity -indicating a move to the efficient aerobic pathway by the mouse (MacArthur et 
al., 2007, MacArthur et al., 2008). This lead to enhanced endurance running performance 
and better recovery from fatiguing muscle contractions compared to the wild type mice. 
The ACTN3 knock out mouse metabolic phenotype is similar to that of skeletal muscle 
following aerobic endurance exercise training in the mouse. It is suspected the ACTN3 
R577X polymorphism contributes to genetic variation in muscle fibre composition and 
further suggested in the literature that the α-actinin 3 deficient muscle is pre-conditioned 
for endurance performance (MacArthur et al., 2008, Seto et al., 2013). The hypothesis 
that the ACTN3 577X allele is associated with enhanced endurance performance is 
controversial as further elite endurance athlete studies have not supported of the Yang et 
al. (2003) hypothesis finding no association of the ACTN3 577X allele and athletic 
performance (Niemi and Majamaa, 2005, Lucia et al., 2006, Döring et al., 2010, Saunders 
et al., 2007, Yang et al., 2007, Muniesa et al., 2010) or contradictory evidence of an R 
allele association with performance (Ahmetov et al., 2010). The previous associations of 
the ACTN3 577X polymorphism and elite endurance performance have been primarily 
completed in mixed endurance athlete cohorts bar Grealy et al. (2012) who reported an 
association in the multiple part event ironman triathlon. Therefore, the aim of the present 
study was to examine the frequency of the ACTN3 R577X genotype and allele in 
Caucasian elite and sub elite marathon runners and to investigate whether there was an 
association between ACTN3 and elite marathon performance. 
 
5.2 METHODOLOGY 
5.2.1 Research Participant Characteristics 
One thousand and seventy five Caucasian adults provided written informed consent to 
take part in this study. This total cohort comprised 399 marathon runners (male, n = 243; 
female, n = 156) and a non-athlete (non-marathon running) cohort, comprising 383 men 
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and 293 women. The marathon athletes were stratified into elite and sub-elite subgroups 
according to their official marathon personal best performance time 
(http://www.poweroften.co.uk; Table 13). Research participant height and body mass are 
shown in Table 14. 
Table 10 Numbers of research participants in the ACTN3 rs1815739 analyses 
  Male Female  Total 
Marathon Athletes 243 156 399 
Elite Marathon Athletes 86 87 173 
Sub-Elite Marathon Athletes 157 69 226 
Non-Athletes 383 293 676 
 
Table 11 ACTN3 rs1815739 participant characteristics (mean (standard deviation)) 
 Athletes Elite Sub-Elite Non-Athletes 
Height (m) Male 1.78 (0.06) 1.79 (0.06) 1.78 (0.06) 1.79 (0.07) 
Female 1.65 (0.07) 1.64 (0.07) 1.66 (0.08) 1.65 (0.07) 
Mass (kg) Male 67.0 (6.5) 67.1 (7.5) 67.0 (5.9) 78.4 (11.5) 
Female 53.6 (5.3) 52.7 (5.4) 54.8 (5.0) 66.3 (12.4) 
Age (years) Male 35.9 (8.0) 37.3 (10.2) 35.0 (6.4) 27.9 (15.3) 
 Female 38.0 (7.4) 36.6 (7.9) 37.4 (6.9) 31.4 (18.4) 
 
5.2.2 DNA Collection 
Participant DNA collection is outlined in section 3.5 of the methods. In brief, 731 EDTA 
treated blood samples, 231 buccal samples and 113 saliva samples were collected from 
participants for the ACTN3 rs1815739 analyses. 
 
5.2.3 DNA Isolation 
Automated DNA extraction was performed using a QIAcube (Qiagen,), following the 
QIAamp blood mini protocol as detailed in the methods section. Briefly, a 200 μL sample 
was lysed with QIAGEN Protease Enzyme. To each sample, 200 μL of 96% ethanol was 
added. Samples were agitated vigorously to mix. The mixture was transferred to a 
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QIAamp mini spin column tube containing a DNA collection filter and bound by 
centrifugation at 8000 rpm for 1 min. Three further wash buffer centrifugation cycles 
followed to wash out any remaining protein and impurities. Genomic DNA remained bound 
to the silica gel DNA filter membrane in the spin column during these wash cycles. After 
each wash the filtrate was discarded. In the final buffer centrifugation, the sample genomic 
DNA was eluted into 100 μL of molecular grade H2O to provide purified genomic DNA. 
The purified genomic DNA was stored at 4°C until the genotyping was performed. 
 
5.2.4 Genotyping 
Each participant’s ACTN3 rs1815739 genotype was established using real-time 
Polymerase Chain Reaction (rtPCR). Genotyping of all participants was completed using 
the ACTN3 rs1815739 TaqMan assay that included the appropriate TaqMan primers and 
probes (Applied Biosystems,). Each 10 μL PCR reaction contained: 5 μL Genotyping 
Master Mix (Applied Biosystems), 4.3 μL nuclease-free H2O (Qiagen), 0.5 μL ACTN3 
rs1815739 TaqMan genotyping assay mix (Applied Biosystems), and 0.2 μL of participant 
DNA. For control wells, 0.2 μL nuclease-free H2O replaced the DNA template. Genotyping 
was completed on the StepOnePlus (Applied Biosystems) real-time PCR system. Briefly, 
there were 40 cycles of denaturation at 95°C for 15 s then annealing and extension at 
60°C for 1 min according to the instructions for optimal performance. StepOnePlus 
software version 2.3 (Applied Biosystems) was used to determine each participant’s 
ACTN3 rs1815739 genotype. All samples were analysed in duplicate. There was 100% 
agreement within all sample duplicates. 
 
5.2.5 Data Analysis and Statistics 
Independent T-tests to determine differences in height and weight distributions amongst 
athletes and non-athletes were performed in SPSS Hardy-Weinberg equilibrium 
assessment was completed using Excel (Microsoft, 2013). SPSS was used to calculate 
and compare genotype and allele frequencies between athlete groups and non-athletes 
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by Pearson’s Chi square test. Analysis between elite marathon and sub-elite marathon 
athlete groups were completed using chi square test of difference in SPSS. Genotype 
associations with personal best were assessed by one way ANOVA in SPSS). 
5.3 ACTN3 RS1815739 RESULTS 
5.3.1 Height and Body Mass 
Table 14 shows the self-reported height of the non-athlete and the marathon athlete 
groups, they were similar for both males (p = 0.849) and females (p = 0.333). The male 
non-athlete group body mass was 11.2 kg heavier than the marathon athlete group (p = 
1.000 x10-13). The female non-athlete group body mass was heavier by 10.9 kg (p = 1.000 
x10-13) all data are self-reported. 
 
5.3.2  ACTN3 rs1815739 Hardy-Weinberg Equilibrium 
The ACTN3 genotype distributions amongst all participants were in Hardy-Weinberg 
equilibrium (Marathon athletes χ2 = 0.008, Elite marathon athletes χ2 = 0.049, Sub-Elite 
marathon athletes χ2 = 0.093, and Non-Athletes χ2 = 1.121, p > 0.05 for all groups, 1 df). 
Hardy-Weinberg equilibrium remained when the data were stratified into males and 
females. 
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5.3.3 ACTN3 rs1815739 Genotype and Allele Frequencies  
Table 12 Genotype and allele frequencies of ACTN3 rs1815739 polymorphism in marathon athletes and non-athletes. 
  ACTN3 rs1815739 Genotype ACTN3 rs1815739 Allele 
Total Cohort RR  RX XX  R X  
Marathon Athletes  119 (29.8%) 197 (49.4%) 83 (20.8%) 435 (54.5%) 363 (45.5%) 
Elite Marathon 
Athletes 
52 (30.1%) 87 (50.3%) 34 (19.7%) 191 (55.2%) 155 (44.8%) 
Sub-Elite Marathon 
Athletes 
67 (29.6%) 110 (48.7%) 49 (21.7%) 244 (54.0%) 208 (46.0%) 
Non-Athletes 230 (34.0%) 317 (46.9%) 129 (19.1%) 777 (57.5%) 575 (42.5%) 
Males  
Marathon Athletes 79 (32.5%) 112 (46.1%) 52 (21.4%) 270 (55.6%) 216 (44.4%) 
Elite Marathon 
Athletes 
30 (34.9%) 37 (43.0%) 19 (22.12%) 97 (56.4%) 75 (43.6%) 
Sub-Elite Marathon 
Athletes 
49 (31.2%) 75 (47.8%) 33 (21.0%) 173 (55.1%) 141 (44.9%) 
Non-Athletes 140 (34.0%) 177 (46.9%) 66 (19.1%) 457 (57.5%) 309 (42.5%) 
Females  
Marathon Athletes 40 (25.6%) 85 (54.5%) 31 (19.9%) 165 ((52.9%) 147 (47.1%) 
Elite Marathon 
Athletes 22 (25.3%) 50 (57.5%) 15 (17.2%) 94 (54.0%) 80 (46.0%) 
Sub-Elite Marathon 
Athletes 18 (26.1%) 35 (50.7%) 16 (23.2%) 71 (51.4%) 67 (48.6%) 
Non-Athletes 90 (34.0%) 140 (46.9%) 63 (19.1%) 320 (57.5%) 266 (42.5%) 
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Table 15 shows no difference in ACTN3 R577X genotype (χ2 = 3.209, p = 0.201 or allele 
frequencies (χ2 = 0.715, p = 0.398) when marathon athletes were compared to non-
athletes. When compared to non-athletes the elite marathon athlete group showed no 
difference in genotype (χ2 = 1.255, p = 0.534) or allele distribution (χ2 = 0.728, p = 0.393). 
There were no differences in genotype or allele frequency of ACTN3 R577X when sub-
elite marathon athletes were compared to non-athletes (genotype χ2 = 2.225, p = 0.329; 
allele χ2 = 2.250, p = 0.134). There were no differences between the elite marathon 
athletes and the sub-elite marathon athletes in either genotype frequency (χ2 = 0.251, p = 
0.882) or allele frequency (χ2 = 0.118, p = 0.732). 
 
The XX genotype (χ2 = 0.880, p = 0.644) and allele (χ2 = 0.729 p = 0.393) frequency 
distributions of the ACTN3 rs1815739 polymorphism were not different amongst the male 
marathon athletes and non-athletes (Table 15). This lack of association was further seen 
when male elite marathon athletes when compared to non-athletes (genotype χ2 = 0.702, 
p = 0.704, allele χ2 = 0.081, p = 0.776; Table 15). The sub-elite male marathon athletes 
showed no difference in genotype frequency distribution (χ2 = 0.699, p = 0.705) or allele 
frequency distribution (χ2 = 0.725, p = 0.395) when compared to non-athletes (Table 3). 
Between group analysis of male elite marathon athletes and all sub-elite marathon 
athletes revealed no difference in genotype (χ2 = 0.532, p = 0.766) or allele (χ2 = 0.293, p 
= 0.588) frequency distributions (Table 15) 
 
The genotype frequency distributions and allele frequency distribution of the ACTN3 
rs1815739 polymorphism were not different amongst the female marathon athletes and 
non-athletes (genotype, χ2 =5.191, p = 0.075; allele, χ2= 0.729, p =  0.393; Table 15). No 
difference was observed in the genotype frequency distributions (χ2 = 4.182, p = 0.124) or 
allele frequency distribution (χ2 = 0.846, p = 0.358) when between group analysis of the 
female elite marathon athlete and non-athletes was completed (Table 15). There was no 
difference in genotype distribution (χ2 = 2.103, p = 0.349) or allele frequency distributions 
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(χ2 = 2.103, p = 0.349) when sub-elite female marathon athletes were compared to non-
athletes (χ2 = 2.047, p = 0.153; Table 3). The female elite marathon athlete cohort showed 
no differences when compared all sub-elite marathon athletes (genotype χ2 =1.016, p = 
0.602; allele χ2 =8.37 x10-4, p = 0.993) as shown in Table 15. 
 
5.3.4 Comparison of Marathon PB and Genotype 
Median marathon performance time for each genotype group are shown in Figure 22 for 
males and Figure 23 for females. Median marathon performance time were not 
significantly different between genotype groups (males F = 0.206, p = 0.814; females F = 
0.257, p = 0.774). 
 
 
Figure 22 Marathon personal best times for males grouped by ACTN3 




Figure 23 Marathon personal best times for females grouped by ACTN3 
rs1815739 genotype. Data are medians and maximum and minimum 
 
5.4 DISCUSSION 
The purpose of this study was to comparatively analyse the frequency of the ACTN3 
R577X polymorphism in elite and sub-elite endurance marathon athletes, and non- 
athletes. In addition, the study tested the association of the ACTN3 R577X polymorphism 
with personal best performance in the marathon. There was no difference in ACTN3 
R577X genotype or allele frequency distribution between the marathon athlete population 
and the non-athlete population compared as whole groups or stratified by sex and elite 
athlete status. No genotype association with personal best time was recorded for either 
males or females. 
 
130 
The ACTN3 genotype frequencies in the non-athlete population were similar to those 
reported for the Australian Caucasian population (Yang et al., 2003). However, they were 
different to the Finnish non-athlete population (Niemi and Majamaa, 2005) who recorded 
fewer XX genotypes (9.2%) and also different to the Spanish non-athlete population of 
Lucia et al .,(2006) who recorded 26% XX genotype in their non-athlete population. Both 
of these studies had approximately 120 non-athlete participants. Those in the study by 
Niemi and Majamaa (2005) were described only as anonymous Finnish blood donors with 
no description of ancestry. In the study by Lucia et al. (2006) the non-athlete population 
was described as 123, healthy, sedentary, unrelated, Caucasian, male controls of 
European ancestry though sedentary behaviour was not reported so it is likely these 
participants exhibited low physical activity rather than true sedentary behaviour. Both of 
these non-athlete cohorts are much smaller than the 676 participants used in the 
Caucasian non-athlete cohort in this study therefore the genotype frequencies of the non–
marathon athlete cohort are more reliable. 
 
In this population the ACTN3 R577X, polymorphism does not appear to confer enhanced 
performance in marathon runners. This investigation supports the work of other groups 
using sporting populations (Lucia et al., 2006, Saunders et al., 2007, Yang et al., 2007, 
Ahmetov et al., 2010, Muniesa et al., 2010, Döring et al., 2010) who reported no 
association between the ACTN3 genotype and elite endurance performance. 
 
It was hypothesised that there may be a genotype dependant difference in marathon PB, 
with those of the XX genotype having a significantly faster marathon PB than those of the 
other two-genotype groups. This hypothesis was based on the rodent and human work of 
Vincent et al. (2007) and (Seto et al., 2013) who showed that the percentage surface area 
and number of type II fibres was higher in RR rather than XX genotypes. As marathon is 
predominantly an endurance event, athletes demonstrate more type 1 slow oxidative 
fibres (Gollnick et al., 1972, Gollnick et al., 1973) than fast-twitch therefore the XX 
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genotype was assumed to be favourable. In addition, Ahmetov et al., (2011) showed that 
ACTN3 XX genotype was associated with an increased slow-twitch fibre proportion and 
with increased preferred racing distance in speed skaters. They concluded that the 
ACTN3 R577X polymorphism was only probably partially associated with muscle fibre 
type composition and that this had an important but small influence on the ability to 
perform at a high level in speed skating. 
 
We found that personal best were not genotype-dependent for either men or women (P ≥ 
0.783). This study supports the work of Grealy et al.,(2012) who concluded, based on 
analysis of triathlon performance times, that ACTN3 alone does not appear to confer any 
advantage to endurance athletes in allowing them to sustain an extreme bout of 
endurance exercise. 
 
These investigations have all used endurance athletes from multiple sporting disciplines 
(800 m - marathon, cycling, rowing, swimming, cross-country skiing and race walking) 
making it difficult to extrapolate whether the ACTN3 R577X polymorphism is associated 
with athlete performance in a particular sport such as marathon. In contrast, this 
investigation has recruited athletes from the same sporting discipline. This is 
advantageous over the heterogeneous sample of endurance athletes of multiple sporting 
disciplines as the physiological characteristics of marathon runners is likely to be more 
homogenous, so more confidence can be placed in the reported results. Another possible 
explanation for the discrepancy in the reported results between the aforementioned 
studies and this study is each study varies in the author’s interpretation of elite athlete 
status. Eynon et al. (2009a) and Niemi and Majamaa (2005) determined elite athlete 
status by national or international representation at a track and field championships, 
whereas the elite athletes reported by Yang et al. (2003) had all represented Australia at 
an international level only. In the current study athletes were classified as elite if they had 
achieved a personal best marathon performance time of 2 hours 30 minutes for male 
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athletes and 3 hours for female athletes. This may in part explain the difference in 
reported results. Eynon et al. (2009a) notes that the groups used in their study were not 
large, due to the small number of elite athletes available in Israel. The long distance 
endurance group contained 77 athletes who had either competed in 10000m or marathon 
at national or international track and field championships. Niemi and Majamaa (2005) also 
had a small endurance athlete population of 52 that ranged from 800 to marathon and 
included race walkers. Although Yang et al. (2003) had a larger overall endurance cohort 
of 194 only 15 of those athletes were track athletes (≥5000m) this may have contributed to 
the false reporting of a positive association due to a small sample size. 
 
5.5 CONCLUSION 
In summary, the findings of this study suggest that the ACTN3 R577X polymorphism does 
not play a role in predisposing elite / sub-elite marathon runner status, or in determining 
marathon PB performance A possible explanation for the observed lack of ACTN3 R577X 
association with elite athlete status in marathon runners is that due to the conserved 
nature of the α-actinin proteins ACTN2 partially compensates for the speculated 
advantageous effect that ACTN3 provides in sarcomeric structural integrity during fast 
skeletal muscle contraction in the human. Although Seto et al. (2013) provide plausible 
evidence in a very small number of human research participants for the ACTN3 model 




6 GENES THAT MAY INFLUENCE ENERGY PRODUCTION - 
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR 
GAMMA, COACTIVATOR 1 ALPHA - PPARGC1A 
6.1 INTRODUCTION  
Endurance events, such as marathon, induce co-ordinated changes in gene expression, 
which are regulated by transcription factors and co-activators. PPARγ coactivator 1α 
(PGC-1α) is a transcription co-activator that regulates gene expression in multiple 
biological responses, including mitochondrial biogenesis and oxidative phosphorylation 
(Lin et al., 2005). As such, in humans, tissues that catabolize fatty acids such as liver, 
skeletal muscle, and myocardium have high levels of PGC-1α mRNA expression, along 
with kidney and to a lesser extent brain, pancreas and white adipose tissue (Esterbauer et 
al., 1999). The interaction of PGC-1α with specific transcription factors, such as nuclear 
receptor PPARγ, nuclear respiratory factors 1 and 2, and muscle specific transcription 
factors, such as MEF2 (Lin et al., 2002), mediates PGC-1α’s regulation of several genes 
encoding key enzymes involved in fatty acid oxidation (Finck and Kelly, 2006, 
Maciejewska et al., 2011) and oxidative phosphorylation (Lucia et al., 2005, Arany et al., 
2005). 
 
PGC-1α knock out mice show decreased expression of genes involved in mitochondrial 
function (Arany et al., 2005) and a reduction in expression of 30-50% genes implicated in 
oxidative phosphorylation, fatty acid oxidation and ATP synthesis cardiac muscle. 
Decreased mitochondrial density and respiratory capacity have been reported in the 
skeletal muscle of type I knock out mice (Leone et al., 2005). Therefore, PGC-1α is a key 
requirement for normal expression of mitochondrial genes in cardiac and skeletal muscle 
(Arany et al., 2005). In humans, PGC-1 α is encoded by the PPARGC1A gene, the 
expression of which is increased in response to endurance training (Tunstall et al., 2002, 
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Pilegaard et al., 2003, Norrbom et al., 2004). This may therefore induce enhanced skeletal 
muscle oxidative capacity via PPARa and PPARγ regulation of gene expression (Lin et 
al., 2002, Lin et al., 2005, Russell et al., 2003). In addition, enhanced mitochondrial 
density and oxidative capacity may promote a transition from fast to slow muscle fibre 
type, utilizing a primarily oxidative metabolism (Lin et al., 2002, Lin et al., 2005). Training 
induced adaptation of the muscle caused in part by increased PGC-1α expression may 
also influence the use of energy substrates in pathways such as fatty acid oxidation, the 
Krebs cycle and glucose transportation and oxidation (Arany et al., 2005, Baar, 2004, 
Baar et al., 2002), which is likely to influence endurance sporting performance. 
 
A G>A SNP at position 23814039 in chromosome 4 in the PPARGC1A gene (rs8192678) 
results in the substitution of Gly for Ser at amino acid position 482. Elderly carriers of the 
A allele have been shown to have lower basal PPARGC1A mRNA levels compared to GG 
homozygotes (Ling et al., 2004). Several studies have investigated an association 
between the PPARGC1A rs8192678 SNP and elite athlete status/performance. Lucia et 
al. (2005) reported an association of the A allele in elite endurance athletes compared 
with non-athlete controls. This finding was replicated by (Eynon et al., 2009b, Eynon et al., 
2009c), who also found lower numbers (0.25) of A-allele carriers in a group of Israeli 
endurance athletes (p = 0.0001. The A-allele was further reported to be associated with 
lower aerobic capacity in Russian rowers (Ahmetov et al., 2007). When 1423 Russian 
athletes of mixed sporting discipline were compared to 1,132 non-athlete controls, the 
PPARGC1A G>A SNP was associated with endurance athlete status, the proportion of 
slow-twitch muscle fibres and maximal oxygen consumption (Ahmetov et al., 2009).  
However, in 60 Turkish elite endurance athletes the AA genotype and A allele was over 
represented in endurance athletes. In essence, when genotype distributions were 
examined according to aerobic performance there was an association between 
PPARGC1A genotype and maximal oxygen consumption (p < 0.001) (Tural et al., 2014). 
This data suggested the PPARGC1A A-allele has a strong effect on aerobic performance 
in 60 Turkish elite endurance athletes (p < 0.001) (Tural et al., 2014). 
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This inconsistency in the published results raises the question of whether endurance 
performance influenced by the PPARGC1A G>A SNP. The purpose of this study was to 
analyse the genotype and allele frequency distribution of the PPARGC1A rs8192678 SNP 
in prima facie Caucasian (elite and sub-elite) marathon runners and a healthy non-athletic 
prima facie Caucasian non-athlete control populations. In addition, marathon performance 
was compared between PPARGC1A genotype and allele groups. Based on the literature 
it was hypothesised that the minor A-allele would be under-represented in the elite 
marathon runner cohort compared to a non-athlete control group, and that carriers of the 
A-allele would have slower marathon performance times compared to GG homozygotes. 
6.2 METHOD 
6.2.1 Research Participant Characteristics 
The PPARGC1A rs8192678 SNP investigation included a marathon cohort of 243 male 
and 156 female Caucasian marathon runners, which was divided into elite and sub-elite 
groups based on personal best performance times. Controls consisted of 224 males and 
82 females to give a total cohort of 306 individuals, who had not competed in sport at an 
elite/sub-elite standard. For completeness of analysis, the marathon and control cohorts 
were characterised according to sex for some of the data analysis. Complete numbers in 
each research group for the PPARGC1A rs8192678 study are outlined in Table 16 
Table 13 Numbers of research participants in the PPARGC1A rs8192678 analyses 
  Male Female  Total 
Marathon Athlete 243 156 399 
Elite Marathon Athletes 86 87 173 
Sub-Elite Marathon Athletes 157 69 226 
Non-Athletes 224 82 306 
 
Table 14 PPARGC1A rs8192678 participant characteristics (mean (standard deviation)) 
 Athlete Elite Sub-Elite Control 
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Height (m) Male 1.78 (0.06) 1.79 (0.06) 1.78 (0.06) 1.79 (0.07) 
Female 1.65 (0.07) 1.65 (0.07) 1.66 (0.08) 1.65 (0.07) 
Mass (kg) Male 67.0 (6.5) 67.1 (7.5) 67.0 (5.9) 77.0 (11.3) 
Female 53.6 (5.3) 52.7 (5.4) 54.8 (5.0) 66.3 (11.0) 
Age (years) Male 36 (8) 37 (8) 37 (7) 31 (18) 
 Female 37 (7) 37 (8) 37 (7) 31 (18) 
 
6.2.2 DNA Collection 
Participant DNA collection is outlined in Chapter 3, Section 3.5 of the methods. In brief, 
521 blood samples, 71 buccal samples and 113 saliva samples were collected from 




Section 3.8 of Chapter 3 describes the DNA genotyping in full. Briefly each participants 
PPARGC1A rs8192678 genotype was detected by real-time PCR, using the TaqMan 
assay that included the appropriate primers and probes (Applied Biosystems). Each 10 µL 
pcr reaction contained: 5 µL Genotyping Master Mix (Applied Biosystems), 4.3 µL 
nuclease-free H2O (Qiagen), 0.5 µL PPARGC1A rs8192678 TaqMan genotyping assay 
mix (Applied Biosystems), and 0.2 µL of participant DNA. For control wells, 0.2 µL 
nuclease-free H2O replaced the DNA template. Genotyping was completed on the 
StepOnePlus real-time PCR machine (Applied Biosystems). Briefly, there were 40 cycles 
of denaturation at 95°C for 15 s then annealing and extension at 60°C for 1 min. 
StepOnePlus software version 2.3 (Applied Biosystems) was used to determine each 
participant’s genotype. All samples were analysed in duplicate and there was 100% 
agreement within all duplicate samples. 
6.2.4 Data Analysis and Statistics 
SPSS (version 21, SPSS Inc) was used to perform the statistical analyses. Independent 
T-tests were used to determine differences in height and body mass between marathon 
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athletes and non-athlete controls. Genotype and allele frequencies between marathon 
athlete groups and non-athlete controls were calculated and compared by Pearson’s Chi 
square test. Analysis of genotype and allele frequency distribution between elite and sub-
elite marathon groups were completed using chi square test of difference. Excel 
(Microsoft, 2013) was used to complete Hardy-Weinberg equilibrium assessment. A 
genotype association with personal best performance time was assessed by one way 
ANOVA.  A post hoc Brown-Forsythe correction was added to the significant one way 
ANOVA result to account for the group variances being unequal as calculated by the 
Levene’s test. This meant that the one way ANVOA analysed the absolute deviations from 
the median rather than the mean. 
 
6.3 PPARGC1A RS8192678 RESULTS 
6.3.1 Height and Body Mass 
The male marathon athlete and non-athlete control cohorts did not differ in height (p = 
0.427). However, on average male marathon athletes weighed 10 kg lighter than the male 
non-athlete controls (p = 1.0 x10-13). In females, there was no difference in the height of 
the marathon athletes when compared to the non-athlete controls (p = 0.495). However, 
the female non-athlete controls were on average 12.7 kg heavier than the female 
marathon athletes were (p = 1.002 x10-10). These data are shown in Table 17 and are self-
reported. 
 
6.3.2 PPARGC1A rs8192678 Hardy-Weinberg Equilibrium 
In both marathon athletes and non-athlete controls the PPARGC1A rs8192678 genotype 
met Hardy-Weinberg equilibrium (Marathon athlete χ2 = 0.673, Non-Athlete χ2 = 0.002, p = 
0.05, 1 df) in all groups tested independently (Elite marathon athletes χ2 = 0.520, Sub-Elite 
marathon athletes χ2 = 3.037). Hardy-Weinberg equilibrium remained when data were 
stratified by sex and re-analysed (Males: Marathon athlete χ2 = 0.222, Elite marathon 
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athletes χ2 = 0.142, Sub-Elite marathon athletes χ2 = 0.569, and Non-Athlete χ2 = 0.460, p 
= 0.05 for all groups), (Females: Marathon athlete χ2 = 0.523, Elite marathon athlete χ2 = 
0.820, Sub-Elite marathon athlete χ2 = 3.414, and Non-athletes χ2 = 1.111, p = 0.05 for all 
groups). 
 
6.3.3 PPARGC1A rs8192678 Genotype and Allele Frequencies 
The results of the distribution of PPARGC1A genotypes and alleles in the athlete and 
controls are presented in Table 18. The initial analysis conducted in the whole marathon 
athlete cohort revealed a tendency to a higher frequency of the A-allele in the marathon 
athlete cohort than in non-athletic controls (χ2 = 2.988, p = 0.084). When considering the 
frequency of the A-allele in the two separate marathon athlete groups to non-athletic 
controls no differences were observed. For completeness, the elite and sub-elite 
marathon athlete cohorts allele frequencies were also compared, again no differences 
were observed. There were no differences in genotype frequency distribution between any 
of the group comparisons (elite marathon athletes, sub-elite marathon athletes, non-
athlete controls) when both male and female marathon athletes were analysed together. 
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Table 15 The genotype and allele frequencies of PPARGC1A rs8192678 polymorphism in marathon athletes and non-athletes 
  PPARGC1A Genotype PPARGC1A Allele 
Total Cohort GG GA AA G A 
Marathon Athletes 179 (44.9%) 171 (42.9%) 49 (12.3%) 529 (66.3%) 269 (33.7%) 
Elite Marathon 
Athletes 
71 (41.0%) 83 (48.0%) 19 (11.0%) 225 (65.0%) 121 (35.0%) 
Sub-Elite Marathon 
Athletes 
108 (47.8%) 88 (38.9%) 30 (13.3%) 304 (67.3%) 148 (32.7%) 
Non-Athletes 146 (47.7%) 131 (42.8%) 29 (9.5%) 423 (69.1%) 189 (30.9%) 
Males  
Marathon Athletes 107 (44.0%) 106 (43.6%) 30 (12.3%) 320 (65.8%) 166 (34.2%) 
Elite Marathon 
Athletes 
30 (34.9%) 43 (50.0%) 13 (15.1%) 103 (59.9%) 69 (40.1%) 
Sub-Elite Marathon 
Athletes 
77 (49.0%) 63 (40.1%) 17 (10.8%) 217 (69.1%) 97 (30.9%) 
Non-Athletes 103 (46.0%) 101 (45.1%) 20 (8.9%) 307 (68.5%) 141 (31.5%) 
Females  
Marathon Athletes 72 (46.2%) 65 (41.7%) 19 (12.2%) 209 (67.0%) 103 (33.0%) 
Elite Marathon 
Athletes 
41 (47.1%) 40 (46.0%) 6 (6.9%) 122 (70.1%) 52 (29.9%) 
Sub-Elite Marathon 
Athletes 
31 (44.9%) 25 (36.2%) 13 (18.8%) 87 (63.0%) 51 (37.0%) 
Non-Athletes 43 (52.4%) 30 (36.6%) 9 (11.0%) 116 (70.7%) 48 (29.3%) 
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In the male cohort, the primary analysis of PPARGC1A rs8192678 genotype and allele 
frequencies showed no association between marathon athletes and non-athlete controls. 
On closer inspection, the minor A-allele was over represented 9.2% in the elite male 
marathon athletes when compared to non-athlete controls (χ2 = 6.871, p = 0.03) (shown in 
Figure 24) An association was also reflected in the male elite marathon cohort towards the 
minor AA genotype (χ2 = 6.890, p = 0.04) when compared to non-athlete controls (OR = 
0.696, 95% CI 0.383 – 1.265, p = 0.235). Further to this, a tendency towards the minor A-
allele was seen when the male elite marathon group was compared to the male sub-elite 




Figure 24 The PPARGC1A rs8192678 allele frequencies in male elite 
marathon athletes all non-athletes the AA genotype (* p = 0.032) and A allele 




































































PPARGC1A Genotype and Allele 




In the female cohort, there was a 7.8% higher AA genotype frequency in sub-elite 
marathon athletes compared to non-athlete controls (χ2 = 7.193, p = 0.04) (shown in 
Figure 25) (OR = 0.531, 95% CI 0.212 – 1.331, p = 0.177) and a tendency for a higher AA 
frequency in sub-elite vs. elite marathon athletes (χ2 = 5.425, p = 0.066). There were no 
further associations of either genotype or allele frequencies in the female cohorts (shown 
in Figure 25). 
 
 
Figure 25 The PPARGC1A rs8192678 allele frequencies in female elite 
marathon athletes, female sub-elite marathon athletes and all non-athletes: 
The AA genotype is more frequent in female sub-elite marathon athletes 
than non-athletes (* p = 0.027). Female sub-elite marathon athletes showed a 
tendency towards a higher AA genotype frequency than elite marathon 
athletes († p = 0.066)  
 
6.3.4 Comparison of Marathon PB and Genotype 
Male and female median performance time for each genotype group are shown in Figure 
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groups in male marathon runners (F = 2.051, p = 0.131). However, in female marathon 
runners, performance time was slower in AA homozygotes compared to individuals of GG 
and GA genotype (F = 3.136, p = 0.022 (Brown-Forsythe correction).  
 
 
Figure 26 Marathon personal best times for males grouped by PPARGC1A 
rs8191678 genotype. Data are medians and maximum and minimum 
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Figure 27 Marathon personal best times for females grouped by PPARGC1A 
rs8191678 genotype. Data are medians and maximum and minimum 
 
6.4 DISCUSSION 
The current study demonstrates that the PPARGC1A G>A SNP is associated with elite 
athlete status in male marathon runners. The minor A-allele was overrepresented in a 
cohort of elite male marathon runners, who complete a marathon in 2 hours 30 minutes or 
less, when compared to non-athlete controls. Non-significant tendencies for a greater 
frequency distribution of the A-allele were observed between the whole marathon athlete 
cohort and non-athletic controls, and the male elite marathon athletes when compared to 
the sub-elite male marathon athletes. Non-significant tendencies for a greater frequency 
distribution of the minor AA genotype were seen when male elite marathon athletes when 
compared to non-athlete controls and female sub-elite marathon athletes when compared 
to non-athlete controls and elite female marathon athletes. A genotype association with 
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personal best time was not observed in males but female AA homozygotes were found to 
be slower than their GA and GG counterparts.  
 
The greater frequency of the minor A-allele among elite male marathon athletes compared 
controls are somewhat in line with a previous finding that elite endurance performance 
was greater in carriers of the A-allele compared to G-allele carriers in 60 Turkish elite 
endurance athletes, who had participated in national/international track and field 
championships. Tural et al. (2014) also reported that AA genotype and the A-allele were 
over-represented in the endurance athletes compared to non-athlete controls. Thus, these 
results suggest the PPARGC1A A-allele contributes to elite endurance athlete status and 
performance. The physiological mechanism(s) underpinning the genotype association with 
elite endurance athlete status in the present study and that by Tural et al. (2014) cannot 
be inferred from the present results. Although (elderly) carriers of the minor A-allele have 
been shown to have lower basal PPARGC1A mRNA levels compared to GG 
homozygotes (Ling et al., 2004), it is possible that the A-allele positively influences 
PPARGC1A mRNA stability, thus potentially increasing translation and skeletal muscle 
PGC-1α content. As well as PGC-1α being a key requirement for normal expression of 
mitochondrial genes in cardiac and skeletal muscle (Arany et al., 2005), it has also been 
found to interact with oestrogen-related receptor-α (ERRα) to increase transcription of the 
lactate dehydrogenase B (LDHB) gene in skeletal muscle (Summermatter et al., 2013). As 
LDH catalyses the conversion of lactate to pyruvate, it is important in lactate clearance. 
Hence, a combination of an increase in mitochondrial density and LDHB expression (via 
increased PGC-1α concentration/activity) should increase time to exhaustion and, 
therefore, endurance performance in PPARGC1A A-allele carriers. 
 
In contrast to the apparent benefit of being an A-allele carrier in terms of elite male 
marathon athletes status, the present study demonstrated that female AA homozygotes 
had a slower personal best marathon time compared to their GG and GA counterparts. 
145 
This sex-dependent genotype association with endurance athlete status/performance may 
be linked to by PGC-1α’s interaction with ERRα, as explained above (Summermatter et 
al., 2013).Due to the similarity between ERR-α and oestrogen receptor-α (ER-α), and the 
finding that the two proteins regulate similar genes (Vanacker et al., 1999), it is possible 
that higher circulating levels of oestrogen in females compared to males inhibits the 
otherwise beneficial effect of the PPARGC1A A-allele, thus explaining why female AA  
homozygotes in the present study had a slower personal best marathon performance 
compared to female marathon athletes of GA and GG genotype. 
 
The slower female marathon performance in AA homozygotes compared to female 
athletes of GG and GA genotypes is in line with the findings of (Lucia et al., 2005), who 
found a higher frequency of the G-allele among a mixture of different types of elite 
endurance athletes (50 male world-class Spanish cyclists and 54 male middle- and long-
distance) compared to controls. This association study was replicated in a large mixed 
cohort of Russian and Polish endurance athletes (Maciejewska et al., 2011). They 
determined that the minor A-allele was under represented in their mixed sporting 
discipline cohort of athletes when compared to a low activity control population. It should 
be noted that the Polish and Russian athlete cohorts did not contain any marathon 
runners in their endurance cohorts and therefore may not be representative of the genetic 
frequency distributions that may influence elite marathon runner status and marathon 
running performance. 
 
This is the first study to investigate an association between the PPARGC1A rs8191678 
G>A SNP and elite endurance athlete status and running performance in a large cohort of 
solely marathon runners. Previous studies investigating the association of this SNP with 
elite athlete status have done so in mixed athlete cohorts, which may confound any 
association due to increased “noise” caused by the different physiological importance of 
PGC-1α in different athlete groups. By examining an association in a pure athlete group, 
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the present study suggests that the minor A-allele is important in determining elite athlete 
status in male marathon runners, while this minor allele appears to be disadvantageous in 
determining performance in female marathon runners.  
 
6.5 CONCLUSION 
In summary, this study found that the minor PPARGC1A A-allele is over-represented in a 
large cohort of elite male marathon runners. However, female homozygotes of the A-allele 
were slower than other female marathon runners of GG and GA genotype. 
This may be due to oestrogen inhibiting the interaction between PGC1- α and ERRα, thus 





7 UNCOUPLING PROTEINS – UCPS 
7.1 INTRODUCTION 
The ability to complete a marathon at an elite speed requires short-term responses and 
long-term training adaptations to the extreme physiological demands placed upon the 
skeletal muscle (Bruton, 2002, Jiang et al., 2009, Stewart and Rittweger, 2006, Coyle, 
2007, Gamboa and Andrade, 2012, Zhou et al., 2000). Mitochondria are a key 
determinant of that adaption providing the energy required for skeletal muscle contraction 
and thus propulsion and through uncoupling proteins, the regulation of energy expenditure 
and heat production during exercise (Zhou et al., 2000, Jiang et al., 2009). Uncoupling 
proteins are mitochondrial intramembranous proteins responsible for the anti-porting of 
anions and protons across the inner mitochondrial membrane (Boron and Boulpaep, 
2012, Boss et al., 1997, Muzzin et al., 1999). In doing so, they regulate oxidative 
phosphorylation coupling to ATP production - vital in an endurance exercise event such as 
marathon. Several publications have suggested further roles for UCPs, though these 
mechanisms are not fully understood (Muzzin et al., 1999). One such suggestion is that 
uncoupling proteins mediate ROS production by skeletal muscle in response to exercise, 
caused by the large fluxes in oxygen through the electron transport chain in heavily 
respiring skeletal muscle and an inevitable oxygen perfusion mismatch causing localised 
hypoxia (Vogt et al., 2001, Boss et al., 1997). This would modulate ATP production 
through intracellular fatty acids and account for the hypothesised possible influences of 
insulin on UCP3 expression and UCP3 expression on GLUT 4 expression in mice 
(Pedersen et al., 2001, Astrup et al., 1999, Tsuboyama-Kasaoka et al., 1998, Nisr and 
Affourtit, 2014). Exercise in rodent models has been reported to increase both UCP2 and 
UCP3 mRNA expression (Tsuboyama-Kasaoka et al., 1998, Jiang et al., 2009, Cortright 
et al., 1999, Zhou et al., 2000) suggesting that glucose and fatty acid metabolism in 
response to exercise may be regulated via UCPs and that in heavily respiring muscle 
UCPs reduce free radical production. This would confer a competitive advantage in the 
marathon as elite runners often in the later stages of the race are reliant on fatty acid 
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based production of ATP. Increased efficiency in the coupling of ATP production and 
oxidative phosphorylation through the uncoupling proteins may provide a competitive 
advantage to endurance athletes and predispose athletes to performance success at the 
elite level. 
 
Gene polymorphisms that have been associated with aerobic capacity (Ahmetov et al., 
2008, Ahmetov et al., 2009), delta efficiency (Dhamrait et al., 2012) and oxidative 
phosphorylation (Jiang et al., 2009, Muzzin et al., 1999, Nisr and Affourtit, 2014), making 
them candidates for associations with elite endurance performance, include UCP2 
rs659366, UCP2 rs660339 and UCP3 rs1800849. In 61 healthy, adults who exhibit low 
physical activity, the T allele of UCP2 rs659366 was associated with delta efficiency 
assessed via cycle ergometry before and after endurance training (Dhamrait et al., 2012). 
UCP2 rs660339 was also associated with endurance performance in 230 Russian rowers 
when compared to non-athletes (Ahmetov et al., 2008). The rowers showed T allele 
associations with increased V̇O2 max and higher frequencies of the T allele in their most 
elite athletes. This group also investigated the frequency of the UCP3 rs1800849 
polymorphism the T allele was associated with elite performance in rowing and increased 
V̇O2 max (Ahmetov et al., 2009). Later, the same research group expanded their study to 
include endurance athletes from other endurance sporting disciplines including 134 
runners (Ahmetov et al., 2008). Again, they assessed the UCP2 rs660339 and UCP3 
rs1800849 polymorphisms reporting a higher frequency of both the UCP2 rs660339 T 
allele and the UCP3 rs1800849 T allele in the athlete cohort when compared to controls 
(Ahmetov et al., 2008). Interestingly, the UCP3 rs1800849 T allele was not associated 
with endurance performance in the athletes competing in the longest race disciplines 
though this stratification by race distance meant there were very few athletes from each 
sporting discipline in each category and this may have reduced statistical power. Further 
association studies of the UCP3 rs1800849 polymorphism in the sport of triathlon reported 
no association of either allele with race completion time (Hudson et al., 2004). These 
149 
athletes were also compared to a control cohort, where no differences were reported in 
either genotype or allele frequency (Hudson et al., 2004). 
 
Thus the findings regarding UCP polymorphisms in endurance athletes are unclear and 
the athlete group’s used previously either contain athletes of multiple sporting disciplines 
or athletes who complete in tri-part events, each with varying phenotypes. Consequently, 
the purpose of this study was to investigate whether there was a difference in genotype 
and/or allele frequency between the marathon cohort and a control group. In essence, it 
was hypothesised that the TT genotype would be over represented in the marathon cohort 
for all three UCP polymorphisms. Similarly it was hypothesized that the T allele would be 
more prevalent in the elite marathon runners when compared to sub-elite marathon and 
controls. Accordingly, it was hypothesised that T allele carriers would be able to complete 




7.2.1 Research Participant Characteristics 
7.2.1.1 UCP2 rs659366 
Five hundred and seventy eight prima facie Caucasian adults provided written informed 
consent to take part in this study. This total cohort comprised 364 marathon runners 
(male, n = 216; female, n = 148) and a control (non-marathon running) cohort, comprising 
224 men and 82 women. The marathon runners were stratified into elite and sub-elite 
subgroups according to their official marathon personal best performance time 
(http://www.poweroften.co.uk; Table 19). Research participant height and body mass are 
shown in Table 22. 
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Table 16 Research participant numbers for the UCP2 rs659366 analyses 
  Male Female  Total 
Marathon Athletes 216 148 364 
Elite Marathon Athletes 75 82 157 
Sub-Elite Marathon Athletes 141 66 207 
Non-Athletes 224 82 306 
 
7.2.1.2 UCP2 rs660339 
Six hundred and fifty eight prima facie Caucasian adults provided written informed 
consent to take part in this study. This total cohort comprised 396 marathon runners 
(male, n = 241; female, n = 155) and a control (non-marathon running) cohort, comprising 
224 men and 82 women. The marathon runners were stratified into elite and sub-elite 
subgroups according to their official marathon personal best performance time 
(http://www.poweroften.co.uk; Table 20). Research participant height and body mass are 
shown in Table 22. 
 
Table 17 Research participant numbers for the UCP2 rs660339 analyses 
  Male Female  Total 
Marathon Athletes 241 155 396 
Elite Marathon Athletes 86 87 173 
Sub-Elite Marathon Athletes 155 68 223 
Non-Athletes 224 82 306 
 
7.2.1.3 UCP3 rs1800849 
Seven hundred and five prima facie Caucasian adults provided written informed consent 
to take part in this study. This total cohort comprised 399 marathon runners (male, n = 
243; female, n = 156) and a non-athlete control cohort, comprising 224 men and 82 
women. The marathon runners were stratified into elite and sub-elite subgroups according 
to their official marathon personal best performance time (http://www.poweroften.co.uk; 
Table 21). Research participant height and body mass are shown in Table 22. 
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Table 18 Research participant numbers for the UCP3 rs1800849 analyses 
  Male Female  Total 
Marathon Athletes 243 156 399 
Elite Marathon Athletes 86 87 173 
Sub-Elite Marathon Athletes 157 69 226 
Non-Athletes 224 82 306 
 
Table 19 UCP2 rs659366, UCP2 rs660339, and UCP3 rs1800849 research participant 
characteristics (mean (standard deviation.)) 
 Athlete Elite Sub-Elite Control 
Height (m) Male 1.78 (0.06) 1.79 (0.06) 1.78 (0.06) 1.79 (0.07) 
Female 1.65 (0.07) 1.65 (0.07) 1.66 (0.08) 1.65 (0.07) 
Mass (kg) Male 67.0 (6.5) 67.1 (7.5) 67.0 (5.9) 77.0 (11.3) 
Female 53.6 (5.3) 52.7 (5.4) 54.8 (5.0) 66.3 (11.0) 
Age  Male 36 (8) 37 (10) 35 (7) 23 (7) 
 Female 37 (7) 37 (8) 37 (7) 25 (10) 
 
7.2.2 DNA Collection 
Participant DNA collection is outlined in in section 1.5 of the methods. In brief, 521 blood 
samples, 71 buccal samples and 113 saliva samples were collected from participants for 
the UCP2 rs659366 analysis. Participant DNA collection from 518 blood samples, 71 
buccal samples and 113 saliva samples was completed for UCP2 rs660339 analysis. Five 
hundred and twenty one blood samples, 71 buccal samples and 113 saliva samples were 
collected from participants to complete the UCP3 rs1800849 analyses. 5mL blood 
samples were taken from a superficial forearm vein and stored in an EDTA treated tube at 
-20°C until processing. Saliva samples were collected into Oragene DNA OG-500 
collection tubes (DNA Genotek Inc., Ontario, Canada) according to the manufacturer’s 
instructions and stored at room temperature until genotyping. Sterile buccal swabs (Omni 
swab, Whatman, Springfield Mill, UK) were rubbed against the cheek approximately 20 
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times to collect buccal cells. Tips were ejected into sterile tubes and stored at -20°C for 
transportation to the lab for DNA isolation. 
 
7.2.3 DNA Isolation  
Automated DNA extraction was performed using a QIAcube (Qiagen, Crawley, UK), 
following the QIAamp blood mini protocol as detailed in the methods section. Briefly, 200 
μL sample was lysed with QIAGEN Protease Enzyme. To each sample, 200 μL of 96% 
ethanol was added. Samples were agitated vigorously to mix. The mixture was transferred 
to a QIAamp mini spin column tube containing a DNA collection filter and bound by 
centrifugation at 6000 g for 1 min. Three further wash buffer centrifugation cycles followed 
to wash out any remaining protein and impurities. Genomic DNA remained bound to the 
silica gel DNA filter membrane in the spin column during these wash cycles. After each 
wash the filtrate was discarded. In the final buffer centrifugation, the sample genomic DNA 
was eluted into 100 μL of molecular grade H2O to provide purified genomic DNA. The 
purified genomic DNA was stored at 4°C until the genotyping was performed. 
 
7.2.4 Genotyping 
UCP genotyping of all participants was completed by rtPCR. Genotyping of all participants 
was completed using the TaqMan assays for UCP2 rs659366, UCP2 rs660339 and UCP3 
rs1800849 (Applied Biosystems). Each TaqMan assay that included the appropriate 
TaqMan primers and probes (Applied Biosystems). Each 10 μL rtPCR reaction contained 
5 μL Genotyping Master Mix (Applied Biosystems), 4.3 μL nuclease-free H2O (Qiagen 
West Sussex, UK), 0.5 μL TaqMan genotyping assay mix (Applied Biosystems), and 0.2 
μL of participant DNA. For control wells, 0.2 μL nuclease-free H2O replaced the DNA 
template. Genotyping was completed on the StepOnePlus real-time PCR system (Applied 
Biosystems). Briefly, there were 40 cycles of denaturation at 95°C for 15 s then annealing 
and extension at 60°C for 1 min, as per Applied Biosystems guidelines. StepOnePlus 
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software version 2.3 (Applied Biosystems) was used for analysis. All samples were 
analysed in duplicate. There was 100% agreement within duplicates of all samples. 
 
7.2.5 Data Analysis and Statistics 
SPSS (version 21, SPSS Inc) was used to perform independent T-tests to compare height 
and body mass between athletes and non-athletes. Genotype and allele frequencies in all 
groups were calculated and compared using chi-square analyses in SPSS. Excel 
(Microsoft, 2013) was used to assess Hardy-Weinberg equilibrium. Genotype associations 
with personal best were assessed in SPSS by one way ANOVA. 
 
7.3 UCP RESULTS 
7.3.1 Participant Height and Body Mass 
Table 22 shows the height and body mass for the male and female marathon athletes and 
non-athlete control. Although the participant numbers are slightly different between the 
three UCP polymorphisms analysed, the data for the mean and standard deviation height 
and mass data did not differ. The male marathon athletes and non-athlete controls did not 
differ in height (p ≥ 0.427). However, the male non-athlete controls were on average 10 kg 
heavier than the male marathon athletes (p = 1.0 x10-13). In females, there was no 
difference in height of the marathon athletes when compared to the non-athlete controls (p 
≥ 0.491). However, female marathon athletes were 12.7 kg lighter than female non athlete 
controls (p ≤ 1.0 x10-13) all data are self-reported. 
7.3.2 Hardy – Weinberg Equilibrium 
7.3.2.1 UCP2 
Hardy-Weinberg equilibrium deviated in UCP2 rs659366 and UCP2 rs660339 amongst 
the whole marathon athlete cohorts (UCP2 rs659366 χ2 = 4.337, UCP2 rs660339 χ2 = 
4.427). In all UCP2 rs659366 further analysis Hardy-Weinberg remained. Hardy-Weinberg 
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equilibrium was not observed among the mixed elite marathon athletes in UCP2 rs660339 
(χ2 = 5.127) and the total male marathon athlete cohort (χ2 = 4.845) though in all further 
analysis of UCP2 rs660339 Hardy-Weinberg equilibrium was observed. 
 
7.3.2.2 UCP3 
UCP3 rs1800849 Hardy-Weinberg equilibrium was present in all groups analysed 
regardless of further stratification by sex or elite marathon athlete status. 
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7.3.3 UCP2 rs659366 Genotype and Allele Frequencies 
Table 20 Genotype and allele frequencies of the UCP2 rs659366 polymorphism in marathon athletes and non-athletes 
  UCP2 rs659366 Genotype UCP2 rs659366 Allele 
Total Cohort CC CT TT C T 
Marathon Athletes 156 (39.1%) 202 (50.6%) 41 (10.3%) 514 (64.4%) 284 (35.6%) 
Elite Marathon 
Athletes 
65 (37.6%) 91 (52.6%) 17 (9.8%) 221 (63.9%) 125 (36.1%) 
Sub-Elite Marathon 
Athletes 
91 (40.3%) 111 (49.1%) 24 (10.6%) 293 (64.8%) 159 (35.2%) 
Non-Athletes 132 (43.1%) 140 (45.8%) 34 (11.1%) 404 (66.0%) 208 (34.0%) 
Males  
Marathon Athletes 97 (39.9%) 121 (49.8%) 25 (10.3%) 315 (64.8%) 171 (35.2%) 
Elite Marathon 
Athletes 
35 (40.7%) 43 (50.0%) 8 (9.3%) 113 (65.7%) 59 (34.3%) 
Sub-Elite Marathon 
Athletes 
62 (39.5%) 78 (49.7%) 17 (10.8%) 202 (64.3%) 112 (35.7%) 
Non-Athletes 90 (40.2%) 112 (50.0%) 22 (9.8%) 292 (65.2%) 156 (34.8%) 
Females  
Marathon Athletes 59 (37.8%) 81 (51.9%) 16 (10.3%) 199 (63.8%) 113 (36.2%) 
Elite Marathon 
Athletes 
30 (34.5%) 48 (55.2%) 9 (10.3%) 108 (62.1%) 66 (37.9%) 
Sub-Elite Marathon 
Athletes 
29 (42.0%) 33 (47.8%) 7 (10.1%) 91 (65.9%) 47 (34.1%) 
Non-Athletes 42 (51.2%) 28 (34.1%) 12 (14.6%) 112 (68.3%) 52 (31.7%) 
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UCP2 rs659366 genotype and allele distributions are detailed in Table 23 and did not 
differ between the entire marathon athlete cohort and non-athlete controls (genotype 
χ2=3.832, Z = 0.648, p = 0.517; allele χ2=0.913, Z = 0.725 p = 0.451) when analysed using 
the Cochran-Armitage test. When analysed using the Pearson chi squared test, there was 
no difference in genotype distribution between elite marathon athletes and non-athlete 
controls (genotype χ2 = 3.273, p = 0.195; allele χ2 = 0.706, p = 0.401) or sub-elite athletes 
and non-athlete controls (genotype χ2 = 1.040, p = 0.595; allele χ2 = 0.285, p = 0.593). 
When elite marathon athletes were compared to sub-elite marathon athletes no difference 
in genotype distribution was observed (χ2 = 0.477, p = 0.788; allele χ2 = 0.770, p = 0.781). 
 
Male marathon runners showed no difference in UCP2 rs659366 genotype or allele 
distributions when compared to all controls (genotype χ2 = 1.600, p = 0.449; allele χ2 = 
0.311, p = 0.577; Table 23). No differences in genotype or allele distribution were 
observed when male elite marathon runners were compared to all controls (genotype χ2 = 
0.711, p = 0.701; allele χ2 = 0.008, p = 0.930; Table 23). There was no difference in 
genotype (χ2 = 1.025, p = 0.599) or allele (χ2 = 0.396, p = 0.529) frequency distribution 
observed when sub-elite marathon runners were compare to controls (Table 23). There 
were no differences between the elite male marathon runners and the total sub-elite 
marathon runners in either genotype (χ2 = 0.147, p = 0.929) or allele frequency (χ2 = 
0.042, p = 0.838; Table 23). 
 
Table 23 also details the genotype and allele frequencies of the female marathon runners 
who demonstrated no difference in genotype or allele distribution frequencies when 
compared to the total control cohort (genotype χ2 = 2.423, p = 0.298; allele χ2 = 0.692, p = 
0.405). This lack of difference in genotype and allele frequency was further noted when 
female elite marathon runners were compared to the entire non-athletes (elite, genotype 
χ2 = 3.244 p = 0.197; allele frequency χ2 = 1.206, p = 0.272) (sub-elite, genotype χ2 = 
0.143, p = 0.931; allele χ2 = 3.10 x10-4, p = 0.986). Between group analysis of the female 
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elite athlete and all sub-elite athletes revealed no difference in either the genotype (χ2 = 
0.981, p = 0.612) or allele (χ2 = 0.414, p = 0.520) frequency. 
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7.3.4 UCP2 rs660339 Genotype and Allele Frequencies 
Table 21: The genotype and allele frequencies of UCP2 rs660339 polymorphism in marathon runners and non-marathon controls 
  UCP2 rs660339 Genotype UCP2 rs660339 Allele 
Total Cohort CC CT TT C T 
Marathon Athletes 133 (33.6%) 210 (53.0%) 53 (13.4%) 476 (60.1%) 316 (39.9%) 
Elite Marathon 
Athletes 
56 (32.4%) 97 (56.1%) 20 (11.6%) 209 (60.4%) 137 (39.6%) 
Sub-Elite Marathon 
Athletes 
77 (34.5%) 113 (50.7%) 33 (14.8%) 267 (59.9%) 179 (40.1%) 
Non-Athletes 117 (38.2%) 147 (48.0%) 42 (13.7%) 381 (62.3%) 231 (37.7%) 
Males  
Marathon Athletes 76 (31.5%) 133 (55.2%) 32 (13.3%) 285 (59.1%) 197 (40.9%) 
Elite Marathon 
Athletes 
27 (31.4%) 49 (57.0%) 10 (11.6%) 103 (59.9%) 69 (40.1%) 
Sub-Elite Marathon 
Athletes 
49 (31.6%) 84 (54.2%) 22 (14.2%) 182 (58.7%) 128 (41.3%) 
Non-Athletes 82 (36.6%) 113 (50.4%) 29 (12.9%) 277 (61.8%) 171 (38.2%) 
Females  
Marathon Athletes 57 (36.8%) 77 (49.7%) 21 (13.5%) 191 (61.6%) 119 (38.4%) 
Elite Marathon 
Athletes 
29 (33.3%) 48 (55.2%) 10 (11.5%) 106 (60.9%) 68 (39.1%) 
Sub-Elite Marathon 
Athletes 
28 (41.2%) 29 (42.6%) 11 (16.2%) 85 (62.5%) 51 (37.5%) 
Non-Athletes 35 (42.7%) 34 (41.5%) 13 (15.9%) 104 (63.4%) 60 (36.6%) 
159 
Marathon runners showed no difference in the genotype (Z = 0.648 p = 0.517) frequency 
distribution or the allele (Z = 0.584 p = 0.619) frequency distribution when compared to 
controls (Table 24). When elite marathon runners and sub-elite marathon runners were 
independently compared to controls (elite Z = 0.589, p = 0.556; sub-elite χ2 = 17.099, p = 
1.9 x 10-4) No differences in elite (Z = 0.402 p = 0.748) or sub-elite (χ2 = 1.084, p = 0.298) 
allele frequency distributions were observed when compared to the control participants. 
There were no differences between the elite marathon runners and the sub-elite marathon 
runners in either genotype (χ2 = 1.433, p = 0.488) or allele frequency (χ2 = 0.024, p = 
0.878). 
 
Table 24 shows in the male athletes there was no difference in the genotype distribution 
(Z = 0.890, p = 0.373) when compared to non-athletes via the Cochran-Armitage test. A 
genotype apparent difference was recorded when male elite and sub-elite athletes were 
compared to non-athletes independently (elite χ2 = 11.173, p = 0.001 OR 1.130, CI 95% 
0.525-2.432 p = 0.754; sub-elite χ2 = 17.584, p = 0.01: OR 0.899, CI 95% 0.495-1.632 p = 
0.726) via Pearsons-Chi squared. Between group analysis of male elite and all sub-elite 
athletes revealed neither a genotype (χ2 = 0.353, p = 0.838) or an allele (χ2 = 0.058, p = 
0.810) association. No allele associations were recorded when the male athlete group 
was compared to the entire non-athletes group (χ2 = 2.005, p = 0.157) nor when the elite 
male marathon runners and sub-elite male marathon runners were compared to non-
athletes independently (elite, χ2 = 0.412, p = 0.521; sub-elite χ2 = 1.658, p = 0.198). 
 
In the female athletes, a genotype association was observed when compared to non-
athletes (genotype χ2=8.376, p = 0.02: OR 1.202, CI 95% 0.568-2.546 p = 0.630) though 
this was not reflected in the allele analysis (allele χ2=0.054, p = 0.816). The female elite 
athletes also reflected a genotype association when compared to non-athletes (genotype 
χ2 = 8.942, p = 0.02: OR 1.450, CI 95% 0.598-3.519 p = 0.411), though this was not 
reflected in the allele distribution (allele χ2 = 0.132, p = 0.716). A lack of association was 
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observed when sub-elite runners were compared to non-athletes (genotype χ2 = 2.140, p 
= 0.343; allele χ2 = 0.003, p = 0.953) and when female elite runners were compared to all 
sub-elite runners (χ2 = 2.461, p = 0.292; allele χ2 = 0.058, p = 0.810). Data for all 
comparisons are displayed in Table 24. 
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7.3.5 UCP3 rs1800849 Genotype and Allele Frequencies 
Table 22: The genotype and allele frequencies of UCP3 rs1800849 polymorphism in marathon runners and non-marathon controls 
  UCP3 rs1800849 Genotype UCP3 rs1800849 Allele 
Total Cohort CC CT TT C T 
Marathon Athletes 219 (54.9%) 159 (39.8%) 21 (5.3%) 597 (74.8%) 201 (25.2%) 
Elite Marathon 
Athletes 
94 (54.3%) 68 (39.3%) 11 (6.4%) 256 (74.0%) 90 (26.0%) 
Sub-Elite Marathon 
Athletes 
125 (55.3%) 91 (40.3%) 10 (4.4%) 341 (75.4%) 111 (24.6%) 
Non-Athletes 167 (54.6%) 118 (38.6%) 21 (6.9%) 452 (73.9%) 160 (26.1%) 
Males  
Marathon Athletes 135 (55.6%) 94 (38.7%) 14 (5.8%) 364 (74.9%) 122 (25.1%) 
Elite Marathon 
Athletes 
50 (58.1%) 30 (34.9%) 6 (7.0%) 130 (75.6%) 42 (24.4%) 
Sub-Elite Marathon 
Athletes 
85 (54.1%) 64 (40.8%) 8 (5.1%) 234 (74.5%) 80 (25.5%) 
Non-Athletes 122 (54.5%) 89 (39.7%) 13 (5.8%) 333 (74.3%) 115 (25.7%) 
Females  
Marathon Athletes 84 (53.8%) 65 (41.7%) 7 (4.5%) 233 (74.7%) 79 (25.3%) 
Elite Marathon 
Athletes 
44 (50.6%) 38 (43.7%) 5 (5.7%) 126 (72.4%) 48 (27.6%) 
Sub-Elite Marathon 
Athletes 
40 (58.0%) 27 (39.1%) 2 (2.9%) 107 (77.5%) 31 (22.5%) 
Non- Athletes 45 (54.9%) 29 (35.4%) 8 (9.8%) 119 (72.6%) 45 (27.4%) 
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UCP3 rs1800849 genotype and allele distributions are detailed in Table 25. No difference 
was recorded in UCP3 rs1800849 genotype frequency distributions (χ2 = 1.666, p = 0.435) 
when the athletes were compared to non-marathon controls (Table 25). This lack of 
association was further reflected in the allele frequency distributions (χ2 = 0.378, p = 0.539; 
Table 25). There were no differences in UCP3 rs1800849 genotype or allele frequency 
distributions between elite and control participants (genotype χ2 = 0.910, p = 0.956; allele χ2 
= 0.003, p = 0.955; Table 25). Between group analysis of sub-elite marathon runners and 
non-marathon controls showed no difference in genotype or allele frequency distributions 
(genotype χ2 =2.150, p = 0.341; allele χ2 = 0.589, p = 0.443). When elite and sub-elite 
groups were compared, UCP3 rs1800849 genotype and allele frequency distributions 
showed no difference (genotype χ2 = 0.736, p = 0.692; allele χ2 = 0.220, p = 0.639). 
 
UCP3 rs1800849 genotype and allele frequency distributions did not differ between the male 
marathon cohort and all non-marathon controls (genotype χ2= 0.473, p = 0.789; allele 
χ2=0.378, p = 0.539). There was no difference in genotype or allele frequency distribution 
between male elite marathon runners and the total non-marathon control group (genotype χ2 
= 0.504, p = 0.777; allele χ2 = 0.265, p = 0.607; Table 25). Male sub-elite runners revealed 
no difference in genotype or allele frequency distributions when compared to all non-
marathon controls (genotype χ2 = 0.917, p = 0.632; allele χ2 = 0.720, p = 0.788; Table 25). 
When male elite runners were compared to all sub-elite runners, no difference in genotype 
distribution was observed (χ2 = 0.998, p = 0.607; Table 25). This lack of association was also 
seen in the allele frequency distribution (allele χ2 = 0.001, p = 0.971; Table 25). 
 
UCP3 rs1800849 genotype distributions were not different amongst the female athletes and 
the total control group (χ2 = 1.688, p = 0.430). No difference in allele distribution was 
observed between female athletes and all non-marathon controls (χ2 = 0.110, p = 0.741). 
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There was no difference in genotype distribution (χ2 = 1.003, p = 0.605) or allele distribution 
(χ2 = 0.187, p = 0.665) between the female elite marathon runners and the total control 
cohort. Female sub-elite marathon runners also showed no difference in genotype frequency 
distribution (χ2 = 1.732, p = 0.421) or allele frequency distribution (χ2 = 0.968, p = 0.325) 
when compared to all non-marathon controls. Sub group analysis between elite female 
marathon runners and the total sub-elite marathon runner cohort showed no difference in 
genotype distribution (χ2 = 1.278, p = 0.528) or allele distribution (χ2 = 0.608, p = 0.435). 
 
In summary, genotype-dependent differences were recorded for UCP2 rs660339 when the 
female marathon athlete cohort was compared to non-athletes (χ2=8.376, p = 0.02). 
Similarly, the male and female elite marathon athlete cohorts showed genotype-dependent 
associations when compared to non-athletes (males χ2 = 11.173, p = 0.001: females 
χ2=8.376, p = 0.02), A genotype difference was recorded between male sub-elite athletes 
and controls (χ2 = 17.584, p = 0.01). No other analysis revealed an association of either 
genotype or allele for UCP2 rs659336, UCP2 rs660339 or UCP3 rs1800849.  
 
7.3.6 Comparison of Marathon PB and Genotype 
Mean performance times were not significantly different between UCP2 genotype groups 
(UCP2 rs659366 males F = 1.546, p = 0.215; females F = 1.389, p = 0.252 Figure 28 and 
29; UCP2 rs660339 males F = 0.678, p = 0.509; females F = 1.620, p = 0.201 Figure 30 and 
31) or the UCP3 genotype (males F = 0.647, p = 0.525, female F = 0.677 p = 0.510; Figure 





Figure 28 Marathon personal best times for males grouped by UCP rs659366 
genotype. Data are medians and minimum and maximum. 
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Figure 29 Marathon personal best times for females grouped by UCP2 
rs659366 genotype. Data are medians and minimum and maximum. 
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Figure 30 Marathon personal best times for males grouped by UCP2 rs660339 
genotype. Data are medians and minimum and maximum. 
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Figure 31 Marathon personal best times for females grouped by UCP2 
rs660339 genotype. Data are medians and minimum and maximum. 
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Figure 32 Marathon personal best times for males grouped by UCP3 rs1800849 
genotype. Data are medians and minimum and maximum. 
169 
 
Figure 33 Marathon personal best times for females grouped by UCP3 
rs1800849 genotype. Data are medians and minimum and maximum. 
 
7.4 DISCUSSION 
The study, via the candidate gene approach, assessed the association of UCP2 rs659366, 
UCP2 660339 and UCP3 rs1800849 polymorphisms with marathon sporting performance. A 
possible genotype-dependent association with personal best marathon running time was 
also investigated. The main finding of this study was an overrepresentation of the CT 
genotype of UCP2 rs660339 in the athlete cohort when compared to non-athletes. This was 




On examination of the elite athletes there was a UCP2 rs660339 CT genotype over-
representation in the entire athlete cohort and non-athletes. Again, this association was 
observed in both the male and female athlete subgroups. In sub-elite athletes, the CT 
genotype was over-represented when compared to non-athletes and this association 
remained when male sub-elite athletes were compared to the complete non-athlete cohort. 
Interestingly, no allele associations were recorded between any of the groups when UCP2 
rs660339 was assessed. These interesting findings may partially be accounted for as a 
result deviation from Hardy-Weinberg equilibrium between the entire athlete cohort and non-
athletes, the entire elite cohort and non-athletes and the male athlete cohort and non-
athletes though this is unlikely. Deviation in Hardy–Weinberg equilibrium may result from a 
number of factors the most apparent is a genotyping error (Wittke-Thompson et al., 2005). 
All samples were genotyped in duplicate and data recorded centrally in a quality controlled 
database making a genotyping error unlikely. The other seven assumptions of Hardy-
Weinberg equilibrium in the main have been accounted for also, leaving only the allele 
frequencies are equal in the sexes and there is no migration, mutation or selection (Wittke-
Thompson et al., 2005). According to the literature, genotype and allele frequencies are not 
sex-specific for this polymorphism and genotype frequencies examined in the study 
population, resembled those of the European Ensembl genome browser 
(http://www.ensembl.org/index.html). Whilst a selection pressure may account for the 
deviation it would expected to result in deviation in all assessments not just selected 
populations of interest so therefore again is unlikely. More likely, this phenomenon is 
accounted for by the complexity of the endurance athletic trait, indeed departure from Hardy-
Weinberg equilibrium has been noted in other studies assessing genotype associations with 
athletic ability (Zarebska et al., 2013, Gomez-Gallego et al., 2009, Druzhevskaya et al., 
2008). No genotype or phenotype associations were observed in any of the between group 
analysis in either UCP2 rs659336 or UCP3 rs1800849. 
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An association between UCP2 rs659366 genotype and personal best time was not observed 
in either males or females. Neither was an association between UCP2 rs660339 genotype 
and personal best in male or female marathon runners. No, UCP3 rs1800849 genotype-
dependent associations with personal best time was observed in males or females. 
 
7.5 CONCLUSION 
In conclusion, this study was the first to analyse an association of endurance athlete status 
with the UCP2 rs659366, UCP2 rs660339 and UCP3 rs1800849 polymorphisms in a large 
group of elite marathon runners. This study found UCP2 rs660339 CT genotype over-
representation in the athlete in the athlete cohort when compared to non-athletes, when 
males and female were analysed in combination and independently. These findings were 
echoed in the elite athletes and non-athletes when analysed as a whole cohort and when the 
athlete group was stratified by sex. In sub-elite athletes, an over-representation of the CT 
genotype was observed when athletes were compared to controls and when male athletes 
were compared to controls. No genotype dependant association of neither UCP2 rs659366, 
UCP2 rs660339 nor UCP3 rs1800849 with personal best time was observed in either male 
or female marathon runners. This supports the hypothesis that UCP2 rs660339 may confer a 
favourable advantage to endurance athletes mediated possibly in part through increased 
efficiency in oxidative phosphorylation coupling to ATP production in skeletal muscle during 
sustained endurance exercise such as marathon running. 
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8 TOTAL GENOTYPE SCORE 
8.1 INTRODUCTION 
Elite endurance athletic performance is a polygenic trait influenced by multiple genetic 
variants that each contribute a small amount to the observed inter-individual variability in 
athletic performance. Previous research has noted that elite endurance athletes carry a 
higher proportion of the genetic variants thought to contribute to elite endurance 
performance than those who compete is elite strength or power based sports and the 
general population. In addition, several studies have examined the combined genetic 
contribution to groups of athletes though it should be noted that these studies have often 
included athletes from multiple sporting discipline, so may not be representative of a single 
sporting discipline athlete population such as the one included in this study. 
 
A number of factors including V̇O2 max, running economy, lactate threshold skeletal muscle 
fibre type and V̇O2 Kinetics, determines elite endurance athlete status in marathon running. 
Genetic factors will undoubtedly influence each of these factors and therefore play a small 
part in genetic contribution to the inter-individual variability in performance seen in 
international competition and the elite endurance athlete status of a marathon runner. It may 
also be assumed that these small contributions to genetic performance V̇O2 max, running 
economy, lactate threshold skeletal muscle fibre type and V̇O2 Kinetics may also confer  
 
Despite some of the earlier chapters in this thesis reporting no association of a genetic 
polymorphism and endurance athlete status, or a tendency, it is possible that the 
contribution of these genotypes is only evident when the individual genotypes are analysed 
cumulatively. By examining, the cumulative effect of several non-significant associations, 
tendencies of association and those significant associations reported earlier it should be 
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possible to identify the contributory effect of the included individual polymorphisms on the 
elite endurance athlete status and further determine if TGS influences personal best 
marathon performance times. 
 
8.2 METHODS 
Participant recruitment inclusion criteria, for both marathon athletes and non-athlete controls 
and genotyping methods of ACE (rs4341), ACTN3 (rs1815739), AGT (rs699), PPARGC1A 
(rs8192678), UCP2 (rs659366), UCP2 (rs660339) and UCP3 (rs1800849) polymorphisms 
are described in detail in chapter 3 sections 3.1 to Section 3.9. Therefore, the methods are 
detailed in brief below. 
 
8.2.1 Participants 
Prima facie Caucasian male and female marathon runners volunteered to participate in this 




Fluorophore based TaqMan® real-time PCR methods were used to determine each 
participants specific genotype for the following polymorphisms ACE (rs4341), ACTN3 
(rs1815739), AGT (rs699), PPARGC1A (rs8192678), UCP2 (659366), UCP2 (rs660339) and 
UCP3 (rs1800849) all detection analysis was completed using StepOnePlus software 
version 2.3 (Applied Biosystems). All samples were analysed in duplicate. There was 100% 
agreement within all sample duplicates. 
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8.2.3 Data Analysis 
The cumulative association of the seven polymorphisms with elite endurance athlete status 
was assessed using a total genotype score (TGS). The favourable genotype and allele for 
elite endurance athlete status was identified using data from the preceding results chapters 




Table 23 Rationale and genotype score allocation for each polymorphism in relation to elite endurance athlete status. 
GENE AND 
POLYMORPHISM 
GENOTYPE SCORE (2 
= OPTIMAL) 
RATIONALE ASSOCIATED PUBLICATIONS (IF 
AVAILABLE) 
ACE (RS4341) II = 2, ID = 1, DD = 0 The II genotype and I allele are consistently 
reported to be overrepresented in elite endurance 
athlete cohorts. 
Myerson et al., (1999), Scanavini et al., 
(2002), Alverez et al., (2000), Ma et al., 
(2013) ACE II genotype associated with 
performance in endurance athletes 
ACTN3 
(RS1815739) 
XX = 2, RX = 1, RR = 0 The XX genotype and X allele are over 
represented, and the RR genotype and R allele 
are underrepresented in in elite endurance athlete 
cohort. The mouse and human models suggest 
enhanced endurance performance with the XX 
genotype and X allele 
Grealy et al., (2012), Seto et al., (2013) 
MacArthur et al., (2007), MacArthur et 
al., (2008), 
AGT (RS699) CC = 2, CT = 1, TT = 0 The CC genotype reported to be associated with 
increased left ventricular mass which would 
increase the stroke volume and help to deliver fuel 
and oxygen to the respiring muscle 
Karjalainen et.al (1999) AGT CC 
genotype and left ventricular mass Diet 
et al (2001) AGT CC genotype and left 
ventricular mass when combined with 
ACE DD genotype 
PPARGC1A 
(RS8192678) 
GG = 2, GA = 1, AA = 0 G allele has been associated with elite endurance 
athletes in comparison to non-athletes controls is 
several research studies. 
Lucia et al (2005), Eynon et al (2009b) 




TT = 2, TC = 1, CC = 0 T allele associated with delta efficiency with 
endurance training 
Dhamarait et al.,(2012) 
UCP2 
(RS660339) 
TT = 2, TC = 1, CC = 0 T allele associated with increased V̇O2 max in 
rowers and runners 








8.2.4 Total genotype score 
The method detailed by Williams and Folland (2008) was used to determine the TGS. The 
TGS was identified by allocation of a ‘genotype score’ (GS) to each polymorphism of 0,1, 
or 2. Genotype score allocation was based on two assumptions firstly that homozygotes of 
the favourable genotype for the elite endurance phenotype were allocated a GS of 2, 
heterozygotes a score of 1 and the non- favourable genotype a score of 0. Secondly, that 
there was co-dominance of allele effect for each polymorphism of interest. The combined 
effects of each GS and the conversion to a total score that is transformed to a percentage 
(see equation 1 below for method) allowed the cumulative influence of all seven gene 
polymorphisms and elite athlete status to be analysed. 
 
Equation 1: calculation of total genotype score (Williams and Folland, 2008) 
TGS = (100/14) * (GSACErs4341 + GSACTN3rs1815739 + GSAGTrs699 + GSPPARGC1Ars8192678 
+ GSUCP2rs659366 + GSUCP2rs660339 + GSUCP3rs1800849) 
 
A TGS of 100 was representative of an ideal elite endurance athlete polygenic profile, 
whereas a TGS of 0 demonstrates as the worst hypothesised polygenic profile for elite 
endurance athlete status. 
 
8.2.5 Statistical analysis 
Hardy-Weinberg equilibrium was assessed for each of the included polymorphisms using 
χ2 test as detail previously in Chapter 3. Where Hardy-Weinberg Equilibrium was 
observed Pearson’s chi squared analysis was conducted to ascertain any associations 
with endurance athlete status. Where Hardy-Weinberg Equilibrium was not observed 
Cochrane–Armitage tests were used to confirm any association with elite endurance 
athlete status. Pearson’s correlation was used to determine linear trend association of 
TGS with personal best time in the male and female marathon cohorts. All statistical 
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Genotype frequencies for polymorphisms ACE, AGT, ACTN3, PARGC1A and UCP3 were 
in Hardy-Weinberg equilibrium. Hardy-Weinberg equilibrium deviated in UCP2 rs659366 
and UCP2 rs660339 amongst the whole marathon athlete cohorts. In all UCP2 rs659366 
further analysis Hardy-Weinberg remained. Hardy-Weinberg equilibrium was not observed 
among the mixed elite marathon athletes in UCP2 rs660339 though in all further analysis 
of UCP2 rs660339 Hardy-Weinberg equilibrium was observed. One of the athletes had a 
minimal score of 0. This athlete was in the sub elite cohort. None of the elite participants 
had the minimal (0) or maximal (100) TGS, scores ranged from 7-85 in the elite cohort. In 
the sub-elite cohort where scores reached 93. When assessed by t- test there was a 
difference in TGS scores between athletes and controls (t = 4.130 p = 0.000041) there 
was no recorded difference between elite, sub-elite groups when assessed by 
Spearman’s correlation (r = 0.27, p = 0.614). There was no association of TGS with 
personal best when assessed by Pearson’s correlation (r = 0.030, p = 0.485). 
 
8.4 DISCUSSION 
The current chapter aimed to identify an association with the combine polymorphisms 
within: ACE, AGT, ACTN3, PPARGC1A, UCP2rs659336, UCP2 rs660339, and UCP3 and 
Endurance athlete status. Athletes TGS scores were different from controls when 
assessed by independent t-test (t = 4.130 p = 0.000041) with a mean difference of 4.686. 
The TGS scores ranged from 0 to 93 in the athletes with the highest frequency TGS score 
of 50 in athletes with a mean of 42 (SD 15.838), whereas in controls the TGS score 
ranged from 0-86 with the highest frequency was 36 and a mean of 37 (SD 13.047).The 
association of TGS and endurance athlete status was also reported by Santiago et al., 
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2010 who recorded that in rowers the athletes were endowed with a more favourable 
combined polygenic profile than the controls group. The Santiago study included three of 
the polymorphisms assessed in this study ACE, ACTN3 and PPARGC1A. A further study 
by Ahmetov et al (2008) published results in accordance with Santiago, they found that 
their group of mixed discipline endurance sporting athletes had higher TGS scores for the 
10 ‘endurance’ genotypes tested in combination than controls. Gene polymorphisms that 
overlapped with this study include PPARGC1A, UCP2 and UCP3. An assessment by 
Spearman’s correlation assessed elite athlete status and TGS. This revealed no 
difference between the elite and sub-elite groups (r = 0.27, p = 0.614). This finding is in 
accordance with Santiago et al., (2010) who found no association between athlete groups 
when stratified into national and world champions. However, Ahmetov et al., (2008) did 
find a positive correlation with the TGS and elite athlete status though this was in a group 
of mixed sporting disciplined athletes and so this result should be viewed with caution. A 
further association between personal best of the combined influence of the 
polymorphisms within: ACE, AGT, ACTN3, PPARGC1A, UCP2rs659336, UCP2 
rs660339, and UCP3 was assessed via Pearson’s correlation. No association was 
apparent between personal best time and TGS score. One athlete in the sub-elite cohort 
had a TGS score of the minimal 0 the highest TGS score of 93 was also recorded in the 
sub-elite cohort. The average TGS in the elite cohort was 41 and in the sub-elite cohort 42 
was the average TGS. Seven common polymorphisms have been shown to contribute to 
the complex genetic profile of a marathon runner when compared to non-athlete controls. 
Further analysis showed elite endurance athlete status was not correlated with TGS. This 
data partially replicate the data presented by Ahmetov et al., 2008 and Santiage et al., 
2010. Collectively the polymorphisms within: ACE, AGT, ACTN3, PPARGC1A, 
UCP2rs659336, UCP2 rs660339, and UCP3 are associated with endurance athlete 
status. 
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9 GENERAL DISCUSSION 
9.1 RATIONALE FOR GENETIC ASSOCIATION STUDIES IN SPORT AND 
EXERCISE SCIENCE AND ENDURANCE PERFORMANCE 
Complex traits such as endurance sporting performance are phenotypes likely affected by 
both multiple genetic and environmental factors. The individual and combinatory 
contribution of these factors to human physical performance is considered complex. 
Nevertheless, careful selection of important and robust phenotypes and evidence-based 
selection of candidate genes can provide a solid basis on which to base studies of 
genetics in endurance human performance. Based on the assessments completed in 
height it is likely that thousands of SNIPS are involved in marathon performance. These 
genetic factors comprise multiple genes and perhaps even multiple polymorphisms within 
those genes contributing in an additive effect to complete a polygenic profile (Bouchard et 
al., 1997, Williams and Folland, 2008, Ahmetov and Fedotovskaya, 2012).  
 
Historically, the study of monozygotic twins (who share an almost identical genomic 
profile) shows a higher correlation in certain phenotypes than dizygotic twin pairs (whose 
genomic profiles are non-identical), thus demonstrating the heritability, or genetic 
component in determining that phenotypic trait (Bouchard et al., 1986a, Bouchard et al., 
1986b, De Moor et al., 2007). 
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9.2 INVESTIGATING CANDIDATE GENES 
The initial approach used by sports scientists and geneticists to identify sporting 
genotype-phenotype associations was the ‘candidate gene approach’ (Bouchard et al., 
1997). Using existing physiological knowledge genetic variations, relevant to human 
physical performance are selected for investigation. An example of this approach in 
humans is a rare mutation in the myostatin (MSTN) gene discovered in a 4-year old 
German boy with greater muscle mass who was considerably stronger than others his age 
(Schuelke et al., 2004). Further genetic variations that have been identified as relevant to 
endurance performance include ACE and ACTN3. This approach to candidate gene 
selection makes understanding and extrapolating the polygenic nature of human physical 
performance rather difficult as gene polymorphisms are often investigated individually 
rather than in combination. In an attempt to fully characterise the polygenic nature of 
human endurance performance, increasingly sports scientists are favouring another 
method the Genome Wide Association Study (GWAS), though this is fraught with its own 
limitations. By the very nature of being ‘elite’ few athletes at this level of sporting 
performance are available for study. Due to the large number of genetic variants being 
analysed in GWAS, very large numbers of participants are required for statistical power 
meaning study designs of this type are difficult to achieve without international consortium 
between research groups. Due to the scope of this project the candidate gene approach 
was selected as an appropriate method of analysis. Of note when selecting a test 
population was the importance of homogeneity to maximize the genetic contribution to the 
elite endurance phenotype of interest. Each gene included had a physiological rationale 
determined from the literature for the proposed association between the candidate gene 
and elite endurance phenotype and research participants met predetermined inclusion 
criteria to ensure validity, reliability and reproducibility of any genetic associations. This 
genetic candidate gene study compared an endurance athlete populations with non-
athlete controls in an attempt to associate common genotypic variants with the elite 
endurance phenotype of a marathon runner. 
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9.3 AIMS OF THESIS 
This thesis aimed to (1) compare the selected genetic polymorphism of elite and sub-elite 
and non –athletes; (2) comparatively analyse personal best marathon completion times 
with selected genetic polymorphisms. The objective was to address aims (1) and (2) for 
specific polymorphisms in the following genes ACE, AGT, ACTN3, PPARGC1A, UCP2 
and UCP3. 
 
9.4 MAIN FINDINGS AND IMPLICATIONS 
9.4.1 Summary of Main Findings 
AGT rs699 analysis revealed over representation of the TT genotype (5.6%, OR = 0.777, 
95% CI 0.562 – 1.074. p = 0.126) and T allele of 4.5% in marathon runner’s vs non-
athletes (OR = 0.832, 95% CI 0.669 – 1.034 p = 0.097. The TT genotype (OR = 0.722, 
95% CI 0.498 – 1.048. p = 0.086) and T allele showed further over representation of 5.6% 
and 5.7% respectively when sub-elite athletes were compared to non-athletes (genotype: 
OR = 0.722, 95% CI 0.498 – 1.048. p = 0.086: allele: OR = 0.790, 95% CI 0.613 – 1.019. 
p = 0.069) (See Table 27). 
 
The A allele of PPARGC1A rs8192678 tended to be more frequent in athletes than non-
athletes (χ2 = 2.988, p = 0.084) (Table 27). The male elite cohort when compared to non-
athletes showed a 3.4% AA genotype (χ2 = 6.890, p = 0.04) over representation (OR = 
0.696, 95% CI 0.383 – 1.265, p = 0.235). On comparison of male elite athletes and non-
athletes the A allele (χ2 = 2.986, p = 0.084) was 9.2% more frequent (OR = 0.686, 95% CI 
0.476-0.987, p = 0.042) (Table 28). Female sub-elite athletes when compared to non-
athletes showed 7.8% over representation of the AA genotype (χ2 = 7.193, p = 0.04) (OR 
= 0.531, 95% CI 0.212 – 1.331, p = 0.177. A female elite vs all sub-elite athletes 
comparison showed the A allele tended to be more frequent in female sub-elite athletes 
(χ2 = 5.425, p = 0.066) (Table 29). On consideration of PB, in women the PPARGC1A GG 
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genotypes ran the marathon approximately 5 min 38 s faster than other genotypes (p = 
0.022). UCP2 rs660339 analysis revealed a CT genotype difference was recorded when 
male elite and sub-elite athletes were compared to non-athletes independently (elite χ2 = 
11.173, p = 0.001 OR 1.130, CI 95% 0.525-2.432 p = 0.754; sub-elite χ2 = 17.584, p = 
0.01: OR 0.899, CI 95% 0.495-1.632 p = 0.726) via Pearson’s-Chi squared. 
 
In the female athletes, a CT genotype association was observed when compared to non-
athletes (genotype χ2=8.376, p = 0.02: OR 1.202, CI 95% 0.568-2.546 p = 0.630). The 
female elite athletes also reflected a CT genotype association when compared to non-
athletes (genotype χ2 = 8.942, p = 0.02: OR 1.450, CI 95% 0.598-3.519 p = 0.411). 
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Table 24 Genotyping summary of findings for all marathon athletes 
































































































































Table 25 Genotyping summary of findings for male marathon athletes 
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Table 26 Genotyping summary of findings for female marathon athletes 
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9.4.2 Novel contributions to the literature 
A complex phenotype is required for endurance performance. Therefore, it is likely that 
‘elite status’ is polygenic. We investigated individually, seven gene polymorphisms (ACE 
rs1799752, ACTN3 rs1815739, AGT rs699, PPARGC1A rs8192678, UCP2 rs659336, 
UCP2 rs660339 and UCP3 rs1800849) and elite endurance athlete status in male and 
female marathon runners. Marathon runners (399 prima facie Caucasians) were stratified 
by personal best (PB) into elite (men <2 h 30 min, women <3 h) and sub-elite (men <2 h 
45 min, women <3 h 15 min) and compared to 676 non-athlete prima facie Caucasian 
controls. This thesis found three polymorphisms AGT rs699, PPARGC1A rs8192678 
UCP2 rs660339 were positively associated with marathon performance in prima facie 
Caucasian endurance athletes. 
 
9.5 EXPLANATION OF VARIATION IN FINDINGS WITH THE PUBLISHED 
LITERATURE 
One of the challenging tasks in sporting genomics is the recruitment of appropriate 
athletes to investigate. Often access particularly of elite athletes is hampered by training 
regimes, competition, sporting management and injury. This invariably introduces 
sampling bias in the population of study. One way that researchers have tried to mitigate 
against this is to increase the sample sizes by combining athletes from multiple sporting 
disciplines, this introduces variation in phenotype and due to the inherent nature of 
phenotype likely genotype. Therefore this study recruited athletes from one sporting 
discipline, marathon in an attempt to limit the variability.  A possible limitation of this thesis 
is that the findings cannot automatically be extended to other sporting disciplines, even 
those that are accepted as “endurance” such as long-distance swimming or cycling, 
because of differences in muscle recruitment patterns, event distance and duration, 
biomechanical factors, etc. However, analysis within a single sporting discipline eliminates 
those factors that are known to differ between sports, thus reducing unwanted ‘noise’ in 
the data set.  
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In combining athletes to increase sample sizes researchers may have included athletes 
from varying geographic ancestry this may inadvertently introduce the confounding 
through racial gene skew. Others, like this investigation, have tried to mitigate against this 
confounding by limiting participant inclusion to one racial group. One limitation of this is 
confirmation of ancestry is often self-reported rather than determined by a panel of SNPs 
related to geographic ancestry and therefore relies on recall, this in itself is not perfect and 
subject to bias though arguably this is still preferential to ensure to limit heterogeneity 
within the sample selected. 
 
The control samples in this project were of a similar age this is due to the recruitment 
process. Most of the controls recruited were students of MMU and thus by demographic of 
being at university were of a similar age. The athlete cohort varied much more in age. It is 
recorded that the distance an athlete competes at often increases with age 
(www.powerof10.org). With marathon being the longest distance to run it falls that the 
participants should be older. Age may be a contributory factor to the advantage of an 
SNIP to sporting performance. It could be postulated that increased gene expression at 
one age may preferentially benefit an athlete on their sporting performance over another 
athlete of a lesser or greater age. It is known that to regulome changes epigenetically with 
age (Boron and Boulpaep, 2012) However, the fixed nature of the genome (i.e. genotype / 
allele frequency) from birth to death should not be influenced and therefore is a stable 
measure against sporting performance over say gene expression. 
 
Another point of note, is the researcher determination of ‘elite’ in their athlete cohort 
Researchers across the field have varying definitions for ‘elite’ making comparisons 
between cohorts challenging. Authors have used achievement markers such as Olympic 
and world records, recorded participation in sporting events at national or international 
level, other have used physiological measurements such as V̇O2 max that are generally 
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associated with sporting performance. Each definition has its limitations and these were 
discussed recently in Swann et al. (2015) and in a BASES article 
(http://www.bases.org.uk/write/ARTICLE_P6.pdf). This thesis defined elite according to 
top 100 UK male and female marathon athlete rankings as defined by the McCain Power 
of 10 website (www.thepowerof10.info/) as accessed on 31ST December 2012. The 
website records athlete particulars and sporting achievements on an annual basis. The 
published data records for athlete rankings date back to 2006. The data were averaged 
and the resulting mean time was rounded to the nearest 10 mins. One limitation of this 
thesis could be considered to be the cut-off threshold times for inclusion: 2 h 30 for men 
and 3 h for women for “elite”. Arguably, to be considered truly elite, only the top 25 should 
be included, or top 1%, or <2 h 20 for men, etc. However, these criteria are all equally 
arbitrary and may significantly influence sample size and therefore statistical power would 
need to be considered. 
 
The explicit detailing of a runners V̇O2 max, V̇O2 Kinetics, Running Economy skeletal 
muscle fibre type proportions lactate thresholds at given workloads etc. could help in 
identifying a more homogenous cohort of athletes. However, this will be hindered by 
natural variation within athlete groups and though it may be possible to group athletes 
more closely based on their phenotypic characteristics there will still be small amounts of 
variation within the groups due to the complex nature of human performance and the 
nature of competition. One way to try to reduce the variation noted between athlete and 
controls is to pair match them for characteristics such as age and ethnicity that may 
influence the results of genetic association. 
 
The sample size in this thesis is larger than any other elite marathon cohort and second to 
another elite cohort from a single endurance event (Grealy et al., 2012). A relationship 
between sample size and statistical power exists where, as the effect size reduces the 
number of participants required to identify a statistically significant difference increases 
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exponentially. So there remain additional benefits to be gained, in terms of statistical 
power, by increasing the sample size in this thesis from its current ~400 yet further (Figure 
34). It should be noted, however, that the law of diminishing returns applies, such that as 
the sample size increases the relative benefit obtained decreases. 
 
Figure 34 Number of subjects needed in each group for a given effect size 
(measured as an odds ratio [OR]) for a case-control design assuming 80% 
statistical power, a minor allele frequency of 20%, an additive model, and an 
alpha level of 0.0001 (500 SNPs) (Bouchard, 2011) 
 
One possible explanation for the lack replication with data in the published literature in 
some of the polymorphisms tested in this thesis is due to small sample sizes in the 
published data there may be the possibility of a type I statistical error (false positive) - i.e. 
low confidence in the observed data. A type 1 error is a major uncertainty with genetic 
association studies particularly in those with small sample sizes where the statistical 
evidence is lacking due to reduced statistical power. Therefore, the expansion of the 
genetic investigations in a larger data set may have reduced the possibility of 
inadvertently reporting false positive associations. Another possible explanation for the 
lack of reproducibility in some of the published studies included in this thesis is publication 
bias. Publication bias occurs when the outcome of an experiment or research study 
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influences the decision to publish or not. Publication bias is an important factor particularly 
in elite athlete populations where sample sizes are usually small and it is difficult to 
determine true polymorphic associations due to the complexities of the phenotypes being 
studied as publishing only positive significant findings disrupts the true nature of the 
research field. Publication bias can make finding support for a hypothesis during a 
literature review challenging as positive results are far more likely to be published than 
those showing null results. For example, if a lab/research group assesses e.g. 10 SNPs in 
an athlete cohort vs non-athlete controls, and sees 1 statistically significant difference, 
they might be tempted to try to publish that ‘more interesting’ result and discount the other 
nine. Hence the literature could become over-populated with positive associations that is 
not reflective of the data the various labs have collected. Even if the lab tries to publish all 
10 SNPs as separate papers, reviewers and editors are likely to be less inclined to 
recommend acceptance for publication the ‘less interesting’ ‘no association’ papers – i.e. 
another reason why the literature could become over-populated with positive associations 
relative to the data collected. While reviewing the literature, it was noted that results 
showing no association between genotype and athlete status are frequently reported as 
part of a broader paper that does include at least some positive association – which 
further adds to the notion that results showing no association are less likely to be 
submitted or accepted for publication on their own merits. Having acknowledged the 
possibility of publication bias and false positives (type I errors) and thus the resultant over-
representation of positive associations in the literature there is a strong likelihood that 
variation will occur between the published results and those chapters in this thesis that 
report no association. 
9.6 DIRECTIONS FOR FUTURE RESEARCH 
The findings of this thesis confirms the complexity of the elite endurance athlete 
phenotype and likely polygenic nature of the associated contributory genetic factors. This 
study was limited to 7 genetic polymorphisms that were selected based on their previously 
reported associations, in the literature, with parameters thought to be favourable to elite 
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performance in an endurance sport such as marathon running. To assess the combined 
effect of these genetic polymorphisms with other likely candidate polymorphism to emerge 
in future a TGS-type analyses could be applied to groups of selected candidate gene data 
to simultaneously consider associations between several polymorphisms and athlete 
phenotypes. Those kinds of analyses could also be conducted on the output from GWAS. 
However, the requirements of very large participant cohorts, standardised phenotypes and 
sophisticated (and considerably more expensive) laboratory genomic analyses means that 
GWAS is not feasible at this time. Indeed Rankinen et al (2016) is the largest effort to date 
to identify common polymorphisms associated with endurance performance in an 
unbiased manner. Rankinen et al (2016) aimed to identify a panel of genetic variants 
responsible for the elite endurance athlete profile using GWAS. They reported that the 
GAMES international consortium was at this stage underpowered to identify genetic 
variants with small effect sizes as none of the p-values approached the 5 x 10-8 required 
for statistical power. They further offered, in interim solution, that some suggestive allelic 
traits resulting from the GWAS should be further explored in larger comparative analysis 
of internationally elite endurance athletes and sedentary controls it is suggested here that 
TGS may be a suitable method to do this.
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